var title_f40_52_41792="Tetracaine: Patient drug information";
var content_f40_52_41792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetracaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/36/17987?source=see_link\">",
"       Tetracaine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/8/38019?source=see_link\">",
"       Tetracaine (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/3/25652?source=see_link\">",
"       Tetracaine (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12131 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41792=[""].join("\n");
var outline_f40_52_41792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/36/17987?source=related_link\">",
"      Tetracaine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41793="Reverse osmosis for water purification";
var content_f40_52_41793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Reverse osmosis for water purification for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of reverse osmosis in which feed water, which is pumped, flows parallel to the membrane. High pressure on the feed side of the membrane forces water across the membrane to form the product water. Ions and other contaminants, which are rejected by the membrane, accumulate in the remaining feed water and leave the membrane module as reject water. Locations of gauges and meters for the on-line measurement of pressure, flow rate, conductivity and temperature are shown. The data obtained with these gauges and meters are used to monitor the performance of the reverse osmosis system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41793=[""].join("\n");
var outline_f40_52_41793=null;
var title_f40_52_41794="Rosacea papules";
var content_f40_52_41794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41794=[""].join("\n");
var outline_f40_52_41794=null;
var title_f40_52_41795="Traumatic intubation CXR";
var content_f40_52_41795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traumatic intubation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top image demonstrates an endotracheal tube with its tip (red arrow) descending below the level of the carina (blue arrow). Bottom image shows massive pneumomediastinum and subcutaneous emphysema caused by a tear in the posterior membranous tracheal wall; the endotracheal tube has been repositioned.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41795=[""].join("\n");
var outline_f40_52_41795=null;
var title_f40_52_41796="Canakinumab: Drug information";
var content_f40_52_41796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Canakinumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/53/12116?source=see_link\">",
"    see \"Canakinumab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/6/14437?source=see_link\">",
"    see \"Canakinumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7874024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ilaris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14946785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ilaris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7879808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interleukin-1 Beta Inhibitor;",
"     </li>",
"     <li>",
"      Interleukin-1 Inhibitor;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7883738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ:",
"     <b>",
"      Cryopyrin-associated periodic syndromes:",
"     </b>",
"     SubQ: Adults &gt;40 kg: 150 mg every 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7883737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/6/14437?source=see_link\">",
"      see \"Canakinumab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cryopyrin-associated periodic syndromes:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     15-40 kg: 2 mg/kg every 8 weeks; may increase to 3 mg/kg if response inadequate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;40 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7883739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14965455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14965456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9512584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ilaris&reg;: 180 mg [contains polysorbate 80, sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14965457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ilaris&trade;: 150 mg [contains polysorbate 80, sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7884596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7883740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Do not inject into scar tissue.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7879810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7883697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (14%), vertigo (9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (20%), nausea (14%), gastroenteritis (11%), weight gain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular and skeletal: Musculoskeletal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (34%), rhinitis (17%), bronchitis (11%), pharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Calcium decreased (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Eosinophils increased (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (3% to 6%), ALT increased (3%), ALP increased (3%), bilirubin increased (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine clearance decreased (3% to 8%), proteinuria (4% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7883693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Confirmed hypersensitivity to canakinumab or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Active, severe infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7883694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions (excluding anaphylactic reactions) have been reported with use; symptoms may be similar to those that are disease related. Use is contraindicated in patients with known hypersensitivity to canakinumab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections: Caution should be exercised when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with latent or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued. Therapy should not be initiated in patients with active or chronic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy: Use may impair defenses against malignancies; impact on the development and course of malignancies is not fully defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tuberculosis: Avoid use in patients with active tuberculosis (TB). Patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treat latent TB infections prior to initiating canakinumab therapy. During and following treatment, monitor for signs/symptoms of active TB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor necrosis factor (TNF)-blocking agents: Should not be used in combination with TNF-antagonists (eg, etanercept). There is an increased risk of serious infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       &bull; Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use caution due to the potential higher risk for infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations including pneumococcal and influenza vaccines before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy. Administration of inactivated (killed) vaccines while on therapy may not be effective.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7899286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interleukin-1 Receptor Antagonist: May enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7883688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7883689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated fetal skeletal development delays. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7883691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Ilaris Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (1): $19266.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7883742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, C-reactive protein (CRP), serum amyloid A; signs of infection; latent TB screening (prior to initiating therapy); Canadian labeling also recommends blood pressure monitoring, annual lipid screening, and monitoring of neutrophil counts (at baseline, after 1-2 months and  periodically thereafter)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ilaris (AT, AU, CH, CZ, DE, DK, EE, FR, GB, IL, NL, NO, NZ, PH, PL, PT, SE, SG, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7883719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1&beta;) (no binding to IL-1 alpha  or IL-1 receptor antagonist) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates IL-1&beta; activation. Deficiency of cryopyrin results in excessive inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7883721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Subcutaneous: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 26 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum: Children: 2-7 days; Adults: ~7 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, &ldquo;Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(23):2416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/52/41796/abstract-text/19494217/pubmed\" id=\"19494217\" target=\"_blank\">",
"        19494217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8906 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-80A65F7FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41796=[""].join("\n");
var outline_f40_52_41796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14946785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7879808\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883738\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883737\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883739\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965455\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965456\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9512584\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965457\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7884596\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883740\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7879810\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883697\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883693\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883694\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298949\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7899286\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883688\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883689\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883691\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322118\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883742\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707699\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883719\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7883721\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/53/12116?source=related_link\">",
"      Canakinumab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/6/14437?source=related_link\">",
"      Canakinumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41797="Chest Xray of pneumothorax after stab wound";
var content_f40_52_41797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a pneumothorax after stab wound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain chest radiograph shows a left apicolateral pneumothorax with typical convex white visceral pleural line (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41797=[""].join("\n");
var outline_f40_52_41797=null;
var title_f40_52_41798="Trabectedin: Drug information";
var content_f40_52_41798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trabectedin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/16/39172?source=see_link\">",
"    see \"Trabectedin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11392727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yondelis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7618429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7618545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Prior to each treatment cycle, ANC should be  &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &ge;9 g/dL, bilirubin &le;ULN; alkaline phosphatase (nonosseous origin), ALT, and AST &le;2.5 times ULN; albumin &ge;25 g/L; serum creatinine &le;1.5 mg/dL  or creatinine clearance &ge;60 mL/minute; and CPK &le;2.5 times ULN. Premedication with dexamethasone I.V. 20 mg 30 minutes before infusion is recommended for hepatoprotective and antiemetic effects; additional antiemetics may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Ovarian cancer, relapsed (Canadian labeling; not approved for use in the U.S.):",
"     </b>",
"     1.1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with doxorubicin liposomal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Soft tissue sarcoma, refractory (unlabeled/investigational use):",
"     </b>",
"     I.V.: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Yovine, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7618546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7618547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Combination therapy with doxorubicin liposomal is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7618548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bilirubin &gt;ULN, clinically relevant liver disease (eg, active chronic hepatitis): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7618549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Delay the next treatment cycle for up to 3 weeks if ANC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , hemoglobin &lt;9 g/dL, bilirubin &gt;ULN; alkaline phosphatase (nonosseous origin), ALT, and AST &gt;2.5 times ULN; albumin &lt;25 g/L, or serum creatinine &gt;1.5 mg/dL or creatinine clearance &lt;60 mL/minute; if persists beyond 3 weeks, consider discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Reduce dose if the following occur in between cycles: ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , bilirubin &gt;ULN, alkaline phosphatase (nonosseous origin) &gt;2.5 times ULN, ALT or AST &gt;5 times ULN which has not recovered by day 21, or any other grade 3 or 4 adverse reaction (eg, nausea, vomiting, fatigue):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     First occurrence: Reduce trabectedin dose to 0.9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (reduce doxorubicin liposomal dose to 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Second occurrence: Reduce trabectedin dose to 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (reduce doxorubicin liposomal dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Third occurrence: Consider treatment discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     CPK &gt;2.5 times ULN: Discontinue trabectedin treatment until full recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     In the treatment of refractory soft tissue sarcoma (unlabeled use), the following dosage adjustments for toxicity were used in clinical trials (Garcia-Carbonero, 2005; Yovine, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Febrile neutropenia, infection, grade 4 neutropenia lasting &ge;5 days or grade 4 thrombocytopenia: Reduce dose to 1.2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 24 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiac or neurologic toxicity grade 2, or other nonhematologic toxicity &ge; grade 3 lasting &gt;21 days: Reduce dose to 1.2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 24 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Recurrent severe toxicity: Further reduce dose to 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 24 hours every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiac or neurologic toxicity &ge; grade 3 lasting &gt;35 days: Discontinue treatment",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11394944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yondelis&trade;: 0.25 mg, 1 mg [contains sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11400144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not commercially available in the U.S. (investigational agent)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not approved for use in the U.S. (investigational agent)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7618552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse through a central line. Premedicate with a corticosteroid (eg, dexamethasone 20 mg I.V.) prior to treatment; additional antiemetics may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Combination therapy with doxorubicin liposomal:  Administer doxorubicin first, flush line with D",
"     <sub>",
"      5",
"     </sub>",
"     W, then follow with trabectedin infusion over 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monotherapy (for soft tissue sarcoma; unlabeled use): Infuse as a continuous infusion over 24 hours; antiemetic prophylaxis was utilized in clinical trials (Yovine, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11393730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7665303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Canadian labeling: Treatment of relapsed ovarian cancer (in combination with doxorubicin liposomal)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11392728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory soft tissue sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7618424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7618644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions as reported for combination therapy with doxorubicin liposomal unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (46%), fever (20%), headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hand-foot syndrome (24%), alopecia (12%), rash (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (11% to 42%), hypophosphatemia (monotherapy: 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (74%; grade 3: 10%), vomiting (56%; grade 3: 12%; grade 4: &lt;1%), anorexia (32%), constipation (32%), diarrhea (26%), abdominal pain (20%), stomatitis (20%), weight gain (monotherapy: 20%), dyspepsia (13%), mucosal inflammation (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (48% to 95%; grade 3: 10% to 13%; grade 4: 3% to 6%), leukopenia (48% to 95%; grade 3: 25% to 45%; grade 4: 8% to 18%), neutropenia (77% to 92%; grade 3: 29% to 30%; grade 4: 34% to 42%), thrombocytopenia (36% to 64%; grade 3: 10% to 12%, grade 4: 8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (96%; grade 3: 46%; grade 4: 5%), AST increased (89%, grade 3: 12%; grade 4: 2%), alkaline phosphatase increased (61%; grade 3: 2%), hyperbilirubinemia (16% to 25%; grade 3:&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Phlebitis (monotherapy: 15%), injection/catheter site reactions (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: CPK increased (2% to 22%; grade 3: 1%, grade 4: 1%), weakness (17%), arthralgia (monotherapy: 12%), paresthesia (monotherapy: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (28%: grade 3: &lt;1%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (15%), cough (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: peripheral edema (9%), palpitation (4%), edema (3%), heart failure events (2%), syncope (2%), left ventricular dysfunction (1%; grade 3: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperpigmentation (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Taste disorder (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (8%, grade 3: 6%, grade 4: 2%), bone marrow failure (2%), granulocytopenia (2%). pancytopenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatotoxicity (2%; grade 3: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Catheter site pain (3%), catheter site inflammation (2%), catheter site erythema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Myalgia (5%), peripheral neuropathy (5%), musculoskeletal pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Renal failure (2%; grade 3:  1%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary embolism (5%), pulmonary edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Neutropenic infection (1%; grade 3: 1%), neutropenic sepsis (1%; grade 3: &lt;1%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Extravasation (with tissue necrosis, requiring debridement), QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7618431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trabectedin or any component of the formulation; concurrent serious or uncontrolled infection; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7618508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Neutropenia and thrombocytopenia are common; may be severe and/or dose-limiting. Neutropenic fever, infection, and sepsis may occur due to neutropenia; bleeding due to thrombocytopenia may occur. Do not administer if baseline neutrophils &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Dose reduction recommended for severe neutropenia (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) lasting &gt;5 days or associated with fever or infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular events: Adverse cardiovascular events have been observed with use in combination with doxorubicin liposomal. Heart failure, including left ventricular dysfunction, cardiac failure, congestive heart failure and ventricular dysfunction has been observed. Obtain baseline MUGA scan or (2-D) echocardiogram prior to treatment; do not treat if left ventricular ejection fraction is below the normal limit. QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation has been reported (single case report).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal events: Nausea and vomiting are common; corticosteroid premedication is recommended; other antiemetics may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Use is not recommended in patients with bilirubin above the upper limit of normal (ULN), alkaline phosphatase, ALT and AST &gt;2.5 times ULN, albumin &lt;25 g/L, or in patients with clinically relevant liver disease (eg, active chronic hepatitis). Acute (reversible) increases in ALT and AST have been reported when used in combination with doxorubicin liposomal; transaminase elevations are not cumulative and the incidence and magnitude generally diminish from cycle to cycle; premedication with dexamethasone appears to reduce the frequency and severity of transaminase elevations. The median onset for grades 3 and 4 transaminase elevations is 8 days and return to below grade 3 within 8 days. Monitor bilirubin, ALT, AST, and alkaline phosphatase. Systemic exposure and the risk for hepatotoxicity are increased in patients with hepatic impairment. Use in combination with other medications associated with hepatotoxicity may increase the risk for hepatotoxicity. Avoid concomitant use with alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection site reactions: Administer through a central line; peripheral administration may cause severe injection site reactions. Extravasation of trabectedin with subsequent tissue necrosis requiring debridement has been reported (case reports).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary embolism: Cases of pulmonary embolism have been reported with doxorubicin liposomal combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Rhabdomyolysis: Use is not recommended if CPK &gt;2.5 times ULN. Rhabdomyolysis has been reported rarely, usually in association with myelosuppression, severe liver impairment, or renal failure.  Monitor CPK closely, especially if muscle weakness/pain or symptoms of renal failure develop. If rhabdomyolysis occurs, institute supportive care and discontinue trabectedin until recovery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Combination therapy with doxorubicin liposomal is not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Monitor renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dexamethasone: Concurrent use of trabectedin with antiemetic regimens containing dexamethasone have been reported to increase the trabectedin AUC. Concurrent use is recommended; however, due to the hepatoprotective and antiemetic effect of dexamethasone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HMG-CoA reductase inhibitors: May increase the risk for rhabdomyolysis when used in combination with trabectedin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should not be immunized with live viral vaccines during or shortly after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11399607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hepatotoxic effect of Trabectedin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11393727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John&rsquo;s wort (may increase the clearance of trabectedin).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11392729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm if administered during pregnancy; do not use during pregnancy unless clearly needed. Women of childbearing potential should use effective contraception during and for 3 months after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11392730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11392731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding is contraindicated during and for 3 months after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7618554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline, weekly for first 2 cycles, then once between cycles), bilirubin, alkaline phosphatase (consider hepatic isoenzymes 5 nucleotidase or GGT to differentiate from elevations of non-osseous origin), ALT, AST (baseline, weekly for first 2 cycles, then once between cycles), renal function (baseline and during treatment), CPK (weekly for first 2 cycles, then between subsequent cycles)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Yondelis (AR, BE, CH, CN, CO, CZ, DE, DK, EE, FR, GB, GR, HK, HN, IE, IL, IT, KP, MY, NL, NO, PL, PT, RU, SE, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7618550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A marine-derived compound which blocks the cell cycle at the G",
"     <sub>",
"      2",
"     </sub>",
"     /M phase by covalently binding to the minor DNA groove, bending the helix toward the major groove and altering DNA transcription. Also alters DNA repair mechanism.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11393776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : &gt;5000 L; distributes extensively into peripheral tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;97%; to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively hepatic; oxidized via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (predominantly); urine (minor)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Garcia-Carbonero R, Supko JG, Maki RG, et al, &ldquo;Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(24):5484-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/52/41798/abstract-text/16110008/pubmed\" id=\"16110008\" target=\"_blank\">",
"        16110008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le Cesne A, Blay JY, Judson I, et al, &ldquo;Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(3):576-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/52/41798/abstract-text/15659504/pubmed\" id=\"15659504\" target=\"_blank\">",
"        15659504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Herzog TJ, Kaye SB, et al, &ldquo;Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(19):3107-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/52/41798/abstract-text/20516432/pubmed\" id=\"20516432\" target=\"_blank\">",
"        20516432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Soft Tissue Sarcoma,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yovine A, Riofrio M, Blay JY, et al, &ldquo;Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(5):890-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/52/41798/abstract-text/14990645/pubmed\" id=\"14990645\" target=\"_blank\">",
"        14990645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9513 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41798=[""].join("\n");
var outline_f40_52_41798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618429\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618545\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618546\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618547\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618548\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618549\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11394944\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11400144\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234358\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618552\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11393730\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7665303\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392728\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618424\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618644\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618431\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618508\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300158\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11399607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11393727\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392729\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392730\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392731\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618554\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961949\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7618550\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11393776\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/16/39172?source=related_link\">",
"      Trabectedin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41799="Treatment of genital herpes simplex virus type 2 in HIV-infected patients";
var content_f40_52_41799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Christine Johnston, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Anna Wald, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41799/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/52/41799/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6232222\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital herpes is a common sexually transmitted virus infection that is found worldwide. Genital herpes is usually secondary to herpes simplex virus type 2 (HSV-2); the remainder of infections is related to HSV-1, which also causes herpes labialis (&ldquo;cold sores&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/1\">",
"     1",
"    </a>",
"    ]. The seroprevalence of HSV-2 infections in HIV-infected patients is high (50 to 90 percent) and genital ulcer disease can be more frequent, severe, and of longer duration than in HIV-seronegative patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the treatment of genital herpes in HIV-infected patients. The natural history, clinical manifestations, and prevention of genital HSV infection in the HIV-infected patient and important viral interactions between HIV and HSV-2 are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=see_link\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251515187\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three classification categories for genital herpes, as noted below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275934\">",
"    <span class=\"h2\">",
"     Primary HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An HSV outbreak is defined as \"primary\" if the patient was HSV-seronegative for both HSV-1 and HSV-2 at the onset of genital lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6553141\">",
"    <span class=\"h2\">",
"     Nonprimary HSV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonprimary first episode infection refers to: a) the acquisition of genital HSV-1 infection in a patient with preexisting antibodies to HSV-2 or b) the acquisition of genital HSV-2 infection in a patient with preexisting antibodies to HSV-1 (eg, an individual with prior orolabial herpes). Most HIV-infected adults with a new diagnosis of HSV infection have nonprimary disease due to prior acquisition of HSV-1 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275941\">",
"    <span class=\"h2\">",
"     Reactivation (recurrent) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral treatment of newly acquired HSV-2 infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate.",
"   </p>",
"   <p>",
"    Compared with HIV-uninfected patients with HSV-2 infection, HIV-infected patients have more frequent and severe recurrences, particularly those with advanced immunosuppression (eg, CD4 cell counts less than 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. HSV-2 reactivation episodes can range from painful ulcers to asymptomatic lesions, or viral shedding without any mucocutaneous erosions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=see_link&amp;anchor=H11525287#H11525287\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12821249\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nucleoside analogues",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    are the preferred antivirals for HSV infections. Each of these agents has been demonstrated to decrease pain, lesion duration, and viral shedding with comparable efficacy and safety among HIV-seronegative patients with primary and recurrent HSV-2 infection. The efficacy of these medications has also been evaluated in a number of clinical trials involving HIV���infected persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H251515460\">",
"     'Clinical trial data'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These nucleoside analogs inhibit HSV DNA polymerase after being phosphorylated by virally-encoded thymidine kinase. This key phosphorylation step limits the activity of these agents to virally-infected cells, thus achieving a favorable side effect profile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3550903\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    have well-established safety records in HIV-infected patients; these drugs are generally well tolerated at the currently recommended doses. Adverse events can include nausea, diarrhea, or headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=see_link\">",
"     \"Famciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=see_link\">",
"     \"Valacyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (2 g four times daily) for the prophylaxis of cytomegalovirus infection were associated with thrombotic thrombocytopenic purpura (TTP) in HIV���infected persons; this syndrome has not been seen with the doses of valacyclovir currently used to treat genital herpes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11529280\">",
"    <span class=\"h1\">",
"     TREATMENT OF FIRST EPISODE HSV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of first episode HSV infection in the HIV-infected host is similar to the treatment in the immunocompetent host. However, clinicians should be aware that treatment of HSV-related disease in the HIV-infected host should continue until all lesions have completely healed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/9\">",
"     9",
"    </a>",
"    ]. Most episodes of first episode disease can be managed with oral agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ; occasionally a patient with severe pain due to genital ulcerative disease, or systemic symptoms such as meningitis, might require initial hospitalization for intravenous acyclovir therapy (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of bodyweight every eight hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Treatment of primary HSV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since most HIV-infected patients have acquired HSV-2 prior to the time of HIV diagnosis, most clinical management decisions are related to reactivation disease, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251515427\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGIES FOR RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of treatment of HSV���2 in HIV���infected persons are similar to those for HIV���uninfected persons. Management options of recurrent disease include episodic therapy or chronic suppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/9\">",
"     9",
"    </a>",
"    ]. The decision to use episodic versus suppressive therapy is driven by patient preferences. Patients who report painful recurrences or have several recurrences per year should be considered for suppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6008840\">",
"    <span class=\"h2\">",
"     Episodic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This approach involves self-administered antiviral therapy for individual outbreaks as they arise. Patients are counseled to start therapy at the first sign of prodromal symptoms (eg, tingling, paresthesias, pruritis), which may occur prior to the onset of discrete lesions. Patients should be provided antiviral medication, as any delay in administration will attenuate the benefit of the intervention. &nbsp;",
"   </p>",
"   <p>",
"    In an HIV-uninfected patient, episodic therapy can be as short as one to five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, the HIV-infected patient with HSV ulcerative disease should be treated for a minimum of five days or until lesion resolution, which can be significantly delayed among patients with advanced immunosuppression (",
"    <a class=\"graphic graphic_table graphicRef80971 \" href=\"mobipreview.htm?18/61/19419\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/4-8,13\">",
"     4-8,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6008946\">",
"    <span class=\"h2\">",
"     Suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This strategy involves the long-term administration of daily antiviral therapy to suppress symptomatic recurrences.",
"   </p>",
"   <p>",
"    There are additional benefits to suppressive antiviral therapy. In HIV-seronegative patients with HSV infection, HSV suppressive therapy reduces the risk of HSV transmission to an uninfected sex partner during episodes of asymptomatic viral shedding. However, whether HSV suppressive therapy in an HIV-infected patient reduces the risk of HSV transmission to an uninfected partner has not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of genital herpes virus infections\", section on 'Chronic suppressive therapy in discordant couples'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials have also demonstrated that suppressive therapy for HSV-2 infection can also lead to declines in HIV RNA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=see_link&amp;anchor=H275545#H275545\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\", section on 'Effect of HSV treatment on HIV replication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251515460\">",
"    <span class=\"h1\">",
"     CLINICAL TRIAL DATA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276016\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-seronegative patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    decreases the time to ulcer healing, the severity of symptoms, and amount of viral shedding compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/1\">",
"     1",
"    </a>",
"    ]. The choice of antiviral agent depends largely on patient preference and cost; clinically, the drugs are thought to have similar efficacy for preventing or resolving HSV-related genital ulcers, as shown by multiple clinical trials in HIV-uninfected patients with recurrent genital ulcerative disease (GUD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Treatment strategies for recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276023\">",
"    <span class=\"h2\">",
"     Limitations of clinical trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few placebo-controlled trials in the HIV-infected host with HSV infection since the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for HSV treatment was established many years ago among immunocompetent hosts. Thus, several clinical trials of episodic therapy among HIV-infected patients have compared acyclovir with other antiviral agents within the same class (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ). However, two clinical trials in HIV-infected patients did demonstrate the comparative benefit of suppressive therapy to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6232229\">",
"     'Suppressive therapy trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no clinical trials comparing strategies of episodic versus suppressive therapy in the HIV-infected patient and the clinical endpoints in the trials have varied. Also, several of these trials have used higher doses of antiviral medications for HSV than were used in the clinical trials among HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of clinical events in each trial is also influenced by the level of immunosuppression among the study participants. Of note, most of the studies discussed below were performed prior to the era of potent ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6232229\">",
"    <span class=\"h2\">",
"     Suppressive therapy trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three clinical trials have evaluated the role of suppressive antiviral therapy in the treatment of HSV recurrences among HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. Of the two placebo-controlled trials, antiviral therapy reduced the number of recurrences and the duration of HSV-associated genital ulcerative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two trials were done prior to availability of combination ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 48-week double���blind clinical trial of suppressive HSV-2 therapy compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      at two different doses (500 mg twice daily and 1 g once daily) to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg twice daily) in 1062 HIV���infected patients, 30 percent of whom had AIDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/5\">",
"       5",
"      </a>",
"      ]. Valacyclovir dosed at 500 mg twice daily was associated with a similar time to onset of ulcer recurrence as acyclovir, while once-daily valacyclovir was inferior. Limitations of the trial included a 43 percent drop-out rate among the study participants (eg, loss of consent, protocol violations, loss to follow-up).",
"     </li>",
"     <li>",
"      In a double���blind trial, 48",
"      <span class=\"nowrap\">",
"       HIV���1/HSV���2",
"      </span>",
"      coinfected persons were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      (500 mg twice daily) or placebo for eight weeks with subsequent cross-over to the other intervention arm; 63 percent of the patients had severe immunosuppression at enrollment and a significant proportion dropped out of the trial due to complications of end-stage AIDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/7\">",
"       7",
"      </a>",
"      ]. Of the 29 patients who completed the cross-over portion of the trial, famciclovir led to a significant decline in the number of days with genital ulcers (14 percent versus 5 percent). Those assigned to the treatment arm also had a significant decline in HSV���2 shedding (11 percent versus 1 percent; RR 0.15; 95% CI 0.06-0.42).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only one trial evaluated daily antiviral therapy for HSV in the era of combination ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      (500 mg twice daily) was compared with placebo for the prevention of genital herpes over a six-month period in a 2:1 assignment of 293 study participants with a history of symptomatic genital herpes, 25 percent of whom had a CD4 cell count of &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/8\">",
"       8",
"      </a>",
"      ]. More than 90 percent were taking three-drug combination ART and 50 percent had HIV suppression on enrollment. After six months of follow-up, significantly more subjects remained recurrence-free in the valacyclovir arm compared with placebo (65 versus 26 percent). The time to onset of first HSV recurrence also favored the valacyclovir arm compared with the placebo arm (&gt;180 days versus 59 days). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3454266\">",
"    <span class=\"h2\">",
"     Episodic therapy trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    appears comparable in efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in HIV-infected patients with a history of recurrent mucocutaneous disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind clinical trial, 293 HIV-infected patients (approximately half of whom had CD4 counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      (500 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg five times daily) for seven days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients were followed serially for evaluation of new lesion formation on therapy and time to complete healing, symptom resolution, and cessation of viral shedding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/6\">",
"       6",
"      </a>",
"      ]. Famciclovir was equivalent to acyclovir for all of these parameters; new lesion formation during treatment occurred in 16 percent and 13 percent, respectively. Both treatments were well tolerated.",
"     </li>",
"     <li>",
"      In a subsequent trial, 639 HIV���infected patients (mean CD4 count 320",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      were randomly assigned to five days of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (1 g twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (200 mg five times daily) for recurrent genital herpes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/5\">",
"       5",
"      </a>",
"      ]. Similar rates of healing were noted in both arms among the 467 patients who did experience a recurrence. However, the trial fell short of the planned 900 study participants because of slow recruitment; thus the conclusions of the study are limited because the trial was underpowered. Patients in both treatment arms tolerated therapy well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6009503\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no significant drug-drug interactions between these antiviral agents and HIV antiretroviral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6008764\">",
"    <span class=\"h1\">",
"     WHICH STRATEGY TO SELECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials comparing the efficacy of episodic or suppressive antiviral therapy for patients with recurrent HSV disease, regardless of HIV status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of genital herpes simplex virus infection\", section on 'Comparisons between episodic and suppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We counsel patients about the general benefit of antiviral therapy compared with no intervention and the relative advantages and disadvantages of either therapeutic approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic therapy is less costly and minimizes drug exposure. However, such an approach may require several days of treatment before symptomatic improvement.",
"     </li>",
"     <li>",
"      Suppressive therapy decreases the number of days with symptomatic disease, which may be particularly desirable in the patient with frequent outbreaks. Patients who report painful recurrences or have several recurrences per year should be considered for suppressive therapy.",
"     </li>",
"     <li>",
"      Suppressive therapy may potentially decrease the risk of HSV sexual transmission to an uninfected partner, although this has not been formally evaluated in HIV-infected patients. However, chronic suppressive therapy also adds to the patient&rsquo;s pill burden and the long-term safety of these agents has not been well studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856590\">",
"    <span class=\"h1\">",
"     DOSING GUIDELINES FOR ANTIVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2010 Sexually Transmitted Disease guidelines, the Centers for Disease Control (CDC) made dosing recommendations for suppressive and episodic therapy for HIV-infected patients with HSV recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/14\">",
"     14",
"    </a>",
"    ]. Several of these regimens use higher doses than those used among HIV-seronegative patients with HSV infection, based on the doses utilized in the clinical trial designs discussed above. Selection of any one particular antiviral agent should be driven mainly by cost and formulary considerations and frequency of dosing.",
"   </p>",
"   <p>",
"    Although most patients can be managed with the oral regimens recommended below, patients with severe ulcerative disease or CNS involvement may require intravenous therapy initially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856617\">",
"    <span class=\"h2\">",
"     Suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For daily suppressive therapy, the CDC recommends any of the following regimens for the HIV-infected patient with recurrent HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      400 to 800 mg orally twice daily to three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      500 mg orally twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      500 mg orally twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , we generally start with the lower dose of 400 mg twice daily and increase to 800 mg twice daily if breakthrough recurrences occur. Of note, once-daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg to 1 gram), which is used in immunocompetent hosts, should be avoided in HIV-infected patients due to concerns regarding lower efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856624\">",
"    <span class=\"h2\">",
"     Episodic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For episodic therapy, the CDC recommends any of the following regimens, all of which are given for a minimum duration of 5 to 10 days, or until lesion healing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      400 mg orally three times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      500 mg orally twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      1 g orally twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4856507\">",
"    <span class=\"h1\">",
"     IMMUNE RECONSTITUTION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution inflammatory syndrome (IRIS) related to HSV-2 infection is defined as either: a) increased severity of ulcerative disease or b) increased frequency of recurrences after the initiation of ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/15\">",
"     15",
"    </a>",
"    ]. IRIS���associated genital herpes has been characterized by multiple genital ulcerations, which may be refractory to antiviral therapy, despite in vitro susceptibility to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of IRIS related to HSV-associated genital ulcerative disease (GUD) has varied greatly in several observational cohorts from 9 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/15,17-19\">",
"     15,17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort of 199 HIV-infected individuals starting ART, 22 (50 percent) of 44 patients had IRIS related to anogenital HSV���2 infection, making it the most common manifestation of IRIS in this cohort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/15\">",
"       15",
"      </a>",
"      ]. Eleven (50 percent) of 22 patients with HSV���2 IRIS had a previous diagnosis of HSV���2; only two (9 percent) were receiving suppressive antiviral therapy at the time of ART initiation.",
"     </li>",
"     <li>",
"      In a cohort of 1551 HIV���infected patients in French Guiana, the risk of genital HSV���2 ulcers was 4.5-fold higher in the first two months after starting ART as compared with no ART, and remained elevated in the first six months after starting therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/17\">",
"       17",
"      </a>",
"      ]. After six months of ART, the rate of genital ulcers was equivalent to persons who were not receiving ART, suggesting that the risk of IRIS���associated genital ulcers is only transiently elevated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No studies on the optimal management of HSV���2 infection in persons starting ART are available. We suggest using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , or a related nucleoside analog, to attain HSV���2 suppression among HSV���2-infected persons starting ART, particularly those with a history of genital ulcerative disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1306949\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of long-term therapy has been demonstrated in HIV-uninfected patients over six years of continuous treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41799/abstract/20\">",
"     20",
"    </a>",
"    ]. Once a patient has achieved immune reconstitution on ART, the number of HSV recurrences may diminish over time. Some experts recommend treatment discontinuation to evaluate the ongoing need for suppressive antiviral therapy on an annual basis to evaluate disease activity once the patient&rsquo;s CD4 count is &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    However, some patients may not desire treatment discontinuation due to concerns about HSV recurrence during treatment interruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11529733\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT HSV DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If lesions continue to expand or do not heal on antiviral therapy, the clinician should suspect HSV drug resistance. Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    all share this mechanism of activity, resistance to one drug generally leads to cross-resistance to all medications within this class. The management of acyclovir-resistant HSV is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34024?source=see_link\">",
"     \"Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11529740\">",
"    <span class=\"h1\">",
"     ANTIVIRAL THERAPY FOR HSV-2 AND HIV-RELATED MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some observational data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    may be associated with decreased HIV-related morbidity. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=see_link&amp;anchor=H2541616#H2541616\">",
"     \"Effect of herpes simplex virus on HIV infection: Implications for HIV prevention\", section on 'HSV-2 antiviral therapy and HIV progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6232214\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The seroprevalence of herpes simplex virus (HSV) type 2 infections in HIV-infected patients is high and recurrent disease can be more frequent, severe, and of longer duration than in HIV-seronegative patient populations. (See",
"      <a class=\"local\" href=\"#H6232222\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral treatment of first episode HSV-2 infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate. Clinical HSV recurrences are a common problem among HIV-infected patients, particularly those with advanced immunosuppression (eg, CD4 cell counts less than 100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H251515187\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nucleoside analogues",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      have well-established safety and efficacy for treatment of genital HSV infections in HIV-infected patients; these drugs are generally well tolerated at the currently recommended doses. Because efficacy appears to be similar among these antiviral agents, selection of any one (eg, acyclovir, famciclovir, or valacyclovir) should be driven mainly by cost, formulary considerations, and frequency of dosing for patient convenience. (See",
"      <a class=\"local\" href=\"#H12821249\">",
"       'Available agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3550903\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principles of treatment of HSV���2 in HIV���infected persons are similar to those for HIV���uninfected persons. Among patients with first episode genital HSV infection, we recommend antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11529280\">",
"       'Treatment of first episode HSV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend HSV antiviral therapy in HIV-infected patients with clinical recurrences of HSV-2 infection compared with no intervention (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Management options of recurrent disease include episodic therapy (eg, self-administered antiviral therapy for individual outbreaks as they arise) or suppressive therapy (daily administration of antiviral therapy for long-term maintenance). (See",
"      <a class=\"local\" href=\"#H251515427\">",
"       'Treatment strategies for recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because these strategies have not been compared with each other in clinical trials in HIV-infected patients, the choice of therapeutic strategy (ie, episodic versus suppressive therapy) should take into account total pill burden (including antiretroviral medications), history of disease severity, long-term toxicity concerns, and concerns regarding sexual transmission to an uninfected partner based on available clinical trial data in HIV-negative as well as HIV-positive patients: (See",
"      <a class=\"local\" href=\"#H6232229\">",
"       'Suppressive therapy trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Suppressive antiviral therapy has been shown to reduce the number of recurrences and the duration of HSV-associated genital ulcerative disease in HIV-infected patients.",
"     </li>",
"     <li>",
"      In HIV-seronegative patients with HSV infection, HSV suppressive therapy reduces the risk of HSV transmission to an uninfected partner. Whether HSV suppressive therapy in an HIV-infected patient reduces the risk of HSV transmission to an uninfected partner has not been evaluated. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recommended doses of antiviral therapy are higher for both suppressive and episodic therapy for HSV recurrences in HIV-infected patients compared with HIV-seronegative patients. In the HIV-infected patient with HSV ulcerative disease, treatment should continue for a minimum of five days or until lesion resolution. (See",
"      <a class=\"local\" href=\"#H4856590\">",
"       'Dosing guidelines for antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initiation of antiretroviral therapy (ART) for HIV-infected patients with advanced immunosuppression can lead to a paradoxical worsening of underlying HSV infection. Among patients with a CD4 cell count &lt;100",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      who have a history of genital ulcerative disease, we suggest coadministration of antiretroviral therapy for HIV and suppressive HSV antiviral therapy. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4856507\">",
"       'Immune reconstitution syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/1\">",
"      Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/2\">",
"      Bagdades EK, Pillay D, Squire SB, et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/3\">",
"      Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/4\">",
"      Warren T, Harris J, Brennan CA. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. Clin Infect Dis 2004; 39 Suppl 5:S258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/5\">",
"      Conant MA, Schacker TW, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002; 13:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/6\">",
"      Romanowski B, Aoki FY, Martel AY, et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 2000; 14:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/7\">",
"      Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/8\">",
"      DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/9\">",
"      Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/10\">",
"      Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/11\">",
"      Patel R, Stanberry L, Whitley RJ. Review of recent HSV recurrent-infection treatment studies. Herpes 2007; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/12\">",
"      Corey L, Bodsworth N, Mindel A, et al. An update on short-course episodic and prevention therapies for herpes genitalis. Herpes 2007; 14 Suppl 1:5A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/13\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/15\">",
"      Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/16\">",
"      Fox PA, Barton SE, Francis N, et al. Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/17\">",
"      Couppi&eacute; P, Sarazin F, Clyti E, et al. Increased incidence of genital herpes after HAART initiation: a frequent presentation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. AIDS Patient Care STDS 2006; 20:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/18\">",
"      Graham SM, Masese L, Gitau R, et al. Increased risk of genital ulcer disease in women during the first month after initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/19\">",
"      Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41799/abstract/20\">",
"      Fife KH, Crumpacker CS, Mertz GJ, et al. Recurrence and resistance patterns of herpes simplex virus following cessation of &gt; or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169:1338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16255 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41799=[""].join("\n");
var outline_f40_52_41799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6232214\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6232222\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251515187\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275934\">",
"      Primary HSV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6553141\">",
"      Nonprimary HSV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H275941\">",
"      Reactivation (recurrent) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12821249\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3550903\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11529280\">",
"      TREATMENT OF FIRST EPISODE HSV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251515427\">",
"      TREATMENT STRATEGIES FOR RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6008840\">",
"      Episodic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6008946\">",
"      Suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251515460\">",
"      CLINICAL TRIAL DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276016\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276023\">",
"      Limitations of clinical trial data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6232229\">",
"      Suppressive therapy trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3454266\">",
"      Episodic therapy trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6009503\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6008764\">",
"      WHICH STRATEGY TO SELECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4856590\">",
"      DOSING GUIDELINES FOR ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4856617\">",
"      Suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4856624\">",
"      Episodic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4856507\">",
"      IMMUNE RECONSTITUTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1306949\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11529733\">",
"      WHEN TO SUSPECT HSV DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11529740\">",
"      ANTIVIRAL THERAPY FOR HSV-2 AND HIV-RELATED MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6232214\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/61/19419\" title=\"table 1\">",
"      Dosing of antiviral medications for genital HSV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29016?source=related_link\">",
"      Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28872?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6308?source=related_link\">",
"      Famciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21751?source=related_link\">",
"      Prevention of genital herpes virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34024?source=related_link\">",
"      Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30003?source=related_link\">",
"      Valacyclovir: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41800="Causes of horizontal strabismus in children";
var content_f40_52_41800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of horizontal strabismus in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41800/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/52/41800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strabismus is the term used to describe an anomaly of ocular alignment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of strabismus in children\", section on 'Terminology'",
"    </a>",
"    .) Strabismus can occur in one or both eyes and in any direction; it can be congenital or acquired, latent or manifest, constant or intermittent, and fixed or variable, depending upon the position of gaze and other factors.",
"   </p>",
"   <p>",
"    Strabismus can be classified according to the direction of deviation: in (esodeviations), out (exodeviations), and up or down (vertical deviations). The causes of horizontal strabismus are reviewed here. The evaluation of strabismus and the causes of vertical strabismus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link\">",
"     \"Evaluation and management of strabismus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=see_link\">",
"     \"Causes of vertical strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three pairs of extraocular muscles move each eye in three directions: vertically (superior and inferior), horizontally (medially [adduction] and laterally [abduction]), and torsionally (intorsion when the eye rotates nasally and extorsion when the eye rotates temporally). The superior oblique muscle is innervated by cranial nerve IV, the lateral rectus muscle by cranial nerve VI, and all others by cranial nerve III (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The understanding of strabismus requires knowledge of the two major principles that govern ocular motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Agonist muscles in both eyes receive equal innervation to ensure coordinated binocular eye movements. Thus, when the right lateral rectus muscle is activated to abduct the right eye, the left medial rectus muscle is activated equally to adduct the left eye.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Agonist/antagonist",
"      </span>",
"      muscle pairs within each eye receive reciprocal innervation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/2\">",
"       2",
"      </a>",
"      ]. Thus, when the right medial rectus muscle contracts to adduct the right eye, its antagonist, the right lateral rectus muscle, relaxes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ESODEVIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deviations of the eye toward the nose, which are the most common type of strabismus in children, are called esodeviations. In one population-based cohort, the cumulative prevalence of esotropia among children younger than six years of age was 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children who have moderate to large esodeviations, the corneal light reflection appears approximately in the center of the fixating eye's pupil and is displaced temporally in the deviated eye (",
"    <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and management of strabismus in children\", section on 'Corneal light reflex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of esodeviation include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accommodative esotropia",
"     </li>",
"     <li>",
"      Idiopathic infantile esotropia",
"     </li>",
"     <li>",
"      Duane syndrome",
"     </li>",
"     <li>",
"      Abducens palsy",
"     </li>",
"     <li>",
"      Sensory esotropia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants younger than four months of age who have constant esotropia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/6\">",
"     6",
"    </a>",
"    ] and infants older than four months who have persistent esodeviation should be referred to an ophthalmologist with expertise in children's eye care for evaluation, because these esodeviations are unlikely to resolve spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Accommodative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accommodative esotropia is the most common cause of esotropia in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. To focus properly on a near object, the ciliary muscle must alter the shape of the lens (accommodation), and both eyes must deviate inward (convergence). In children who have normal ocular alignment, accommodation is associated with a predictable and physiologic amount of convergence. In children who have accommodative esotropia, the physiologic convergence cannot be overcome by fusional divergence, and as a result, esotropia occurs (",
"    <a class=\"graphic graphic_picture graphicRef57340 \" href=\"mobipreview.htm?32/8/32902\">",
"     picture 1",
"    </a>",
"    ). Accommodative esotropia occurs more commonly in children who have hyperopia (farsightedness).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accommodative esotropia usually presents in the second year of life but may rarely be present in children as young as three months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/10\">",
"     10",
"    </a>",
"    ] and can occur later in life. Early-onset accommodative esotropia appears to occur more commonly in premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/10\">",
"     10",
"    </a>",
"    ]. At the time of onset, the crossing usually is intermittent and often more pronounced with near than with distant fixation. Over time, the deviation can become more pronounced and constant. Amblyopia occurs in approximately 20 percent of patients with accommodative esotropia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of amblyopia\", section on 'Strabismic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with accommodative esotropia can achieve long-term stabilization of ocular alignment with cycloplegic refraction and prescription of hyperopic spectacles (",
"    <a class=\"graphic graphic_picture graphicRef57340 \" href=\"mobipreview.htm?32/8/32902\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Surgical correction of residual esodeviation may be necessary in some patients, more likely in those with delayed diagnosis and treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Topical miotic agents (eg, phospholine iodide, diisopropyl fluorophosphate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/52/30531?source=see_link\">",
"     carbachol",
"    </a>",
"    ) have been used by some practitioners to manipulate accommodation, but lack of availability, limited experience, and side effects limit use of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Idiopathic infantile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic infantile esotropia, or \"congenital\" esotropia, is another common type of childhood strabismus (",
"    <a class=\"graphic graphic_picture graphicRef72282 \" href=\"mobipreview.htm?2/38/2661\">",
"     picture 2",
"    </a>",
"    ). This esodeviation has onset before six months of age and occurs in children who have a low refractive error and typically are neurologically normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. Although the esotropia is usually not present at birth, theory suggests that there is central anomaly of fusion, which is present at birth. The cause of the fusion anomaly remains unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The esotropia of idiopathic infantile esotropia typically is a large-angle esotropia, usually greater than 25 to 30 prism diopters. Children who have idiopathic infantile esotropia sometimes turn their faces toward the fixing eye, which is preferably positioned in adduction (cross-fixation). Thus, the right eye views objects in the left visual field, and vice versa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/14\">",
"     14",
"    </a>",
"    ]. Idiopathic infantile esotropia is associated with a variety of other ocular motility abnormalities that may manifest later in childhood. These commonly develop despite surgical therapy and initial good ocular alignment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The most common of these abnormalities include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oblique muscle dysfunctions, which are associated with anomalies of eye movement in side gaze and other complex abnormalities of eye movement.",
"     </li>",
"     <li>",
"      Dissociated strabismus complex, which refers to a latent tendency of one eye to deviate upward and outward during daydreaming or when fixation is disrupted (eg, by occluding one eye).",
"     </li>",
"     <li>",
"      Latent nystagmus, which refers to nystagmus that occurs (or worsens) when one eye is occluded.",
"     </li>",
"     <li>",
"      Amblyopia, which may develop in as many as 17 to 50 percent of affected children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of amblyopia\", section on 'Strabismic amblyopia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ophthalmologic history and examination usually can help the clinician distinguish idiopathic infantile esotropia from the other causes of esodeviation. Duane syndrome and Moebius syndrome are present at birth, whereas idiopathic infantile esotropia typically has onset during the first six months of life but is rarely present at birth. In addition, children with Duane syndrome usually have a small-angle esotropia (usually less than 20 prism diopters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22\">",
"     22",
"    </a>",
"    ], and those with Moebius syndrome usually have involvement of the facial and other cranial nerves. Children who have infantile esotropia usually have a low refractive error, whereas those with accommodative esotropia usually have greater hyperopia, and those with sensory esotropia have poor vision in the affected eye, usually because of an anatomic abnormality.",
"   </p>",
"   <p>",
"    Idiopathic infantile esotropia may be particularly difficult to differentiate from congenital or early-onset abducens palsy, because infants who have idiopathic infantile esotropia and large deviations may have difficulty abducting one or both eyes because of secondary contracture of the medial rectus muscle(s). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=see_link&amp;anchor=H6#H6\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\", section on 'Evaluation'",
"    </a>",
"    .) Oculocephalic testing, with or without monocular occlusion, may be helpful in making this distinction. Furthermore, abduction velocity (saccades) can usually be documented to be brisk in patients with idiopathic infantile esotropia, but not in those with abducens palsy. Distinguishing between the two disorders is important because the evaluation and treatment may differ. In addition to routine pediatric care, including neurologic examination, children with idiopathic infantile esotropia require only regular eye examinations. In contrast, children with abducens palsy often require additional evaluation, including neuroimaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;One step in the treatment of children with idiopathic infantile esotropia is to maximize visual acuity by treatment of amblyopia if it is present. Surgery designed to strengthen or weaken the extraocular muscles is the mainstay of therapy. The procedure most commonly performed is designed to weaken the medial rectus muscle(s). It usually is performed in both eyes. Successful ocular alignment initially is achieved in the majority of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/6\">",
"     6",
"    </a>",
"    ]. However, many children later develop recurrent esotropia, consecutive or secondary exotropia, or other eye movement abnormalities associated with the esotropia syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/23\">",
"     23",
"    </a>",
"    ]. Earlier realignment appears to be associated with better sensory outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injection of botulinum toxin into the medial rectus muscle of one or both eyes also has been used to treat idiopathic infantile esotropia. Injection of this toxin creates temporary paresis of the medial rectus muscle. More than one injection is needed in most children. Long-term improvement may result from changes in the rectus muscle's",
"    <span class=\"nowrap\">",
"     length/tension",
"    </span>",
"    relationships or in the child's fusional capacity during the temporary paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/25\">",
"     25",
"    </a>",
"    ]. In a randomized trial comparing reoperation and botulinum toxin injection in 55 children who failed initial surgical treatment, the long-term outcomes were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duane syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duane syndrome, also called Duane retraction syndrome or the Stilling-Turk-Duane syndrome, is a congenital strabismus that is usually caused by failure of normal development of the abducens nerve (the sixth cranial nerve) and abnormal innervation of the lateral rectus muscle by the oculomotor nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22,28-34\">",
"     22,28-34",
"    </a>",
"    ]. Patients with Duane syndrome may have esotropia or exotropia, and the following classification system is commonly utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22,35\">",
"     22,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I (esotropic Duane syndrome) &ndash; Patients have difficulty with abduction of the affected eye (",
"      <a class=\"graphic graphic_picture graphicRef76031 \" href=\"mobipreview.htm?34/17/35092\">",
"       picture 3",
"      </a>",
"      ) (70 to 80 percent of cases).",
"     </li>",
"     <li>",
"      Type II (exotropic Duane syndrome) &ndash; Patients have difficulty with adduction of the affected eye (",
"      <a class=\"graphic graphic_picture graphicRef55074 \" href=\"mobipreview.htm?2/49/2836\">",
"       picture 4",
"      </a>",
"      ) (7 percent of cases).",
"     </li>",
"     <li>",
"      Type III &ndash; Patients have difficulty with both abduction and adduction (",
"      <a class=\"graphic graphic_picture graphicRef62765 \" href=\"mobipreview.htm?26/28/27074\">",
"       picture 5",
"      </a>",
"      ) (15 percent of cases). These patients can have esotropia or exotropia in the primary position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Duane syndrome accounts for between 1 and 5 percent of strabismus cases and has a prevalence of 0.1 percent in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22,30\">",
"     22,30",
"    </a>",
"    ]. Most cases are sporadic, but an autosomal dominant inheritance pattern has been described. Genetic loci have been mapped to chromosomes 8q13 and 2q31 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/30,36-38\">",
"     30,36-38",
"    </a>",
"    ]. Duane syndrome may be seen in association with other conditions, including Klippel-Feil anomaly, hemifacial microsomia, and Wildervanck syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duane syndrome affects the left eye in 59 percent of cases, the right in 23 percent, and both in 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/28,39\">",
"     28,39",
"    </a>",
"    ]. Familial cases usually are bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/40\">",
"     40",
"    </a>",
"    ]. The angle of deviation typically is small (&lt;20 to 30 prism diopters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22\">",
"     22",
"    </a>",
"    ]. One of the characteristic features of Duane syndrome is the retraction of the globe and narrowing of the palpebral fissure during attempted adduction (",
"    <a class=\"graphic graphic_picture graphicRef76031 \" href=\"mobipreview.htm?34/17/35092\">",
"     picture 3",
"    </a>",
"    ). This feature is caused by the simultaneous contraction of the medial and lateral rectus muscles that occurs during attempted adduction. Some patients with Duane syndrome may have normal ocular alignment in the straight-ahead (or primary) position and manifest deviation only in the lateral-gaze position.",
"   </p>",
"   <p>",
"    Other clinical features include abnormal tilt or turn of the head (torticollis) to permit fusion and upshoot",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    downshoot of the affected eye in adduction. These movements are thought to be caused by a \"leash\" phenomenon of the lateral rectus muscle or aberrant innervation of the vertical rectus muscles. Patients with Duane syndrome also may have amblyopia and unequal refractive errors (anisometropia). Extraocular features of Duane syndrome include thenar hypoplasia and radial ray abnormalities, deafness, and fusion of the second and third cervical vertebrae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/28,41\">",
"     28,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for Duane syndrome is the same as for other forms of strabismus. Indications for strabismus surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strabismus in the primary position of gaze (straight ahead)",
"     </li>",
"     <li>",
"      Abnormal head posture",
"     </li>",
"     <li>",
"      Significant upshoot or downshoot of the eye in adduction",
"     </li>",
"     <li>",
"      Significant enophthalmus in adduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abducens nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paralysis of the sixth cranial nerve (abducens nerve) is an uncommon cause of esotropia in children. Deviation in children with abducens nerve palsy increases with gaze toward the affected side and decreases with gaze toward the unaffected side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/4\">",
"     4",
"    </a>",
"    ]. Abducens nerve palsy in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=see_link\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sensory esotropia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory esotropia may occur in children of any age. Sensory esotropia results when vision in the affected eye is sufficiently poor that fixation and eye alignment cannot be maintained. Sensory deviation can be caused by congenital or early-onset cataract, optic nerve anomalies, retinal detachment, and retinoblastoma. Esotropia is the second most common presenting sign in patients with retinoblastoma (after leukocoria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=see_link\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Moebius syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moebius syndrome is a rare cause of esotropia. Patients with Moebius syndrome have unilateral or bilateral anomalies of multiple cranial nerves, particularly the facial nerve and the abducens nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Two genetic loci have been mapped: one at 13q12.2-q13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and the other at 3q21-q22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/47\">",
"     47",
"    </a>",
"    ]. Moebius syndrome may occur in association with the Poland anomaly, which consists of absence of the pectoralis major muscle and limb abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/48\">",
"     48",
"    </a>",
"    ], and as a result of in utero exposure to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/31/17908?source=see_link\">",
"     misoprostol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Moebius syndrome typically present with facial diplegia and absence of facial expression. Feeding difficulties may be present if the ninth cranial nerve (the glossopharyngeal nerve) is involved. Other variably present manifestations include peripheral neuropathy, intellectual disability (mental retardation), arthrogryposis, limb deficiencies, flexion finger contractures, and hypogonadotropic hypogonadism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for the strabismus associated with Moebius syndrome is the same as for other forms of strabismus. Indications for strabismus surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strabismus in the primary position of gaze (straight ahead)",
"     </li>",
"     <li>",
"      Abnormal head posture",
"     </li>",
"     <li>",
"      Significant upshoot or downshoot of the eye in adduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, those patients with involvement of the facial nerve require observation for and treatment of corneal exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EXODEVIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Horizontal ocular deviations in which the visual axis deviates outward are called exodeviations. Children with exodeviations typically present during the first decade. The prevalence is approximately 1 percent in children younger than 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/50\">",
"     50",
"    </a>",
"    ]. In children who have moderate to large exodeviation, the corneal light reflex appears in the center of the fixating eye and is displaced nasally in the deviated eye (",
"    <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"     figure 1",
"    </a>",
"    ). The most common cause of exodeviation in children is intermittent exotropia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Other causes include type II Duane syndrome, oculomotor nerve paresis, congenital fibrosis of the extraocular muscles, sensory exotropia (related to decreased visual acuity in one eye), and consecutive exotropia (exotropia after surgery to correct esotropia). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Duane syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intermittent exotropia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent exotropia is the most common exodeviation of childhood, affecting almost 1 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/52\">",
"     52",
"    </a>",
"    ]. The usual onset occurs when the child is two to three years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with intermittent exotropia usually present with a complaint that one eye \"floats\" or \"drifts\" when the child is tired or inattentive. In the early stages of this condition, the child can control the deviation and realign the eyes when his or her attention is brought to the problem. He or she may need to blink to help reestablish fusion, and excessive blinking may be the presenting complaint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The child with intermittent exotropia may have normal ocular alignment and no obvious problems at the initial clinical examination. With progression, the ocular deviation is more difficult for the child to control and tends to become manifest. Children with intermittent exotropia usually do not experience diplopia because the developing visual system of the child suppresses the unwanted image from the deviating eye up to approximately eight or nine years of age. The risk of developing amblyopia is approximately 20 percent. In one population-based study, more than 90 percent of children with intermittent exotropia developed myopia by the age of 20 years, whether or not they were treated surgically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with intermittent exotropia can be categorized according to the degree of exodeviation with distance fixation versus near fixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic exotropia is the term used to describe an exodeviation that is approximately the same size at distance compared with near fixation.",
"     </li>",
"     <li>",
"      Divergence excess-type intermittent exotropia is present when the exodeviation is greater at distance compared with near fixation.",
"     </li>",
"     <li>",
"      Convergence insufficiency-type intermittent exotropia is present when the exodeviation is greater at near compared with distance fixation (",
"      <a class=\"graphic graphic_picture graphicRef72919 \" href=\"mobipreview.htm?34/22/35175\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Convergence insufficiency intermittent exotropia may be associated with asthenopia (ie, eye strain) or diplopia with reading or schoolwork. It also is a common finding in presbyopic adults who require bifocals to read.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of treatments have been proposed for intermittent exotropia. However, no single treatment has proven superior for all cases, and long-term follow-up demonstrates a high recurrence rate regardless of initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/9,56,57\">",
"     9,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation &ndash; Simple observation is an acceptable method of treatment in patients who are able to control their exodeviation the majority of the time and who are otherwise asymptomatic. The symptoms that should be monitored include headache, eye strain, double vision, the closing of one eye in sunlight (eg, monocular manifest deviation), and increasing frequency of deviation. As a general rule, the prognosis for normal binocular vision and stereopsis is good if the exotropia is manifest infrequently. Intervention in these children should be determined on a case-by-case basis at the discretion of the clinician and the parents.",
"     </li>",
"     <li>",
"      Occlusion therapy, over-minused spectacles, and orthoptic exercises &ndash; Vision therapy can be passive or active. Passive vision therapy includes alternate part-time occlusion of one eye and usually is used in younger children to prevent the development of or reduce suppression. In some patients, passive vision therapy has been demonstrated to result in improved control of intermittent exotropia and to delay or avoid the need for surgical intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. However, as with all treatments for intermittent exotropia, failure and recurrence after discontinuation of therapy are common occurrences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The prescription of myopic spectacles is another method of passive vision therapy for intermittent exotropia and is appropriate in patients who are already spectacle wearers, who are willing to wear glasses,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who are in reasonably good control of their deviation. This method of treatment works by stimulating accommodation and accommodative convergence, thereby diminishing and even eliminating exodeviation in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/60\">",
"       60",
"      </a>",
"      ]. As with other methods of therapy, failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrence with this treatment is a common occurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Active vision therapy involves a combination of eye exercises and vision-training maneuvers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/61\">",
"       61",
"      </a>",
"      ]. This therapy may be prescribed to take place at home or administered at weekly or more frequent office encounters. In a randomized controlled trial of 221 children (aged 9 to 17 years), an intensive program of office-based vision therapy with home reinforcement was more effective in reducing signs and symptoms than several home-based therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/62\">",
"       62",
"      </a>",
"      ]. \"Active\" vision therapy consisted of a rigorous protocol, including a variety of exercises designed to improve vergence and accommodation. Placebo therapy consisted of procedures designed to simulate real vision",
"      <span class=\"nowrap\">",
"       therapy/orthoptics",
"      </span>",
"      without the expectation of affecting vergence, accommodation, or saccadic function.",
"      <br/>",
"      <br/>",
"      Although this study suggests that intensive office-based therapy is superior to placebo therapy, additional studies are needed to determine whether office-based therapy is superior to equally intensive home-based therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Strabismus surgery &ndash; Strabismus surgery is the treatment used most often by ophthalmologists for advanced intermittent exotropia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/64\">",
"       64",
"      </a>",
"      ]. Surgical guidelines typically recommend intervention when the exodeviation is manifest frequently",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if the patient is symptomatic. The surgery involves weakening the lateral rectus muscles of both eyes, weakening the lateral rectus muscle and tightening the medial rectus muscle in a single eye, or strengthening the medial rectus muscles in both eyes. All procedures are similarly effective depending on the type and magnitude of exodeviation. Recurrence occurs commonly after surgery for intermittent exotropia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=see_link&amp;anchor=H18#H18\">",
"       \"Evaluation and management of strabismus in children\", section on 'Overview of management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oculomotor nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oculomotor nerve provides efferent innervation to four extraocular muscles (the medial rectus, superior rectus, inferior rectus, and inferior oblique), the levator palpebral superioris muscle, and the pupillary constrictor muscle, via its parasympathetic component (",
"    <a class=\"graphic graphic_table graphicRef72952 \" href=\"mobipreview.htm?37/58/38827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Complete oculomotor palsy presents with the classic triad:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exotropia and hypotropia of the involved eye",
"     </li>",
"     <li>",
"      Mydriasis",
"     </li>",
"     <li>",
"      Complete ptosis (",
"      <a class=\"graphic graphic_picture graphicRef59305 \" href=\"mobipreview.htm?16/26/16805\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presentation of incomplete oculomotor paresis varies depending upon which muscle(s) are affected primarily. Clinical findings may include deficits in elevation or depression, ptosis, and anisocoria. In contrast to other forms of exodeviation, the exodeviation of oculomotor nerve palsy or paresis is associated with reduced ability (or inability) to adduct the affected eye. These patients also often use an anomalous head position to maintain alignment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link&amp;anchor=H3#H3\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are suspected of having oculomotor nerve palsy should be referred to a pediatric ophthalmologist who is skilled in the evaluation and management of ocular motility abnormalities. Neuroimaging may be necessary to determine the underlying etiology (",
"    <a class=\"graphic graphic_table graphicRef71965 \" href=\"mobipreview.htm?2/36/2636\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link&amp;anchor=H13#H13\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Congenital fibrosis of the extraocular muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital fibrosis of the extraocular muscles (CFEOM) can mimic third-nerve palsy. CFEOM has several phenotypes: FEOM1 and FEOM3 cause hypodeviations, whereas FEOM2 causes exotropia. FEOM2 is characterized by bilateral ptosis with the eyes fixed in an exotropic position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/65\">",
"     65",
"    </a>",
"    ]. This autosomal recessive disorder is caused by mutations in the",
"    <em>",
"     ARIZ",
"    </em>",
"    gene on chromosome 11q13, which codes a transcription factor protein that is required for development of the third and fourth cranial nerves in the mouse and zebrafish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Neuropathologic changes suggest that FEOM2 is caused by a primary defect in the superior and inferior divisions of the oculomotor nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41800/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/58/27553?source=see_link\">",
"       \"Patient information: Crossed eyes and lazy eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Esodeviations (deviations of the eye toward the nose) are the most common type of strabismus in children. In moderate to large esodeviations, the corneal light reflex appears approximately in the center of the fixating eye's pupil and is displaced temporally in the deviated eye (",
"      <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Esodeviations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of esodeviation include accommodative esotropia, idiopathic infantile esotropia, Duane syndrome, abducens palsy, and sensory esotropia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Esodeviations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Constant esotropia in an infant younger than four months and persistent intermittent or constant esotropia in a child older than four months of age are unlikely to resolve spontaneously. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Esodeviations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exodeviations (outward deviations of the eye) typically present during the first decade of life. In moderate to large exodeviation, the corneal light reflex appears approximately in the center of the fixating eye and is displaced nasally in the deviated eye (",
"      <a class=\"graphic graphic_figure graphicRef63631 \" href=\"mobipreview.htm?28/23/29040\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Exodeviations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of exodeviation in children is intermittent exotropia. Other causes include type II Duane syndrome, oculomotor nerve paresis, congenital fibrosis of the extraocular muscles, sensory exotropia, and consecutive exotropia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Exodeviations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/1\">",
"      Ono H, Mapp AP. A restatement and modification of Wells-Hering's laws of visual direction. Perception 1995; 24:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/2\">",
"      Ciuffreda KJ, Stark L. Descartes' law of reciprocal innervation. Am J Optom Physiol Opt 1975; 52:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/3\">",
"      Greenberg AE, Mohney BG, Diehl NN, Burke JP. Incidence and types of childhood esotropia: a population-based study. Ophthalmology 2007; 114:170.",
"     </a>",
"    </li>",
"    <li>",
"     McManaway JW III, Frankel CA. Strabismus. In: Primary Pediatric Care, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/5\">",
"      Mohney BG. Common forms of childhood esotropia. Ophthalmology 2001; 108:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/6\">",
"      Birch E, Stager D, Wright K, Beck R. The natural history of infantile esotropia during the first six months of life. Pediatric Eye Disease Investigator Group. J AAPOS 1998; 2:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/7\">",
"      Pediatric Eye Disease Investigator Group. Spontaneous resolution of early-onset esotropia: experience of the Congenital Esotropia Observational Study. Am J Ophthalmol 2002; 133:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/8\">",
"      Pediatric Eye Disease Investigator Group. The clinical spectrum of early-onset esotropia: experience of the Congenital Esotropia Observational Study. Am J Ophthalmol 2002; 133:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/9\">",
"      Donahue SP. Clinical practice. Pediatric strabismus. N Engl J Med 2007; 356:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/10\">",
"      Coats DK, Avilla CW, Paysse EA, et al. Early-onset refractive accommodative esotropia. J AAPOS 1998; 2:275.",
"     </a>",
"    </li>",
"    <li>",
"     Mazow ML, Kaldis LC, Prager TC. An evaluation of accommodative esotroplas. In: Strabismus II, Reinecke RD (Ed), Grune &amp; Stratton, New York 1984. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/12\">",
"      Lambert SR. Accommodative esotropia. Ophthalmol Clin North Am 2001; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/13\">",
"      Mulvihill A, MacCann A, Flitcroft I, O'Keefe M. Outcome in refractive accommodative esotropia. Br J Ophthalmol 2000; 84:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/14\">",
"      Guthrie ME, Wright KW. Congenital esotropia. Ophthalmol Clin North Am 2001; 14:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/15\">",
"      Helveston EM. Congenital esotropia in perspective. J AAPOS 1998; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/16\">",
"      von Noorden GK. A reassessment of infantile esotropia. XLIV Edward Jackson memorial lecture. Am J Ophthalmol 1988; 105:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/17\">",
"      Neely DE, Helveston EM, Thuente DD, Plager DA. Relationship of dissociated vertical deviation and the timing of initial surgery for congenital esotropia. Ophthalmology 2001; 108:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/18\">",
"      Wilson ME, McClatchey SK. Dissociated horizontal deviation. J Pediatr Ophthalmol Strabismus 1991; 28:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/19\">",
"      Guyton DL. Dissociated vertical deviation: etiology, mechanism, and associated phenomena. Costenbader Lecture. J AAPOS 2000; 4:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/20\">",
"      Calcutt C, Murray AD. Untreated essential infantile esotropia: factors affecting the development of amblyopia. Eye (Lond) 1998; 12 ( Pt 2):167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/21\">",
"      Dickey CF, Metz HS, Stewart SA, Scott WE. The diagnosis of amblyopia in cross-fixation. J Pediatr Ophthalmol Strabismus 1991; 28:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/22\">",
"      Alexandrakis G, Saunders RA. Duane retraction syndrome. Ophthalmol Clin North Am 2001; 14:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/23\">",
"      Helveston EM, Neely DF, Stidham DB, et al. Results of early alignment of congenital esotropia. Ophthalmology 1999; 106:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/24\">",
"      Birch EE, Fawcett S, Stager DR. Why does early surgical alignment improve stereoacuity outcomes in infantile esotropia? J AAPOS 2000; 4:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/25\">",
"      McNeer KW, Tucker MG, Spencer RF. Management of essential infantile esotropia with botulinum toxin A: review and recommendations. J Pediatr Ophthalmol Strabismus 2000; 37:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/26\">",
"      Tejedor J, Rodr&iacute;guez JM. Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin. Br J Ophthalmol 1999; 83:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/27\">",
"      Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev 2012; 2:CD006499.",
"     </a>",
"    </li>",
"    <li>",
"     Duane retraction syndrome 1; DURS1. file://omim.org/entry/126800 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/29\">",
"      Parsa CF, Grant PE, Dillon WP Jr, et al. Absence of the abducens nerve in Duane syndrome verified by magnetic resonance imaging. Am J Ophthalmol 1998; 125:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/30\">",
"      Appukuttan B, Gillanders E, Juo SH, et al. Localization of a gene for Duane retraction syndrome to chromosome 2q31. Am J Hum Genet 1999; 65:1639.",
"     </a>",
"    </li>",
"    <li>",
"     Duane retraction syndrome 2; DURS2. file://omim.org/entry/604356 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/32\">",
"      Kim JH, Hwang JM. Presence of the abducens nerve according to the type of Duane's retraction syndrome. Ophthalmology 2005; 112:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/33\">",
"      Kim JH, Hwang JM. Abducens nerve is present in patients with type 2 Duane's retraction syndrome. Ophthalmology 2012; 119:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/34\">",
"      Denis D, Dauletbekov D, Girard N. Duane retraction syndrome: Type II with severe abducens nerve hypoplasia on magnetic resonance imaging. J AAPOS 2008; 12:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/35\">",
"      Huber A. Electrophysiology of the retraction syndromes. Br J Ophthalmol 1974; 58:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/36\">",
"      Calabrese G, Stuppia L, Morizio E, et al. Detection of an insertion deletion of region 8q13-q21.2 in a patient with Duane syndrome: implications for mapping and cloning a Duane gene. Eur J Hum Genet 1998; 6:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/37\">",
"      Evans JC, Frayling TM, Ellard S, Gutowski NJ. Confirmation of linkage of Duane's syndrome and refinement of the disease locus to an 8.8-cM interval on chromosome 2q31. Hum Genet 2000; 106:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/38\">",
"      Miyake N, Chilton J, Psatha M, et al. Human CHN1 mutations hyperactivate alpha2-chimaerin and cause Duane's retraction syndrome. Science 2008; 321:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/39\">",
"      DeRespinis PA, Caputo AR, Wagner RS, Guo S. Duane's retraction syndrome. Surv Ophthalmol 1993; 38:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/40\">",
"      Sevel D, Kassar BS. Bilateral Duane syndrome. Occurrence in three successive generations. Arch Ophthalmol 1974; 91:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/41\">",
"      Marshman WE, Schalit G, Jones RB, et al. Congenital anomalies in patients with Duane retraction syndrome and their relatives. J AAPOS 2000; 4:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/42\">",
"      Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     Moebius syndrome 1; MBS1 file://omim.org/entry/157900 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     Facial paresis, hereditary, congenital; (HCFP1); formerly Moebius syndrome 2. www.ncbi.nlm.nih.gov:80/entrez/dispomim.cgi?id=601471 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/45\">",
"      Slee JJ, Smart RD, Viljoen DL. Deletion of chromosome 13 in Moebius syndrome. J Med Genet 1991; 28:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/46\">",
"      Ziter FA, Wiser WC, Robinson A. Three-generation pedigree of a M&ouml;bius syndrome variant with chromosome translocation. Arch Neurol 1977; 34:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/47\">",
"      Kremer H, Kuyt LP, van den Helm B, et al. Localization of a gene for M&ouml;bius syndrome to chromosome 3q by linkage analysis in a Dutch family. Hum Mol Genet 1996; 5:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/48\">",
"      Rojas-Mart&iacute;nez A, Garc&iacute;a-Cruz D, Rodr&iacute;guez Garc&iacute;a A, et al. Poland-Moebius syndrome in a boy and Poland syndrome in his mother. Clin Genet 1991; 40:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/49\">",
"      Pastuszak AL, Sch&uuml;ler L, Speck-Martins CE, et al. Use of misoprostol during pregnancy and M&ouml;bius' syndrome in infants. N Engl J Med 1998; 338:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/50\">",
"      Govindan M, Mohney BG, Diehl NN, Burke JP. Incidence and types of childhood exotropia: a population-based study. Ophthalmology 2005; 112:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/51\">",
"      Mohney BG, Huffaker RK. Common forms of childhood exotropia. Ophthalmology 2003; 110:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/52\">",
"      Hutchinson AK. Intermittent exotropia. Ophthalmol Clin North Am 2001; 14:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/53\">",
"      Coats DK, Paysse EA, Kim DS. Excessive blinking in childhood: a prospective evaluation of 99 children. Ophthalmology 2001; 108:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/54\">",
"      Ekdawi NS, Nusz KJ, Diehl NN, Mohney BG. The development of myopia among children with intermittent exotropia. Am J Ophthalmol 2010; 149:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/55\">",
"      Kushner BJ, Morton GV. Distance/near differences in intermittent exotropia. Arch Ophthalmol 1998; 116:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/56\">",
"      Coffey B, Wick B, Cotter S, et al. Treatment options in intermittent exotropia: a critical appraisal. Optom Vis Sci 1992; 69:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/57\">",
"      Buck D, Powell CJ, Sloper JJ, et al. Surgical intervention in childhood intermittent exotropia: current practice and clinical outcomes from an observational cohort study. Br J Ophthalmol 2012; 96:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/58\">",
"      Spoor DK, Hiles DA. Occlusion therapy for exodeviations occurring in infants and young children. Ophthalmology 1979; 86:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/59\">",
"      Caltrider N, Jampolsky A. Overcorrecting minus lens therapy for treatment of intermittent exotropia. Ophthalmology 1983; 90:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/60\">",
"      Kushner BJ. Does overcorrecting minus lens therapy for intermittent exotropia cause myopia? Arch Ophthalmol 1999; 117:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/61\">",
"      Duckman RH. Management of binocular anomalies: efficacy of vision therapy, exotropia. Am J Optom Physiol Opt 1987; 64:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/62\">",
"      Convergence Insufficiency Treatment Trial Study Group. Randomized clinical trial of treatments for symptomatic convergence insufficiency in children. Arch Ophthalmol 2008; 126:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/63\">",
"      Wallace DK. Treatment options for symptomatic convergence insufficiency. Arch Ophthalmol 2008; 126:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/64\">",
"      Ing MR, Nishimura J, Okino L. Outcome study of bilateral lateral rectus recession for intermittent exotropia in children. Trans Am Ophthalmol Soc 1997; 95:433.",
"     </a>",
"    </li>",
"    <li>",
"     Fibrosis of extraocular muscles, congenital, 2;FEOM2. file://omim.org/entry/602078 (Accessed on February 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/66\">",
"      Nakano M, Yamada K, Fain J, et al. Homozygous mutations in ARIX(PHOX2A) result in congenital fibrosis of the extraocular muscles type 2. Nat Genet 2001; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41800/abstract/67\">",
"      Wang SM, Zwaan J, Mullaney PB, et al. Congenital fibrosis of the extraocular muscles type 2, an inherited exotropic strabismus fixus, maps to distal 11q13. Am J Hum Genet 1998; 63:517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6265 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-5CD169F5DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41800=[""].join("\n");
var outline_f40_52_41800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESODEVIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Accommodative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Idiopathic infantile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duane syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abducens nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sensory esotropia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Moebius syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EXODEVIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intermittent exotropia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oculomotor nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Congenital fibrosis of the extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6265|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/23/29040\" title=\"figure 1\">",
"      Corneal light reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6265|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/8/32902\" title=\"picture 1\">",
"      Accommodative esotropia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/38/2661\" title=\"picture 2\">",
"      Congenital esotropia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/17/35092\" title=\"picture 3\">",
"      Duane syndrome type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/49/2836\" title=\"picture 4\">",
"      Duane syndrome type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/28/27074\" title=\"picture 5\">",
"      Duane syndrome type 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/22/35175\" title=\"picture 6\">",
"      Convergence insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/26/16805\" title=\"picture 7\">",
"      Ptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/58/38827\" title=\"table 1\">",
"      Actions extraocular muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/36/2636\" title=\"table 2\">",
"      Etiology third nerve palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26790?source=related_link\">",
"      Causes of vertical strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/58/27553?source=related_link\">",
"      Patient information: Crossed eyes and lazy eye (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41801="Asperger disorder: Management and prognosis in children and adolescents";
var content_f40_52_41801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Asperger disorder: Management and prognosis in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     L. Erik von Hahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41801/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/52/41801/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Psychiatric Association recognized Asperger disorder as a specific entity by publishing diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) in 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/1\">",
"     1",
"    </a>",
"    ]. A modest but growing literature on Asperger disorder has emerged since then, though questions remain about Asperger disorder as a distinct clinical entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The DSM-V may propose a classification scheme that subsumes Asperger disorder under the general term &ldquo;autism spectrum disorder&rdquo;.",
"   </p>",
"   <p>",
"    The management and prognosis of Asperger disorder will be reviewed here. The clinical features and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15689?source=see_link\">",
"     \"Asperger disorder: Clinical features and diagnosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management and prognosis of autism and pervasive developmental disorder-not otherwise specified also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/872?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with Asperger disorder have varying degrees of impairment in social and behavioral function (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"mobipreview.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15689?source=see_link\">",
"     \"Asperger disorder: Clinical features and diagnosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of children with Asperger disorder is individualized according to the child's age and needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. It requires a multidisciplinary approach that makes use of the child's strengths (eg, verbal cognitive ability, formal language skills) to address his or her weaknesses (eg, nonverbal and social problem-solving skills, pragmatic language skills) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, adherence to rules and routines may be exploited to develop positive habits (eg, using verbal algorithms to handle social interactions: \"Look, listen, think, and then respond\" when engaged in conversation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interventions that are used in the management of Asperger disorder are informed by psychotherapeutic and educational literature but have not been studied systematically. They typically are carried out by mental health professionals, developmental pediatricians, and special education personnel.",
"   </p>",
"   <p>",
"    The types of interventions that may be used in the management of Asperger disorder are described below. In children with developmental disabilities in general, and in children with Asperger disorder specifically, it is difficult to identify and address developmental deficits in isolation, as they are all interrelated. As such, interventions cannot be parceled out to individual specialists. Everyone on the child's team must be aware of the child's weaknesses and work to address them in a variety of classroom and community settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BEHAVIORAL AND EDUCATIONAL INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral and educational interventions for autism spectrum disorders are discussed separately. A review of behavioral treatments for autism spectrum disorders, with specific mention of treatments for Asperger disorder, is available in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Behavioral and educational interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Emotional regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overarousal and anxiety may occur when the child is faced with certain sensory inputs (eg, crowded room, thunderstorm) or challenges to his or her cognitive self-regulation (eg, changes to routine or schedule). Overarousal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety must be addressed, if present, before other interventions can be implemented. The goal is to allow the child to interact with the environment in a more adaptive manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/8\">",
"     8",
"    </a>",
"    ]. Behavioral and educational interventions for anxiety are discussed here. Psychopharmacologic interventions for anxiety are discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Anxiety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382756035\">",
"    <span class=\"h3\">",
"     Accommodations and treatment for arousal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions to reduce the level of sensory inputs may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Providing part or all of education in a smaller setting with fewer children",
"     </li>",
"     <li>",
"      Installing carpet or pads under desks and chairs to reduce excessive noise in the classroom",
"     </li>",
"     <li>",
"      Reducing exposure to tactile inputs, such as uncomfortable clothing, etc",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, occupational therapists can provide sensory-regulation strategies using the treatments that are used for so-called \"sensory integration dysfunction\". These therapies may involve graded and systematic stimulation with specific sensory stimuli, which can attenuate the student's over-responsiveness to the stimuli. Other activities, which typically are motor based (eg, swinging, jumping on a trampoline), may be used to calm the child. These activities may need to be offered throughout the day so that the child can participate in learning. The efficacy of sensory integration therapy has not been objectively demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. However, use in individual cases may be warranted if empirical benefit is demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382756042\">",
"    <span class=\"h3\">",
"     Teaching a vocabulary for emotions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with Asperger disorder commonly require specific teaching in the identification of emotions (in self and others) and may also require specific teaching in the use of strategies to help regulate emotions. Once individuals with Asperger disorder learn to label feelings, they can be taught to use emotion-regulation strategies (eg, sensory or other strategies to regulate feelings; breathing to help refocus on the task at hand). Emotional self-regulation skills can be taught at school or in clinic settings, by occupational therapists (sensory strategies), guidance counselors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychologists. During the teenage years, mental health services are commonly needed to address anxiety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Counseling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382756049\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of formal cognitive-behavioral therapy (CBT) in the treatment of anxiety in individuals with autism spectrum disorders is not yet clear. In CBT for anxiety in children without autism spectrum disorders, the child is taught about anxiety and how to restructure his or her thoughts about the anxiety. The child also is exposed to situations that provoke anxiety and taught how to tolerate those situations more successfully. Such techniques can also be used in children with autism spectrum disorders, though they may need to be embedded into the child&rsquo;s education in communication skills, social skills, and goal-setting skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382756064\">",
"    <span class=\"h3\">",
"     Parent involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parent involvement in treatment for anxiety, as well as for other aspects of autism, is critical to the child&rsquo;s success. A review of parent involvement in the treatment of anxiety in children with high-functioning autism is available in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Executive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with Asperger disorder have difficulty \"seeing the big picture\", which affects social interactions and a wide range of adaptive functions. They tend to over-focus on their preferred topics and interests to the exclusion of completion of other tasks (eg, homework, activities of daily living, social interactions etc). This difficulty with &ldquo;staying focused&rdquo; and &ldquo;seeing the bigger picture&rdquo; is often similar to the type of difficulty seen in children with attention deficit hyperactivity disorder (ADHD). The behavioral strategies to facilitate task completion are thus also similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link&amp;anchor=H966764713#H966764713\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with Asperger disorder typically do better when they are provided with an environment that is structured, organized, and organizing. They may need extra prompts and reminders to stay on task and to complete tasks. Task lists, organizers, visual schedules, and clearly defined behavioral and learning expectations are important strategies to reduce confusion and its attendant frustration and behavior disturbances, to increase on-task behavior, and to improve learning. Strategic seating in the classroom can make it easier for classroom staff to provide more frequent check-ins and assure that the student stays on task and completes tasks. Organizational strategies must be supported in all settings (eg, school, home, community) and used by all of the personnel involved in the child's education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Language skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Asperger disorder do not use or understand language normally. They need explicit guidance about how the meaning of language can change with changes in tone of voice or intonation, and how to pair language with nonverbal communication.",
"   </p>",
"   <p>",
"    Speech and language therapy for children with Asperger disorder focuses on the use of language in social settings and the nuances of ambiguous language.",
"   </p>",
"   <p>",
"    Strategies that may enhance understanding for children with Asperger disorder include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding the use of abstract terms, metaphors, idioms",
"     </li>",
"     <li>",
"      Providing instruction that is concrete and explicit",
"     </li>",
"     <li>",
"      Asking the student to repeat what was said",
"     </li>",
"     <li>",
"      Providing frequent interpretations of social events or interactions",
"     </li>",
"     <li>",
"      Using visual supports",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At the same time, children with Asperger disorder can be taught about ambiguities in language and can be taught to ask for clarification when they are not sure about what was said. This facilitates conversations with unfamiliar peers or adults who may not know about their language differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Social skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social-skills deficits in children with Asperger disorder include impairments in the use of nonverbal behaviors (eg, eye contact, facial expression), failure to develop appropriate peer relationships, and a lack of social or emotional reciprocity (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"mobipreview.htm?12/57/13212\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Social-skills training programs are designed to teach children the skills to help them to navigate the social environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/16\">",
"     16",
"    </a>",
"    ]. Social skills intervention programs have measurable benefits, but heterogeneity in the training programs (ie, whether or not formal psychotherapeutic techniques such as cognitive-behavioral therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inclusion of parents in the training program) make it difficult to know which components of the training program are the most effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/17\">",
"     17",
"    </a>",
"    ]. Although social-skills training is associated with measurable improvements in explicitly taught skills, subsequent performance in real-time social interactions may not reflect the skills acquired in the training setting. Videotaping and role-playing can help to mimic real-life situations, but monitoring by adults outside of formal learning settings is often necessary to assure social success. As such, it is helpful for parents, teachers, and other professionals to reinforce the lessons learned during social skills training sessions by reminding the",
"    <span class=\"nowrap\">",
"     child/student",
"    </span>",
"    of social skills lessons and applying them to everyday social interactions at home, at school, and in the community.",
"   </p>",
"   <p>",
"    Social-skills training may include the following areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic social skills (social conventions). Basic social-skills training teaches social conventions, such as greetings, taking turns, sharing toys or conversational topics, understanding the rules of certain environments, knowing how to speak to unfamiliar adults, etc.",
"     </li>",
"     <li>",
"      Conversational skills. Conversational skills are best taught in a group setting. Strategies may include the provision of scripts to help open conversations or manage routine situations in the community (eg, making purchases at the grocery store) or teaching an explicit linear sequence for conversation (\"Look, listen, think, and then respond\").",
"     </li>",
"     <li>",
"      Social cognition. Children with Asperger disorder can be taught to pay attention to the verbal and nonverbal language of social interactions by using linear sequences. They can be asked to identify the words, facial expressions, or gestures and to think about the different meanings that may be intended.",
"     </li>",
"     <li>",
"      Real-time social participation. Adults can help children with Asperger disorder in real-life social situations by providing a game plan before the event or situation. The event can be planned out in advance with a picture or list so the child can know what to expect. Once at the event, the child can be taught to use a nonverbal signal to indicate that he or she needs help or to stop what they are doing and respond to the adult when the adult thinks that help is needed. A few scripts can be memorized to initiate social interactions or to help with difficult or confusing situations (eg, \"I'm confused, can you please say that another way?\").",
"      <br/>",
"      <br/>",
"      Adult supervision is necessary to teach the individual with Asperger disorder about teasing and bullying (eg, how to differentiate peers who are being friendly versus peers who are not). Adult supervisors can step in and mediate situations that the individual with Asperger disorder is not able to recognize or manage on his or her own. Adult guidance and supervision is also necessary in the use of the Internet, given the special nature of social interactions that occur via screen-based activities.",
"     </li>",
"     <li>",
"      Self-advocacy. As they become more familiar with their own differences, individuals with Asperger disorder can help others understand their limitations. As examples, they can be taught to ask others to repeat statements when they are unsure of what they are being told, or explain to peers that they do not always remember to let others talk or give a peer a turn; they can ask their peers for feedback should this occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adaptive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adaptive function needs to be assessed throughout the child's school career. Although performance in strictly academic domains may be normal or above average, many individuals with Asperger disorder perform poorly when asked to complete tasks at home or in the community. They may not be able to order food or behave appropriately in a restaurant, make purchases in a grocery store, manage their personal care, manage household tasks, etc. Academic success is less meaningful if the",
"    <span class=\"nowrap\">",
"     child/student",
"    </span>",
"    remains dependent upon adults to manage other, more routine tasks of the day and if the",
"    <span class=\"nowrap\">",
"     child/student",
"    </span>",
"    is unable to use knowledge in context.",
"   </p>",
"   <p>",
"    Adaptive-skills or life-skills training can form part of the child's social-skills training but may also need to be addressed as a separate component of the child&rsquo;s individualized education program. Adaptive skills can be taught explicitly through scheduling, practicing, and rehearsing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/6\">",
"     6",
"    </a>",
"    ]. Specific target areas can be identified from scores on adaptive behavior scales (eg, the Vineland Adaptive Behavior Scale, Scales of Independent Behavior-Revised, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461586015\">",
"    <span class=\"h2\">",
"     Motor skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Students with Asperger disorder are often clumsier than their peers and may need accommodations for handwriting or adaptations for physical education classes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461586075\">",
"    <span class=\"h2\">",
"     Educational plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational difficulties for children with Asperger disorder include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obsessive and restricted range of interests, and their interference with participation in social and academic",
"      <span class=\"nowrap\">",
"       tasks/activities",
"      </span>",
"     </li>",
"     <li>",
"      Generalizing their knowledge to areas outside the classroom",
"     </li>",
"     <li>",
"      Separating relevant information from irrelevant information",
"     </li>",
"     <li>",
"      Attending to salient social and curricular cues",
"     </li>",
"     <li>",
"      Fine motor skills (affects handwriting, art, industrial arts)",
"     </li>",
"     <li>",
"      A concrete and literal thinking style",
"     </li>",
"     <li>",
"      Poor problem-solving and organizational skills",
"     </li>",
"     <li>",
"      Multitasking, such as writing and listening at the same time (which affects the ability to take notes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The educational plan should be tailored to the child's neuropsychologic profile. It should include a formulation of individualized goals and objectives, strategies and supports, and assessment of progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Environmental structure and support are necessary to allow the child to anticipate and understand activities, schedules, and expectations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/6,18\">",
"     6,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A complete discussion of other educational interventions for children with Asperger disorder is beyond the scope of this review. References [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/18\">",
"     18",
"    </a>",
"    ] and [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/19\">",
"     19",
"    </a>",
"    ] review approaches used in educational settings, some of which are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Priming or previewing (familiarizing students with material before it is used in the classroom, which helps to make new tasks predictable and reduces stress and anxiety).",
"     </li>",
"     <li>",
"      Classroom assignment modifications, such as decreasing the amount of reading, provision of highlighted texts or study guides, allowing verbal response rather than written essays, etc.",
"     </li>",
"     <li>",
"      Note-taking (providing a complete or skeleton outline so that the student does not have to take so many notes).",
"     </li>",
"     <li>",
"      Use of graphic organizers (eg, timelines) to highlight important concepts and display the relationships between them.",
"     </li>",
"     <li>",
"      Enrichment activities for students who have already mastered curriculum content.",
"     </li>",
"     <li>",
"      Use of scheduling, scripts, rules, and lists to help with organization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the early school years, academic support typically centers on the student's need for organization and structure. However, organizational supports often are needed throughout the student&rsquo;s school career. These supports consist of strategies that are similar to those used for children with ADHD. After grade four, academic support is necessary for impairments in reading comprehension and written language skills, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Academic supports for reading and writing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite normal intelligence, most children with Asperger disorder require academic support for reading and writing, particularly during the middle and high school years. Some school teams do not recognize the pragmatic language, reading, and writing impairments of children with Asperger disorder and do not provide the necessary support. This may occur because children with Asperger disorder usually are verbal and appear knowledgeable. They often perform in the normal range during formal testing situations, in which the child is asked to respond to discrete questions and complete well-defined tasks in a highly structured setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Reading",
"      </strong>",
"      &ndash; Reading can be challenging for children with Asperger disorder, particularly after they reach grade three or four and when they are required to read passages of text not related to their preferred interest. Children with Asperger disorder are likely to focus on irrelevant details in the text. They have a limited capacity to see the \"big picture\" and to answer comprehension questions that require inference or reasoning skills. Organizing the child's approach to reading is an important intervention. Reading comprehension improves when children with Asperger disorder are provided with a systematic method for analyzing text (eg, identifying the topic sentence for each paragraph, summarizing the supporting statements in each paragraph, etc).",
"     </li>",
"     <li>",
"      <strong>",
"       Writing",
"      </strong>",
"      &ndash; Writing also can be challenging for children with Asperger disorder. They may write long passages of text that are focused on details and are tangential. Graphic organizers (eg, charts and written algorithms) are useful in helping the student to follow a writing format that includes a main idea with correctly placed supporting details.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H387094610\">",
"    <span class=\"h3\">",
"     Transition planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;As youth with Asperger disorder approach adulthood, their individualized education program (IEP) should include transition planning. Transition planning refers to the planning needed to assure the greatest independence in adult life. A review of transition planning for children with Asperger disorder is provided in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health counseling, ideally by someone familiar with Asperger disorder, should be included as part of management. The goals of mental health counseling are successful identification of emotions, an important tool for self-regulation. These skills can be reinforced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    integrated into the educational program and self-advocacy-skills training. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Emotional regulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychopharmacologic interventions may be a useful adjunct to",
"    <span class=\"nowrap\">",
"     behavioral/environmental",
"    </span>",
"    interventions for comorbid symptoms and conditions in children with Asperger disorder. Psychopharmacologic agents do not treat Asperger disorder itself and should be initiated only after appropriate educational and behavioral interventions are in place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles for the psychopharmacologic management of individuals with Asperger disorder are the same as for individuals with other psychiatric conditions. Medications should be used to target specific symptoms, and symptoms should be measured over time (preferably using rating scales) to monitor efficacy. Children with Asperger disorder should have periodic trials off of medication; as the child gains greater understanding and self-confidence, medication may become unnecessary.",
"   </p>",
"   <p>",
"    Children with Asperger disorder do not respond to psychopharmacologic agents the same way as typical children. Children with Asperger disorder are more sensitive to medication effects and more likely to have adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, given their weaknesses communicating and identifying their emotions, it can be difficult to determine the predominant target symptom (eg, anxiety, depression, impulsivity, anger), and, therefore, it can also be difficult to identify the best psychopharmacologic agent.",
"   </p>",
"   <p>",
"    Although psychopharmacotherapy for children and adolescents with Asperger disorder is ideally prescribed by specialists familiar with Asperger disorder (eg, developmental pediatricians, child psychiatrists, etc), access to such specialists is not always available. Primary care clinicians who undertake the prescription of psychotropic agents to individuals on the autism spectrum should do so in consultation with a developmental pediatrician, a child psychiatrist, or another mental health professional who is familiar with this population to understand target symptoms correctly and to choose an appropriate medication. Medications should be started at lower doses, doses should be increased more slowly, and patients should be monitored for side effects more closely than for patients without Asperger disorder.",
"   </p>",
"   <p>",
"    There are few studies on psychopharmacologic interventions in children and adolescents with Asperger disorder. Most of the information about the psychopharmacologic treatment for Asperger disorder is extrapolated from studies on autism in general",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from studies on conditions comorbid with Asperger disorder, such as anxiety or attention deficit hyperactivity disorder (ADHD). Studies of pharmacotherapy in children with autism generally are small, retrospective, and open label. They typically do not include exposure to behavioral or educational interventions as a first step [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/21\">",
"     21",
"    </a>",
"    ]. That being said, there are well-designed prospective randomized controlled trials that demonstrate the beneficial effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    in the treatment of disruptive behaviors, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    in the treatment of disruptive behaviors and",
"    <span class=\"nowrap\">",
"     hyperactivity/inattention",
"    </span>",
"    in children with autism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/23-28\">",
"     23-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The psychopharmacologic approaches described below are targeted to specific symptoms and comorbid conditions. No pharmacologic treatments target core social perception or the pragmatic language deficits of Asperger disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety may present as fearfulness of certain situations or in response to certain triggers, obsessive-compulsive behaviors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disruptive behaviors and difficulty managing anger.",
"   </p>",
"   <p>",
"    Anxiety in children with Asperger disorder is treated with the same therapies that are used to treat anxiety in other children. Pharmacotherapy is one arm of a multimodal approach that may include individual therapy, cognitive behavioral therapy, and behavioral",
"    <span class=\"nowrap\">",
"     interventions/incentives;",
"    </span>",
"    accommodations to address sensory sensitivities; and special education services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/29\">",
"     29",
"    </a>",
"    ]. The components of the multimodal therapy may vary from patient to patient.",
"   </p>",
"   <p>",
"    The role of selective serotonin reuptake inhibitors (SSRI) in the treatment of anxiety in patients with autism spectrum disorders (ASD) is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/30\">",
"     30",
"    </a>",
"    ]. There are no randomized trials that specifically assess the efficacy of SSRI in individuals with Asperger disorder. However, in a meta-analysis of randomized controlled trials in children without ASD, selective serotonin reuptake inhibitors (SSRI) were more effective than placebo in reducing core symptoms of anxiety in children and adolescents (58 versus 31 percent, relative risk of response 1.9, 95% CI 1.6-2.26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, in a randomized crossover trial,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    was beneficial in the treatment of repetitive behaviors in childhood and adolescent autism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the beneficial effects of SSRI in the treatment of anxiety in children without ASD and their success in the treatment of repetitive behaviors, which are sometimes linked to anxiety, it is reasonable to try SSRI for children with Asperger disorder who also have anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/33\">",
"     33",
"    </a>",
"    ]. The choice of SSRI depends mostly on personal preference and familiarity.",
"   </p>",
"   <p>",
"    Individuals with Asperger disorder may respond to very low doses of these agents, but typical pediatric dosing may be necessary. It is important to \"start low and go slow\". As a general guideline, the following doses are used in the clinic of the author of this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/63/33785?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      is initiated at 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for preschool and early-school-age children, and up to 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for teenagers, The dose is titrated upward over the course of several weeks until symptoms improve, using a total dose of 5 to 40",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/18/7465?source=see_link\">",
"       Sertraline",
"      </a>",
"      is initiated at 12.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for preschool and early-school-age children, and 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for teenagers. The dose is titrated upward to a total daily dose of 50 to 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over the course of several weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hyperactivity and inattention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Asperger disorder can be hyperactive, inattentive, and disorganized. These behaviors may be related to comorbid attention deficit hyperactivity disorder (ADHD) or to other factors that affect function in children with Asperger disorder (eg, overarousal and anxiety). If the behaviors do not improve with environmental or behavioral interventions, they may respond to stimulant medications,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    . They may respond to an SSRI if the hyperactivity or inattention is due to anxiety. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Anxiety'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stimulant medications",
"      </strong>",
"      &ndash; The response rate to stimulants is lower in ASD than it is in ADHD without ASD. In a well-designed randomized trial, effect sizes ranged from 0.29 to 0.54, depending upon dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/34\">",
"       34",
"      </a>",
"      ]. This contrasts with effect sizes of 0.73 to 0.96 in children with ADHD without ASD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/35\">",
"       35",
"      </a>",
"      ]. Children with ASD also have a higher rate of adverse reactions (eg, irritability, anxiety, and aggression) to stimulant therapy than children without ASD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/27\">",
"       27",
"      </a>",
"      ]. Despite the lower response rate and increased risk of adverse effects, a trial of stimulants may be warranted if symptoms of hyperactivity, inattention, and impulsivity do not respond to environmental and behavioral interventions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The use of stimulants and other medications for symptoms of hyperactivity, inattention, and impulsivity is discussed separately. The same treatment strategies used in the treatment of ADHD apply to individuals with Asperger disorder who have symptoms of ADHD (ie, use a stimulant medication before using a second-line agent). However, \"start low and go slow\" is a useful adage to keep in mind. As an example, a preschool or early-school-age child could be started with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      at 2.5 mg or 5 mg once or twice daily to assess tolerance before titrating upward to assess therapeutic effect. A teenager could be started with methylphenidate 10 mg once or twice daily before titrating upward. In the author&rsquo;s clinic, families are typically asked to use the first dose of the medication on a weekend day so that they can monitor for side effects. If well tolerated and effective, the child can subsequently be sent to school on medications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=see_link&amp;anchor=H2007898721#H2007898721\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Dose titration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"       Atomoxetine",
"      </a>",
"      &ndash; Children with Asperger disorder who have inattention and distractibility may respond more positively to second-line agents for ADHD (eg, atomoxetine) than to stimulants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/36\">",
"       36",
"      </a>",
"      ]. Atomoxetine is theoretically a good choice for individuals with ASD because it targets both inattention and hyperarousal. However, as with stimulants, the overall effect sizes for second-line agents are smaller than for children with isolated ADHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha 2 adrenergic agonists",
"      </strong>",
"      &ndash; Alpha-2-adrenergic agonists (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/53/42839?source=see_link\">",
"       guanfacine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      ) also may be useful in individuals with Asperger disorder, particularly those who have sensory sensitivities and a high state of arousal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/27,36-38\">",
"       27,36-38",
"      </a>",
"      ]. Randomized controlled trials of these agents in children with autism are limited by small size [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate identification of depression in children and adolescents with Asperger disorder is a major challenge because they are less likely than other youth to correctly identify and monitor mood symptoms. Depressive symptoms in children and adolescents with Asperger disorder may be exacerbated by negative social experiences (eg, isolation, marginalization, and bullying) and increased awareness of differences and social difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. Depression is more likely to occur in older children",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    teenagers with Asperger disorder.",
"   </p>",
"   <p>",
"    Antidepressant therapy may be indicated if depressive symptoms persist despite counseling and psychosocial interventions. The same medications that are used for depression in typical children can be used to treat symptoms of depression in children with Asperger disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link\">",
"     \"Psychopharmacological treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of SSRI and serotonin norepinephrine reuptake inhibitors (SNRI) in the treatment of children with ASD has not been documented through a sufficient number of randomized controlled trials to draw any firm conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/30\">",
"     30",
"    </a>",
"    ]. Nonetheless,",
"    <span class=\"nowrap\">",
"     SSRI/SNRI",
"    </span>",
"    may be warranted for individuals with Asperger disorder who demonstrate clear symptoms of depression (eg, terminal insomnia, psychomotor disturbance, anorexia, changes in mood from baseline, etc). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using antidepressants to treat depressive symptoms in children and adolescents with Asperger disorder, the clinician must be mindful of the increased incidence of behavioral activation (impulsivity, silliness, agitation, and disinhibition) and other side effects, including a potentially increased risk of suicidal ideation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link&amp;anchor=H18#H18\">",
"     \"Psychopharmacological treatment for adolescent depression\", section on 'Adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with Asperger disorder may respond to very low doses of",
"    <span class=\"nowrap\">",
"     SSRI/SNRI,",
"    </span>",
"    but typical pediatric doses may be necessary. It is important to \"start low and go slow\". General guidelines for dosing of SSRI in children and adolescents with Asperger disorder are provided above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Anxiety'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mood stabilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsants (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/23/35191?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/34/3626?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ) may be indicated for mood stabilization if there is evidence of mood swings and a mood disorder (eg, bipolar disorder) despite educational and behavioral interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Disruptive behaviors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruptive behaviors include aggression, tantrums, and self-injury. These behaviors may occur in response to anxiety and frustration, often related to rigid thinking patterns and difficulty with social cognition (ie, cognitive features of Asperger disorder, as opposed to strictly emotional ones). If present, these should be the first targets of management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/22\">",
"     22",
"    </a>",
"    ]. Disruptive behaviors can also be due to anxiety disorders, mood disorders, or impulse control problems. The behavioral and psychopharmacologic agent of choice to treat the behavior depends upon the postulated cause of the disruptive behavior.",
"   </p>",
"   <p>",
"    Pharmacotherapy may be indicated if nonpharmacologic therapies are unsuccessful. Pharmacologic interventions may initially be targeted toward anxiety or impulse control. Treatments for anxiety and impulse control problems may not be effective for managing disruptive behaviors, however, at which point treatment with an atypical antipsychotic agent may be warranted. We suggest",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    , an atypical antipsychotic, for disruptive behaviors unresponsive to interventions for anxiety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impulse control problems, or when the disruptive behaviors are believed to be due to anger dysregulation alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized controlled trials and systematic reviews indicate a positive response to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    in individuals with autism and disruptive behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/23-26,41-43\">",
"     23-26,41-43",
"    </a>",
"    ]. In a multisite, placebo-controlled trial of 101 children with autism, treatment with risperidone for eight weeks was associated with improvement in tantrums, aggression, and self-injurious behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized controlled trials,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    was also effective, but less so than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/44\">",
"     44",
"    </a>",
"    ]. Different atypical antipsychotic agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/31/13817?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34185?source=see_link\">",
"     olanzapine",
"    </a>",
"    ) and different classes of drugs (eg, alpha-2 agonists, anticonvulsant mood stabilizers,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    , SSRI, and beta blockers) have been used to treat disruptive behaviors in children and adolescents with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. However, there is less clinical experience with these agents, and they are not as well studied as risperidone. Risperidone is the most commonly used antipsychotic for the treatment of disruptive behaviors in children with ASD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/45\">",
"     45",
"    </a>",
"    ]. Given its beneficial effects in children with ASD, it is a reasonable therapy for children with Asperger disorder.",
"   </p>",
"   <p>",
"    Dosing of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     \"Risperidone: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    include weight gain, increased appetite, hyperlipidemia, insulin resistance, fatigue, drowsiness, dizziness, and drooling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/46\">",
"     46",
"    </a>",
"    ]. Less common but more concerning side effects associated with antipsychotic medications include dystonic reactions, tardive dyskinesia, akathisia (subjective sense of restlessness, often accompanied by voluntary movements of the limbs or trunk), and neuroleptic malignant syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/23,24,26,47\">",
"     23,24,26,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    should be monitored for adverse effects with routine office visits and periodic blood tests. A consensus statement from the American Psychiatric Association, the American Diabetes Association, and others includes a baseline assessment of weight, blood pressure, fasting plasma glucose, and fasting lipid profile for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/48\">",
"     48",
"    </a>",
"    ]. The author's clinic also monitors complete blood count, liver function tests, and an electrocardiogram at baseline, and reassesses weight, blood pressure, fasting glucose, fasting lipid profile, and liver function tests at three months and every three to six months thereafter, depending upon drug dose changes or the discovery of metabolic abnormalities.",
"   </p>",
"   <p>",
"    Switching to another antipsychotic agent is commonly recommended if there is excessive weight gain or other adverse effects.",
"   </p>",
"   <p>",
"    Discontinuation of medication may be warranted depending upon symptom severity. This is especially true if the individual has been treated for a long interval (ie, a year or more) and would benefit from a trial off medications to reassess efficacy and need for treatment. Withdrawal of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"     risperidone",
"    </a>",
"    and other antipsychotics is often accompanied by a period of behavioral dysregulation. Successful discontinuation of risperidone requires a gradual taper over several weeks to months. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     FAMILY SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supporting the family and siblings is a crucial aspect of management of children and adolescents with Asperger disorder and other autism spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/8\">",
"     8",
"    </a>",
"    ]. Supporting the family may include providing education about autism spectrum disorders, anticipatory guidance, help with access to resources, emotional support, and help with advocacy for service or educational programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that assess outcomes in Asperger disorder have a number of limitations, including small sample size, inclusion of individuals with autistic disorder, extrapolation from studies addressing the autism spectrum as a whole, selection bias, variable case definitions, and lack of an outcome measure applicable over the course of the life span [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, some general conclusions can be drawn. The outcome for children with Asperger disorder is variable. It appears to be related to IQ and early language skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/49\">",
"     49",
"    </a>",
"    ]. Although many children improve, difficulties with communication skills, social adjustment, and adaptive function persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/6,49,51-55\">",
"     6,49,51-55",
"    </a>",
"    ]. Approximately 15 to 25 percent of patients have good outcomes (gainful employment, independent living, and social relationships) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a longitudinal study of 70 patients with Asperger disorder (aged 16 to 36 years at the time of diagnosis) in which outcome was assessed five years after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41801/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      27 percent had a good outcome (&ldquo;good&rdquo; was defined as being employed or in more advanced",
"      <span class=\"nowrap\">",
"       vocational/educational",
"      </span>",
"      training AND living independently or had two or more",
"      <span class=\"nowrap\">",
"       friends/a",
"      </span>",
"      steady relationship).",
"     </li>",
"     <li>",
"      47 percent had a fair outcome (&ldquo;fair&rdquo; was defined as being employed or in more advanced",
"      <span class=\"nowrap\">",
"       vocational/educational",
"      </span>",
"      training OR living independently OR had two or more",
"      <span class=\"nowrap\">",
"       friends/a",
"      </span>",
"      steady relationship).",
"     </li>",
"     <li>",
"      23 percent had a restricted outcome (&ldquo;restricted&rdquo; was defined as being neither employed, nor in more advanced",
"      <span class=\"nowrap\">",
"       vocational/educational",
"      </span>",
"      training, nor living independently or having two or more",
"      <span class=\"nowrap\">",
"       friends/a",
"      </span>",
"      steady relationship).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources on Asperger disorder for providers, patients, and families are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef70862 \" href=\"mobipreview.htm?32/27/33213\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Behavioral and educational therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of children with Asperger disorder is individualized according to the child's age and needs. It requires a multidisciplinary approach that makes use of the child's strengths (eg, verbal cognitive ability, formal language skills) to address his or her weaknesses (eg, nonverbal and social problem-solving skills, pragmatic language). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overarousal and anxiety must be addressed before other interventions can be implemented. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Emotional regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with Asperger disorder typically do better when they are provided with an environment that is structured, organized, and organizing. Organizational strategies must be supported in all settings and used by all of the personnel involved in the child's education. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Executive dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Speech and language therapy for children with Asperger disorder focuses on the use of language in social settings and the nuances of ambiguous language. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Language skills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Target areas for social skills training include social conventions, conversational skills, social cognition, social participation, and self-advocacy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Social skills'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adaptive skills can be taught explicitly through scheduling, practicing, and rehearsing. Specific target areas can be identified from scores on adaptive behavior scales. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Adaptive function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Academic support usually centers on organizational skills during the early school years and reading comprehension and writing skills in the upper grades. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Academic supports for reading and writing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pharmacotherapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychopharmacologic interventions may be a useful adjunct to",
"      <span class=\"nowrap\">",
"       behavioral/environmental",
"      </span>",
"      interventions. However, they should be initiated only after behavioral interventions are in place. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children and adolescents with Asperger disorder who have symptoms of anxiety that are not controlled with counseling and",
"      <span class=\"nowrap\">",
"       behavioral/environmental",
"      </span>",
"      interventions may benefit from treatment with a selective serotonin reuptake inhibitor. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Anxiety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of hyperactivity, inattention, impulsivity, and disorganization that do not improve with environmental or behavioral interventions may respond to stimulant medication or to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/46/12007?source=see_link\">",
"       atomoxetine",
"      </a>",
"      . However, the response rate is lower, and there is a higher incidence of adverse reactions in autism spectrum disorders than in attention deficit hyperactivity disorder without autism. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hyperactivity and inattention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidepressant therapy may be indicated if depressive symptoms persist despite counseling and psychosocial interventions. The same medications that are used for depression in typical children should be used to treat symptoms of depression in children with Asperger disorder. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Depression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=see_link\">",
"       \"Psychopharmacological treatment for adolescent depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacotherapy may be indicated for disruptive behaviors (aggression, tantrums, and self-injury) if nonpharmacologic therapies are unsuccessful. When the clinician and",
"      <span class=\"nowrap\">",
"       parents/caregivers",
"      </span>",
"      agree that pharmacotherapy is indicated, initial pharmacotherapy may target anxiety and impulse control if these appear to contribute to disruptive behaviors. We suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=see_link\">",
"       risperidone",
"      </a>",
"      for disruptive behavior that is not related to anxiety or impulse control problems, or that appears to be due to anger dysregulation specifically (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Disruptive behaviors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/2\">",
"      Klin A, Volkmar FR. Asperger syndrome: diagnosis and external validity. Child Adolesc Psychiatr Clin N Am 2003; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/3\">",
"      Tantam D, Girgis S. Recognition and treatment of Asperger syndrome in the community. Br Med Bull 2009; 89:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/4\">",
"      Macintosh KE, Dissanayake C. Annotation: The similarities and differences between autistic disorder and Asperger's disorder: a review of the empirical evidence. J Child Psychol Psychiatry 2004; 45:421.",
"     </a>",
"    </li>",
"    <li>",
"     Saulnier CA, Volkmar FR. Asperger syndrome. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.120.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/6\">",
"      Woodbury-Smith MR, Volkmar FR. Asperger syndrome. Eur Child Adolesc Psychiatry 2009; 18:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/7\">",
"      Kasari C, Lawton K. New directions in behavioral treatment of autism spectrum disorders. Curr Opin Neurol 2010; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson CP, Myers SM. Autism spectrum disorders. In: Developmental-Behavioral Pediatrics: Evidence and Practices, Wolraich ML, Drotar DD, Dworkin PH, Perrin EC (Eds), Mosby Elsevier, Philadelphia 2008. p.519.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/9\">",
"      Baranek GT. Efficacy of sensory and motor interventions for children with autism. J Autism Dev Disord 2002; 32:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/10\">",
"      Dawson G, Watling R. Interventions to facilitate auditory, visual, and motor integration in autism: a review of the evidence. J Autism Dev Disord 2000; 30:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/11\">",
"      Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry 2005; 46:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/12\">",
"      Schaaf RC, Miller LJ. Occupational therapy using a sensory integrative approach for children with developmental disabilities. Ment Retard Dev Disabil Res Rev 2005; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/13\">",
"      Moree B, Davis T. Cognitive-behavioral therapy for anxiety in children diagnosed with autism spectrum disorders: modification trends. Research in Autism Spectrum Disorders 2010; 4:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/14\">",
"      Reaven J. The treatment of anxiety symptoms in youth with high-functioning autism spectrum disorders: developmental considerations for parents. Brain Res 2011; 1380:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/15\">",
"      Krasny L, Williams BJ, Provencal S, Ozonoff S. Social skills interventions for the autism spectrum: essential ingredients and a model curriculum. Child Adolesc Psychiatr Clin N Am 2003; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/16\">",
"      Rao PA, Beidel DC, Murray MJ. Social skills interventions for children with Asperger's syndrome or high-functioning autism: a review and recommendations. J Autism Dev Disord 2008; 38:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/17\">",
"      Cappadocia MC, Weiss JA. Review of social skills training groups for youth with Asperger syndrome and high-functioning autism. Research in Autism Spectrum Disorders 2011; 5:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/18\">",
"      Myles BS, Simpson RL. Effective practices for students with Asperger Syndrome. Focus on Exceptional Children 2001; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/19\">",
"      Williams K. Understanding the student with Asperger Syndrome: Guidelines for Teachers. Intervention in School and Clinic 2001; 36:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/20\">",
"      Lawrence DH, Alleckson DA, Bjorklund P. Beyond the roadblocks: transitioning to adulthood with Asperger's disorder. Arch Psychiatr Nurs 2010; 24:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/21\">",
"      Matson JL, Dempsey T. Autism spectrum disorders: Pharmacotherapy for challenging behaviors. J Dev Phys Disabil 2008; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/22\">",
"      Towbin KE. Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatr Clin N Am 2003; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/23\">",
"      McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/24\">",
"      Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/25\">",
"      Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/26\">",
"      Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/27\">",
"      Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/28\">",
"      Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/29\">",
"      White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 2009; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/30\">",
"      Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/31\">",
"      Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009; :CD005170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/32\">",
"      Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/33\">",
"      Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/34\">",
"      Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/35\">",
"      Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/36\">",
"      Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007; 43:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/37\">",
"      Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/38\">",
"      Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/39\">",
"      Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/40\">",
"      Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/41\">",
"      Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007; :CD005040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/42\">",
"      Barnard L, Young AH, Pearson J, et al. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/43\">",
"      Huffman LC, Sutcliffe TL, Tanner IS, Feldman HM. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 2011; 32:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/44\">",
"      Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/45\">",
"      McVoy M, Findling R. Child and adolescent psychopharmacology update. Psychiatr Clin North Am 2009; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/46\">",
"      Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/47\">",
"      Stein MT. Risperidone (Risperdal). JW Pediatr Asolesc Med 2007; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/48\">",
"      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/49\">",
"      Seltzer MM, Shattuck P, Abbeduto L, Greenberg JS. Trajectory of development in adolescents and adults with autism. Ment Retard Dev Disabil Res Rev 2004; 10:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/50\">",
"      Cederlund M, Hagberg B, Billstedt E, et al. Asperger syndrome and autism: a comparative longitudinal follow-up study more than 5 years after original diagnosis. J Autism Dev Disord 2008; 38:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/51\">",
"      Gilchrist A, Green J, Cox A, et al. Development and current functioning in adolescents with Asperger syndrome: a comparative study. J Child Psychol Psychiatry 2001; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/52\">",
"      Green J, Gilchrist A, Burton D, Cox A. Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. J Autism Dev Disord 2000; 30:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/53\">",
"      Seltzer MM, Krauss MW, Shattuck PT, et al. The symptoms of autism spectrum disorders in adolescence and adulthood. J Autism Dev Disord 2003; 33:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/54\">",
"      Howlin P. Outcomes in adult life for more able individuals with autism or Asperger syndrome. Autism 2000; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41801/abstract/55\">",
"      Mawhood L, Howlin P, Rutter M. Autism and developmental receptive language disorder--a comparative follow-up in early adult life. I: Cognitive and language outcomes. J Child Psychol Psychiatry 2000; 41:547.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 606 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41801=[""].join("\n");
var outline_f40_52_41801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BEHAVIORAL AND EDUCATIONAL INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Emotional regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H382756035\">",
"      - Accommodations and treatment for arousal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H382756042\">",
"      - Teaching a vocabulary for emotions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H382756049\">",
"      - Cognitive-behavioral techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H382756064\">",
"      - Parent involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Executive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Language skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Social skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adaptive function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461586015\">",
"      Motor skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461586075\">",
"      Educational plan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Academic supports for reading and writing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H387094610\">",
"      - Transition planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hyperactivity and inattention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mood stabilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Disruptive behaviors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      FAMILY SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Behavioral and educational therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pharmacotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/606\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/606|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/57/13212\" title=\"table 1\">",
"      DSM IV criteria Asperger disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/27/33213\" title=\"table 2\">",
"      Asperger resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15689?source=related_link\">",
"      Asperger disorder: Clinical features and diagnosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4122?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Behavioral and educational interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/52/30538?source=related_link\">",
"      Psychopharmacological treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/5/32857?source=related_link\">",
"      Risperidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41802="Prevention of venous thromboembolic disease in surgical patients";
var content_f40_52_41802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of venous thromboembolic disease in surgical patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Menaka Pai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     James D Douketis, MD, FRCPC, FACP, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/52/41802/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/52/41802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the 2003 nationwide inpatient sample from the Health Care Cost and Utilization Project in the United States, there were over 38 million discharges in 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/1\">",
"     1",
"    </a>",
"    ]. Twenty percent of those were surgical inpatients and, using the ACCP Guidelines for risk stratification, it was estimated that 15 percent, 24 percent, and 17 percent were at moderate, high, or very high risk for venous thromboembolism (VTE, which includes deep vein thrombosis and pulmonary embolism).",
"   </p>",
"   <p>",
"    Despite significant advances in the prevention and treatment of VTE, pulmonary embolism remains the most common preventable cause of hospital death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/2-6\">",
"     2-6",
"    </a>",
"    ], responsible for approximately 150,000 to 200,000 deaths per year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Thus, it is vital that efforts continue to be made to find the safest and most effective means of preventing and managing VTE.",
"   </p>",
"   <p>",
"    Practical approaches to the prevention of VTE in surgical patients will be reviewed here. Prevention of VTE in medical patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed discussions about specific pharmacologic agents employed for VTE prevention are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROBLEM OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States there have been a number of initiatives aimed at calling attention to the prevalence of VTE and increasing the use of prophylaxis of VTE in the hospital setting. These initiatives have come from the National Quality Forum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/9\">",
"     9",
"    </a>",
"    ], the Surgical Care Improvement Project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/10\">",
"     10",
"    </a>",
"    ], the Centers for Medicine and Medicinal Services, the Joint Commission on Accreditation of Health Care Organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/11\">",
"     11",
"    </a>",
"    ], and the Office of the Surgeon General of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar initiatives have been developed in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/13\">",
"     13",
"    </a>",
"    ], the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and Europe.",
"   </p>",
"   <p>",
"    According to the Agency for Healthcare Research and Quality, the prevention of VTE is the number one strategy to improve patient safety in hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, as part of the Surgical Care Improvement Project, the Center for Medicare and Medicaid Services (CMS) now considers appropriate VTE prophylaxis to be a pay-for-performance quality measure for specific procedures (",
"    <a class=\"graphic graphic_table graphicRef50947 \" href=\"mobipreview.htm?34/54/35693\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Effective and safe prophylactic measures are now available for most high risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/20-23\">",
"     20-23",
"    </a>",
"    ], and numerous evidence-based guidelines have been published for the prevention of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the availability of these guidelines and the availability of safe and effective prophylactic agents, numerous audits have demonstrated that appropriate thromboprophylaxis is not being offered to large numbers of surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ENDORSE study evaluated VTE risk and prophylaxis in all hospital inpatients &ge;18 years of age admitted to a surgical ward in 358 hospitals from 32 different countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/28,34\">",
"       28,34",
"      </a>",
"      ]. For the 30,827 surgical patients in this study, 64.4 percent (range between countries: 44 to 80 percent) were judged to be at risk for VTE according to the American College of Chest Physicians (ACCP) Guidelines available at that time. However, only 58.5 percent (range between countries: 0.2 to 92 percent) of the at-risk surgical patients received ACCP-recommended VTE prophylaxis.",
"     </li>",
"     <li>",
"      In a Canadian study of 10,744 patients &ge;65 years of age who had hip or knee replacement therapy, only 19 percent received thromboprophylaxis at the time of hospital discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/30\">",
"       30",
"      </a>",
"      ]. Of importance, the risk of short-term mortality (ie, death within three months of discharge) was significantly lower among those who received post-discharge thromboprophylaxis (hazard ratio 0.34; 95% CI 0.20-0.57).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various strategies to improve the use of thromboprophylaxis have been demonstrated to be effective, including computerized order sets with electronic alerts, or pre-printed orders and quality improvement in the form of clinician education programs, audit, and feedback, but further efforts are required at improving the translation of data from clinical trials into clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/35-42\">",
"     35-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous risk factors for the development of VTE in surgical patients, including the type and extent of surgery or trauma, duration of hospital stay, a history of previous VTE or cancer, immobility, recent sepsis, presence of a central venous access device, pregnancy or the postpartum period, and inherited or acquired hypercoagulable states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/43-60\">",
"     43-60",
"    </a>",
"    ]. For surgical patients, prophylaxis has been recommended according to assignment of the patient to one of the defined surgical risk groups described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of appropriate prophylaxis, the incidence of",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    DVT detected by objective diagnostic screening tests has ranged from 10 to 80 percent in various hospitalized medical and surgical groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/24\">",
"     24",
"    </a>",
"    ]. From earlier studies, the incidence of fatal pulmonary embolism in the absence of prophylaxis was estimated to be 0.1 to 0.8 percent in patients undergoing elective general surgery, 2 to 3 percent in patients having elective total hip replacement, and 4 to 7 percent of patients undergoing surgery for a fractured hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These estimates are likely lower today because of the increasing use of early ambulation and shorter lengths of hospitalization. However, data from audits and registries demonstrate that the incidence of VTE, and in particular fatal pulmonary embolism, remains excessively high, even after hospital discharge.",
"   </p>",
"   <p>",
"    As an example, in a prospective cohort study of 947,454 middle aged women in the UK, an estimated 1 in 140 women undergoing inpatient surgery in the UK will be admitted with venous thromboembolism during the 12-week period following surgery, 1 in 815 after outpatient surgery, and only 1 in 6200 women not undergoing surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/61\">",
"     61",
"    </a>",
"    ]. No information was available on the use or non-use of VTE prophylaxis in this cohort of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgical risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of post-operative VTE depends upon a number of factors related to the surgical procedure itself (eg, degree of invasiveness, type and duration of anaesthesia, requirement for immobilization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], as well as a number of patient-related adverse risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/15,24,25,64\">",
"     15,24,25,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      Prior VTE in patient or family members",
"     </li>",
"     <li>",
"      Presence of malignancy or obesity",
"     </li>",
"     <li>",
"      Presence of an inherited or acquired hypercoagulable state",
"     </li>",
"     <li>",
"      One or more significant medical comorbidities (eg, heart disease, infection, inflammatory conditions, recent stroke)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain procedures can be shown to increase thrombin generation, further increasing thrombotic risk (eg, reaming out of the femur during total hip replacement surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 ACCP Guidelines have divided patients undergoing surgical procedures into very low, low, moderate, or high risk groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66\">",
"     66",
"    </a>",
"    ]. Although there have been many attempts to quantitate these risks, no one method has been found to be universally acceptable. Thus, the caveat is that if a patient has additional risk factors, consideration should be given to either increasing the intensity or the duration of the prophylactic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25,38\">",
"     25,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most widely tested surgical risk assessment model (the Modified Caprini Risk Assessment Model, Caprini score) has been slightly modified for use in the 2012 ACCP Guidelines and is described in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef83739 \" href=\"mobipreview.htm?22/50/23341\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/64,66,67\">",
"     64,66,67",
"    </a>",
"    ]. This risk model will be used throughout this review to determine the surgical risk groups listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288083\">",
"    <span class=\"h3\">",
"     Very low risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very low risk patients have been defined as those undergoing general and abdominal-pelvic surgery with a Caprini score of zero, and those undergoing plastic and reconstructive surgery with a Caprini score of zero to two. Their estimated baseline risk of VTE in the absence of prophylaxis is estimated to be less than 0.5 percent.",
"   </p>",
"   <p>",
"    A prospective observational cohort study using the American College of Surgeons National Surgical Quality Improvement Program was used to identify independent predictors of 30-day VTE events requiring treatment following outpatient or same-day surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/68\">",
"     68",
"    </a>",
"    ]. The 30-day incidence of VTE for the 173,501 subjects in the derivation cohort was 0.15 percent, and was 0.06 and 1.18 percent among those in the lowest and highest risk categories, respectively. Results of this study&nbsp;must be interpreted in context; it was unable to provide details on the use of VTE prophylaxis or common VTE risk factors, such as personal or family history of VTE. Nine independent risk factors were identified, including age 40 to 59 years, age &ge;60 years, current pregnancy, active cancer, increased body mass index, operative time &ge;120 minutes, arthroscopic surgery, saphenofemoral junction surgery, and venous surgery not involving the great saphenous vein. Even the highest risk patients using this outpatient model fit in the &ldquo;low risk&rdquo; surgical group, despite the fact that some of the identified risk factors may place a given patient in the highest Caprini risk group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Low risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low risk surgical patients have been defined as those undergoing general and abdominal-pelvic surgery with a Caprini score of 1 to 2, or those undergoing plastic and reconstructive surgery with a Caprini score of 3 to 4. Their estimated baseline risk of VTE in the absence of prophylaxis is estimated to be approximately 1.5 percent.",
"   </p>",
"   <p>",
"    In most cases, low risk surgical patients are those undergoing minor elective abdominal or thoracic surgery. However, in some settings the risk of VTE remains uncertain, and there have not been good randomized clinical trials demonstrating effectiveness of any particular form of VTE prophylaxis. These include vascular surgery, laparoscopic surgery, knee arthroscopy in the absence of more complicated surgery, elective spine surgery (eg, spinal fusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/69\">",
"     69",
"    </a>",
"    ]), shoulder and elbow surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/70\">",
"     70",
"    </a>",
"    ], isolated lower extremity fractures, Achilles tendon rupture repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/71\">",
"     71",
"    </a>",
"    ], and podiatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Moderate risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate risk surgical patients have been defined as those undergoing general and abdominal-pelvic surgery with a Caprini score of 3 to 4, or those undergoing plastic and reconstructive surgery with a Caprini score of 5 to 6. Their estimated baseline risk of VTE in the absence of prophylaxis is estimated to be approximately 3 percent.",
"   </p>",
"   <p>",
"    Patients undergoing general gynecologic, urologic, thoracic, ankle fracture, or neurosurgical procedures usually fall into the moderate risk category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/24,25,72\">",
"     24,25,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     High risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;High risk surgical patients have been defined as those undergoing general and abdominal-pelvic surgery with a Caprini score of 5 or more, or those undergoing plastic and reconstructive surgery with a Caprini score of 7 to 8. Their estimated baseline risk of VTE in the absence of prophylaxis is estimated to be approximately 6 percent. Examples of patients in the high risk group are those undergoing hip or knee arthroplasty, pelvic or hip fracture surgery, colorectal surgery, major trauma, spinal cord injury, or cancer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25,73,74\">",
"     25,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971783\">",
"    <span class=\"h4\">",
"     Orthopedic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors increase the risk of VTE during orthopedic surgery, including the supine position on the operating table, the anatomic position of the extremity in a patient undergoing knee arthroplasty, and the use of a thigh tourniquet. As examples, internal injury may result from positioning of the extremity, and compression of the femoral vein may occur due to flexion and adduction of the hip during surgery on this joint.",
"   </p>",
"   <p>",
"    The use of prophylactic anticoagulation in high risk settings substantially reduces, but does not completely eliminate, the risk of VTE. One meta-analysis of 47 studies in 44,844 patients who underwent either total or partial knee (TPKA) or total or partial hip (TPHA) arthroplasty and received currently approved VTE prophylaxis found that the rates of symptomatic VTE prior to hospital discharge were approximately 1.1 and 0.53 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/75\">",
"     75",
"    </a>",
"    ]. Because the endpoint was symptomatic VTE during (but not after) hospitalization, the true rate of relevant VTE events was presumably underestimated.",
"   </p>",
"   <p>",
"    The importance of early ambulation in reducing the incidence of VTE following total knee and total hip arthroplasty has also been emphasized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. As an example of the relevant issues, in a case-control study of 593 patients undergoing total knee arthroplasty (TKA) the following factors were significantly associated with the development of postoperative symptomatic VTE prior to hospital discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral simultaneous TKA rather than unilateral TKA (OR 4.2; 95% CI 1.9-9.1)",
"     </li>",
"     <li>",
"      Use of FDA-approved pharmacologic prophylaxis versus mechanical prophylaxis (OR 0.5; 95% CI 0.3-0.8)",
"     </li>",
"     <li>",
"      Ambulation on or before the second postoperative day (OR 0.3; 95% CI 0.1-0.9)",
"     </li>",
"     <li>",
"      Severe obesity (BMI &gt;35 versus BMI &le;35) was not a significant predictor for VTE (OR 0.9; 95% CI 0.5-1.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423403\">",
"    <span class=\"h4\">",
"     Obese patients and those undergoing bariatric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obese surgical patient is considered to be at moderate to high risk for VTE, with an estimated Caprini score of 4 or more for those undergoing bariatric surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66,80\">",
"     66,80",
"    </a>",
"    ]. However, the preferred anticoagulant (eg, unfractionated versus LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) and appropriate prophylactic anticoagulation dosing are both unclear; available studies on this subject have been considered to be of low quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66,81,82\">",
"     66,81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more complete discussion of this subject, which includes suggested dosing (",
"    <a class=\"graphic graphic_table graphicRef65464 \" href=\"mobipreview.htm?8/6/8302\">",
"     table 3",
"    </a>",
"    ), is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H14#H14\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Anticoagulants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H26#H26\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION OF VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overall approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to the prevention of fatal pulmonary embolism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prophylaxis &mdash; Primary prophylaxis is carried out using either drugs or physical methods that are effective for preventing DVT.",
"     </li>",
"     <li>",
"      Secondary prevention &mdash; Secondary prevention involves the early detection and treatment of subclinical venous thrombosis by screening postoperative patients with objective tests that are sensitive for the presence of DVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, no single screening method (eg, contrast venography, ultrasonography, MRI venography) has found universal acceptance for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Accordingly, primary prophylaxis is preferred in most clinical circumstances; it is more cost effective than treatment of complications once they occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/85\">",
"     85",
"    </a>",
"    ]. Secondary prevention with screening is reserved for patients in whom primary prophylaxis is either contraindicated or shown to be ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristics of an ideal primary prophylactic method include ease of administration, effectiveness, safety (particularly with respect to bleeding), no need for laboratory monitoring, and cost effectiveness or at least cost neutrality when compared with current standards.",
"   </p>",
"   <p>",
"    The measures currently available for VTE prophylaxis in surgical patients include low dose unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low molecular weight (LMW) heparin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , intermittent pneumatic compression (IPC)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graduated compression stockings (GCS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25\">",
"     25",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and, where available, oral factor Xa or factor IIa (thrombin) inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Timing of commencement of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis is ideally started either before or shortly after surgery and continued at least until the patient is fully ambulatory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25,86\">",
"     25,86",
"    </a>",
"    ]. The administration of thromboprophylaxis in close proximity to surgery has been shown to enhance its efficacy in a systematic review that compared prophylaxis with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/87-89\">",
"     87-89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large risk reduction in venographically-detected DVT was observed when the LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      was initiated at half the usual high risk dose in proximity to total hip replacement (ie, either within two hours before surgery or four to six hours after surgery).",
"     </li>",
"     <li>",
"      When LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was started either 12 hours before surgery or 18 to 24 hours after surgery, the efficacy advantage of LMW heparin over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was not observed. However, starting LMW heparin within two hours of surgery was associated with an increased risk of major bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Values and preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of values and preferences was introduced starting with the 2004 ACCP Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/38\">",
"     38",
"    </a>",
"    ]. This issue requires considerable thought by both the clinician and the patient. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the treatment of established pulmonary embolism (PE), a greater value is normally placed on the prevention of death from recurrent PE than from the relatively low risk of bleeding from the use of anticoagulation.",
"     </li>",
"     <li>",
"      In orthopedic surgery, greater value is placed on the avoidance of bleeding from anticoagulation over the relatively low frequency of death from pulmonary embolism if thromboprophylaxis is not used. Thus in North America a common regimen with LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is to start at 18 to 24 hours postoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/88\">",
"       88",
"      </a>",
"      ]. It also explains why the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , with its delayed onset of effective anticoagulation, remains popular, particularly in the United States.",
"      <br/>",
"      <br/>",
"      A systematic review and meta-analysis of randomized clinical trials evaluating VTE prophylaxis in patients undergoing elective cranial neurosurgery has estimated that for every 1000 patients who receive heparin prophylaxis, 91 VTE events will be prevented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/90\">",
"       90",
"      </a>",
"      ]. Approximately 35 of these will be proximal DVT or PE, and only 9 to 18 will be symptomatic. On the other hand, 7 intracerebral hemorrhages and 28 more minor bleeds were estimated to occur if a heparin preparation is employed, versus none if a mechanical method of thromboprophylaxis is used. Such analyses can be employed to better inform clinicians and their patients about DVT prophylaxis options for cranial neurosurgical procedures. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Mechanical methods of thromboprophylaxis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Definition of major bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commonly used traditional classification for major bleeding is recommended and has been approved by the International Society for Thrombosis and Hemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/91\">",
"     91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatal bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Symptomatic bleeding in a critical area or organ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Bleeding causing a fall in hemoglobin of &ge;2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or leading to transfusion of two or more units of whole blood or red cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extended prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the result of shortened hospital length of stay, many patients will require out-of-hospital prophylaxis. This is particularly true after total hip replacement, where the evidence is that patients require 28 to 35 days of prophylaxis with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , rather than 7 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is effective in extended prophylaxis, the incidence of major bleeding was higher than that seen with LMW heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, a study following surgery for hip fracture demonstrated that extended prophylaxis for three weeks was superior to prophylaxis for 10 to 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Although one trial indicated that prophylaxis beyond day 10 was not required in patients having total knee replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/98\">",
"     98",
"    </a>",
"    ], patients who have additional risk factors probably would benefit from extended prophylaxis.",
"   </p>",
"   <p>",
"    Patients undergoing cancer surgery or major abdominal surgery also benefit from extended prophylaxis, most commonly for a period of 4 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/99-103\">",
"     99-103",
"    </a>",
"    ]. Extended prophylaxis for cancer surgery patients has also been recommended in the 2012 guidelines issued by the ACCP as well as the NCCN (National Comprehensive Cancer Network) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66,104\">",
"     66,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H11#H11\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Surgical patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention in surgical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparisons of agents across studies of hip or knee surgery have been difficult, since the drugs under investigation and the dosing schedules have varied from one clinical trial to another. Even within the same clinical trial there can be considerable intercenter variability. In addition, bleeding rates have varied quite widely across studies, at least in part because different definitions for bleeding have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Definition of major bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Rivaroxaban'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of randomized trials have compared LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with UFH,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in patients undergoing total hip replacement surgery, and to a lesser extent total knee replacement surgery. A meta-analysis comparing vitamin K antagonists versus LMW heparin for the prevention of VTE in orthopedic surgery indicated that the vitamin K antagonists are less effective than LMW heparin, without any significant difference in bleeding risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been shown to be superior to UFH or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , but inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in terms of efficacy, with similar bleeding rates in patients undergoing total hip or total knee replacement surgery.",
"   </p>",
"   <p>",
"    The use of the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    differs between regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In North America,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      is commonly used in the dose of 30 mg twice daily starting 12 to 24 hours postoperatively.",
"     </li>",
"     <li>",
"      In Europe,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      at a dose of 40 mg is started 12 hours preoperatively and is then given once daily.",
"     </li>",
"     <li>",
"      Other LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparations have usually been given in a once daily dosage, starting postoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis in patients undergoing cancer surgery concluded that there was no difference between LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and UFH in terms of efficacy, DVT location, or bleeding complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review of the use of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to prevent VTE in patients with lower leg immobilization concluded that LMW heparin in outpatients significantly reduced the incidence of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/108\">",
"     108",
"    </a>",
"    ]. A further meta-analysis reviewed the use of intermittent pneumatic compression (IPC) with or without pharmacologic prophylaxis used in the form of LMW heparin. It was shown that, compared with IPC alone, combined prophylactic modalities decreased the incidence of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients undergoing neurosurgical procedures, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was shown to be superior to IPC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. In patients suffering major trauma, LMW heparin was superior to UFH in the prevention of both total and proximal DVTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS FOR VTE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pharmacologic agents are now available for VTE prevention in surgical patients, including unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , the LMW heparins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , the vitamin K antagonists, and the new oral antithrombotic agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    . These will be discussed below. When available, meta-analyses of the comparative effectiveness among these various agents will also be discussed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/113-117\">",
"     113-117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Low dose unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) for prophylaxis of VTE is usually given in a dose of 5000 units two hours preoperatively and then every 8 to 12 hours postoperatively (ie, either twice or three times daily).",
"   </p>",
"   <p>",
"    An early prospective randomized study of over 4000 patients found that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    reduced the incidence of fatal PE in patients undergoing major surgical procedures from 0.7 to 0.1 percent compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/118\">",
"     118",
"    </a>",
"    ]. Pooled data from meta-analyses confirmed that low dose UFH reduced the incidence of all DVT, proximal DVT, and all PE including fatal PE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/20,21,119,120\">",
"     20,21,119,120",
"    </a>",
"    ]. Most of the patients in these trials underwent abdominal or thoracic surgery (particularly for gastrointestinal disease), but some patients had gynecologic or urologic surgery, mastectomy, or vascular procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the relatively low side effect profile of low dose UFH, its advantages are that it is relatively inexpensive and easily administered, and anticoagulant monitoring is not required. However, the platelet count should be monitored regularly in all patients receiving low dose UFH to detect the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Platelet count monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMW heparin) preparations are available. These drugs have the advantage that they can be given subcutaneously once or twice daily at a constant dose without laboratory monitoring. In addition, there is a lower incidence of heparin-induced thrombocytopenia than with UFH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link&amp;anchor=H8#H8\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in a randomized double blind study of patients undergoing hip replacement surgery,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) occurred in 9 of 332 patients (2.7 percent) receiving UFH compared with none of 333 patients receiving LMW heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/121\">",
"     121",
"    </a>",
"    ]. A meta-analysis of all studies comparing the incidence of HIT occurring after exposure to UFH versus LMW heparin after any surgical intervention confirmed that the incidence of HIT is significantly less with LMW heparin (RR 0.20, 95% CI 0.04-0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/123\">",
"     123",
"    </a>",
"    ]. However, this conclusion is limited by a scarcity of high quality studies including HIT as an outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H2#H2\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The LMW heparins have been extensively studied for the prevention of VTE. Studies in surgical patients have included those undergoing general surgery, including gynecologic and urologic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/22,23,124,125\">",
"     22,23,124,125",
"    </a>",
"    ], orthopedic surgery including total hip and knee replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/89,92,93,126-132\">",
"     89,92,93,126-132",
"    </a>",
"    ], hip fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], lower leg fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/108,133-135\">",
"     108,133-135",
"    </a>",
"    ], arthroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/136-138\">",
"     136-138",
"    </a>",
"    ], trauma including spinal cord injury and neurosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/110-112,139-142\">",
"     110-112,139-142",
"    </a>",
"    ], and cancer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/99-101,107,143-145\">",
"     99-101,107,143-145",
"    </a>",
"    ]. Meta-analyses of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the prevention of VTE in general surgery have shown efficacy to be at least as good as with UFH, with equal safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most countries, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is the prophylactic agent of choice for preventing VTE in high risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is discussed elsewhere in UpToDate, but issues related to its use in surgical patients will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    has been evaluated in the prevention of VTE in patients undergoing orthopedic surgery, general surgery, and in hospitalized medical patients. Fondaparinux 2.5 mg",
"    <span class=\"nowrap\">",
"     once/day",
"    </span>",
"    by subcutaneous injection has been compared with the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg once daily starting 12 hours preoperatively in patients undergoing total hip or total knee replacement, with enoxaparin 30 mg twice daily in patients undergoing total hip replacement, and with enoxaparin 40 mg daily in patients suffering hip fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/96,129,146\">",
"     96,129,146",
"    </a>",
"    ]. In a 2002 meta-analysis of four available trials, it was concluded that the efficacy of fondaparinux was superior to that of enoxaparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these studies, major bleeding occurred more frequently in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    -treated subjects, but there was not an increase in bleeding leading to death or re-operation or bleeding into a critical organ with fondaparinux compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/147\">",
"     147",
"    </a>",
"    ]. Most of the patients who bled had their initial fondaparinux injection less than eight hours postoperatively.",
"   </p>",
"   <p>",
"    As part of the study in patients having a hip fracture, at the end of the initial prophylactic period of seven days, patients were randomly assigned to either continue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    for a further three weeks or to receive a placebo injection for the same period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/97\">",
"     97",
"    </a>",
"    ]. Fondaparinux decreased the incidence of both asymptomatic and symptomatic VTE in the patients receiving extended prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    was shown to have efficacy equal to the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    in patients undergoing high risk abdominal surgery, with a similar incidence of major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/125\">",
"     125",
"    </a>",
"    ]. In the subgroup of patients with cancer, fondaparinux therapy resulted in a significant decrease in the composite end point of asymptomatic or symptomatic DVT and non-fatal or fatal PE.",
"   </p>",
"   <p>",
"    However, in at least one trial (ie, in patients undergoing elective hip replacement surgery),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    was found to be not significantly better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    30 mg twice daily, the regimen used in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/129\">",
"     129",
"    </a>",
"    ]. In other studies, fondaparinux appeared to be better than enoxaparin 40 mg once daily, the regimen favored in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/96,146\">",
"     96,146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single center, retrospective cohort study in 5061 consecutive unselected patients undergoing major orthopedic surgery reported that thromboprophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    was associated with significantly fewer episodes of symptomatic VTE and major bleeding events than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/148\">",
"     148",
"    </a>",
"    ]. Prospective comparison studies are warranted to confirm these findings. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Rivaroxaban'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Oral anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral anticoagulation with vitamin K antagonists (VKA) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , can be commenced preoperatively, at the time of surgery, or postoperatively for the prevention of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ]. However, therapy started at the time of surgery or in the early postoperative period may not prevent small venous thrombi from forming because the anticoagulant effect of the VKAs is not achieved until the third or fourth day of treatment with these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use of warfarin\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonetheless,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appears to effectively inhibit extension of such thrombi if present, thereby preventing clinically important VTE. Because of its delayed onset of action along with bleeding rates similar to those seen with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , warfarin has been favored as a thromboprophylactic agent by orthopedic surgeons in the United States.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    has been compared with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients undergoing total hip or knee replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/89,150,151\">",
"     89,150,151",
"    </a>",
"    ]. Most studies have shown superior benefit with LMW heparin without any increase in bleeding rates. In a comparison of warfarin with intermittent pneumatic compression after total hip replacement, warfarin was significantly more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/13\">",
"     13",
"    </a>",
"    ]. In one earlier study, warfarin was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or placebo for the prevention of DVT following surgery for hip fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    reduces the incidence of VTE when used for four weeks following total hip replacement. When compared with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , each given for four weeks postoperatively after total hip replacement, warfarin showed equal efficacy but a significantly increased incidence of major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     New oral antithrombotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orally active agents that specifically inhibit either activated factor X or activated factor II (thrombin) have undergone extensive evaluation with favorable results from a number of phase III studies.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    , a factor Xa inhibitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran etexilate",
"    </a>",
"    , a factor IIa inhibitor, have both been approved for use by regulatory agents in the United States and several other countries.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    , a factor Xa inhibitor, has been approved for use in Canada for postoperative prophylaxis of VTE following elective knee or hip replacement surgery, but has not been approved for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    (Xarelto&reg;) is a specific inhibitor of activated factor X with excellent oral bioavailability and a half life of approximately nine hours. It is primarily excreted renally, although some is excreted through the gastrointestinal tract. As a result, caution is recommended in patients with renal insufficiency; its use is contraindicated in patients with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    It is also contraindicated in patients with severe hepatic disease and dosage reduction is recommended in patients &gt;65 years of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H20#H20\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies were carried out in patients undergoing total hip replacement. The first compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    10 mg orally once daily with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg once daily subcutaneously starting 12 hours preoperatively, both for 35 &plusmn; 4 days (RECORD 1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/153\">",
"     153",
"    </a>",
"    ]. The second (RECORD 2) compared oral rivaroxaban 10 mg once daily for 35 &plusmn; 4 days with enoxaparin 40 mg once daily starting 12 hours preoperatively for 12 &plusmn; 2 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In RECORD 1,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      showed superiority to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      for the reduction of total VTE, major VTE (ie, a composite of proximal DVT, non-fatal PE, or VTE related death), with no difference in major bleeding events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RECORD 2 showed superiority of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      in the incidence of total VTE, major VTE, and proximal or distal DVT, and notably in the incidence of symptomatic VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/154\">",
"       154",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients undergoing total knee replacement (RECORD 3),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      10 mg orally once daily was compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      40 mg subcutaneously daily starting 12 hours preoperatively, with either agent continued for 12 &plusmn; 2 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/155\">",
"       155",
"      </a>",
"      ]. In this study, rivaroxaban was superior to enoxaparin in the reduction of total VTE, major VTE and distal DVT, and significantly reduced the incidence of symptomatic VTE.",
"     </li>",
"     <li>",
"      In the RECORD 4 study, patients undergoing total knee replacement were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      10 mg daily PO or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      30 mg twice daily starting 12 to 24 hours postoperatively, with both given for 12 &plusmn; 4 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/156\">",
"       156",
"      </a>",
"      ]. There was a significant decrease in total VTE with rivaroxaban, but the difference in the incidence of major VTE and symptomatic VTE did not reach statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pooled analysis of four phase III studies was performed comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (either 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 30 mg twice per day) for thromboprophylaxis after total hip or knee replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/157\">",
"     157",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , thromboprophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      was associated with significantly fewer symptomatic VTE events and all-cause mortality (odds ratio 0.48; 95% CI 0.30-0.76)&nbsp;during the treatment period.",
"     </li>",
"     <li>",
"      The composite of major and non-major clinically relevant bleeding during the treatment period was 2.8 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      versus 2.5 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (odds ratio 1.17; 95% CI 0.93-1.46).",
"     </li>",
"     <li>",
"      In all studies with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      there was no significant elevation of liver enzymes or increase in thrombotic events during the treatment period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective cohort study from the ORTHO-TEP registry evaluated the relative efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    thromboprophylaxis in 5061 unselected consecutive patients undergoing major orthopedic surgery. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/148\">",
"     148",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rates of symptomatic VTE were significantly lower for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (2.1 versus 5.6 percent)",
"     </li>",
"     <li>",
"      Rates of severe bleeding were significantly lower for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (2.9 versus 4.9 percent)",
"     </li>",
"     <li>",
"      The mean length of hospitalization was significantly shorter in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      group (8.3 versus 9.3 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar retrospective cohort study from the ORTHO-TEP registry evaluated the relative efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    versus low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    thromboprophylaxis in 5061 unselected consecutive patients undergoing hip and knee replacement surgery. Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/158\">",
"     158",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rates of symptomatic VTE were significantly lower for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (2.1 versus 4.1 percent)",
"     </li>",
"     <li>",
"      Rates of major bleeding were significantly lower for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (2.9 versus 7.0 percent)",
"     </li>",
"     <li>",
"      The mean length of hospitalization was significantly shorter in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      group (8.3 versus 11.1 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective studies will be required in order to confirm both of these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dabigatran etexilate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran etexilate",
"    </a>",
"    is an orally absorbed pro-drug with approximately 5 percent bioavailability. It is converted to the active agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , which has a half-life of approximately eight hours after a single dose and 17 hours after multiple doses. Dabigatran is a direct thrombin inhibitor that is active against both free and clot-bound thrombin. The activity of dabigatran is directed against the conversion of fibrinogen to fibrin, but it also inhibits platelet activation by thrombin and the activation of clotting factors V, VIII, and XI by thrombin. As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , the antithrombotic activity of dabigatran cannot be reversed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the prevention of VTE,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    has been studied in patients undergoing total hip or total knee replacement surgery. Based on a phase II dose-finding study in patients undergoing total hip or knee replacement surgery, a safe and effective daily dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran etexilate",
"    </a>",
"    was suggested to be in the range between 100 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. A meta-analysis of available efficacy and safety data from three trials has concluded that dabigatran, at the recommended dose of 220 mg once daily, was non-inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for VTE prophylaxis after total knee or total hip arthroplasty, with a similar toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients undergoing total knee replacement surgery (the REMODEL study) oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    150 mg or 220 mg daily was compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg daily starting 12 hours pre-operatively, with mandatory venography at day 6 to 10 and follow up for 10 to 14 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/162\">",
"     162",
"    </a>",
"    ]. In the dabigatran 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    group the first dose was given one to four hours postoperatively at a dose of 75 mg and thereafter 150 mg",
"    <span class=\"nowrap\">",
"     once/day,",
"    </span>",
"    and in the 220",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    dabigatran group the initial dose was 110 mg, followed by 220",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    This trial was designed as a non-inferiority study and achieved non-inferiority compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for the prevention of total VTE and reduction of all cause mortality. There was no difference in the incidence of symptomatic VTE. Bleeding rates were low and comparable in both groups, with 89 percent of major bleeding events being noted at the surgical site.",
"   </p>",
"   <p>",
"    The RENOVATE trial in patients undergoing total hip replacement surgery compared oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    starting within one to four hours postoperatively with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg once daily starting 12 hours pre-operatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/163\">",
"     163",
"    </a>",
"    ]. All treatment continued for 28 to 35 days, at which time venography was done [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/163\">",
"     163",
"    </a>",
"    ]. For the composite endpoint of total VTE and all-cause mortality, both arms of the dabigatran study showed non-inferiority to enoxaparin, with similar bleeding rates and with most major bleeding events being at the surgical site.",
"   </p>",
"   <p>",
"    The REMOBILIZE trial was carried out in patients undergoing total knee replacement surgery. In this study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran etexilate",
"    </a>",
"    150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    starting with a dose of either 75 or 110 mg 6 to 12 hours postoperatively, respectively in the two groups, was compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    30 mg twice daily, starting 12 to 24 hours postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/164\">",
"     164",
"    </a>",
"    ]. Venography was performed at day 12 to 15.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    failed to meet the predefined criteria for non-inferiority against enoxaparin in terms of the composite endpoint. Rates for major VTE or death were similar and major bleeding events were comparable. As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , dabigatran was not as effective against the North American regimen of enoxaparin (ie, 30 mg twice daily) as it was against the dosing favored in Europe (ie, 40 mg once daily).",
"   </p>",
"   <p>",
"    In all three studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    there was no significant elevation of liver enzymes or in thrombotic events following the treatment period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/162-164\">",
"     162-164",
"    </a>",
"    ]. Based on evidence from these trials, dabigatran has been approved for use in a number of countries in Europe and in Canada.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3436597\">",
"    <span class=\"h3\">",
"     Apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     Apixaban",
"    </a>",
"    is a specific inhibitor of activated factor X with excellent oral bioavailability and a half life of approximately eight hours. It is primarily metabolized by the liver. Its use is not recommended in those with a creatinine clearance &lt;15",
"    <span class=\"nowrap\">",
"     mL/minute",
"    </span>",
"    or in those with severe hepatic impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H21#H21\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Apixaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a double-blind randomized study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    for thromboprophylaxis after knee replacement, apixaban did not meet the prespecified criteria for noninferiority, but its use was associated with lower rates of clinically relevant bleeding and it had a similar adverse event profile to enoxaparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/165\">",
"     165",
"    </a>",
"    ]. Other phase II and III trials have shown that apixaban compared favorably to both enoxaparin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    as VTE prophylaxis in total knee replacement surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/166-168\">",
"     166-168",
"    </a>",
"    ] and that thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with significantly lower rates of venous thromboembolism without increased bleeding in patients undergoing total hip replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/169\">",
"     169",
"    </a>",
"    ]. Apixaban (Eliquis) has subsequently been approved in Europe for use after",
"    <span class=\"nowrap\">",
"     hip/knee",
"    </span>",
"    surgery. Dose reduction is not required if the creatinine clearance is &ge;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized, dose-ranging study compared three different schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    (oral daily doses of 5 mg twice daily, 10 mg twice daily, or 20 mg once daily) or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    followed by a vitamin K antagonist (VKA), all given for a total of 84 to 91 days, in 520 patients with symptomatic DVT. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/171\">",
"     171",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary efficacy end-point, a composite of symptomatic recurrent VTE and asymptomatic deterioration of bilateral compression ultrasound or perfusion lung scan obtained at the end of treatment, occurred in 4.7 and 4.2 percent of those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      and LMW",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"       /VKA,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The primary safety end-point, a composite of major and clinically relevant, non-major bleeding was noted in 7.3 and 7.9 percent of those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      and LMW",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"       /VKA,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      There was no evidence for a dose-response relationship with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      for either the efficacy or safety end-points. Routine liver function testing revealed no evidence of liver toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9637947\">",
"    <span class=\"h3\">",
"     Edoxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the use of edoxaban for the prevention of VTE come from two randomized trials in Japanese patients undergoing total knee replacement or total hip replacement. These trials (STARS E-3 and STARS J-5) compared edoxaban with the low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/172\">",
"     172",
"    </a>",
"    ]. A pooled analysis of the results showed that when compared with enoxaparin, edoxaban was associated with a lower incidence of DVT and PE (5.1 versus 10.7 percent) and a similar safety profile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H1492700#H1492700\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Edoxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10240393\">",
"    <span class=\"h3\">",
"     Enoxaparin versus the new orally active anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials and meta-analyses have evaluated the relative efficacy and safety of the orally active direct factor Xa inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) and direct thrombin inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ) versus low molecular weight heparins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    ) in surgical patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efficacy and safety data were pooled from six phase III trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40 mg once daily or 30 mg twice daily) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    (10 mg once daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    (220 mg once daily) as thromboprophylaxis in 18,405 patients undergoing hip or knee arthroplasty. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      had a twofold higher risk of symptomatic VTE plus all-cause mortality (1.2 versus 0.6 percent; OR 2.04; 95% CI 1.32-3.17), but demonstrated a significantly lower risk of bleeding (2.5 versus 3.1 percent; OR 0.79; 95% CI 0.62-0.99).",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      had a similar risk of symptomatic VTE plus all-cause mortality (0.9 versus 1.1 percent; OR 0.76; 95% CI 0.44-1.31) and a similar risk of bleeding (5.0 versus 5.6 percent; OR 0.90; 95% CI 0.71-1.15).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pooled analysis of 10 randomized controlled trials that included 32,144 patients undergoing total hip or total knee replacement compared efficacy and safety outcomes between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (40 mg daily) and the new anticoagulants (NA)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    . Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, a significant effect favoring NAs over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      was found for the primary efficacy outcomes of total VTE and all-cause mortality (RR 0.71; 95% CI 0.56-0.90), major VTE (RR 0.59; 95% CI 0.41-0.84), and proximal DVT (0.51; 95% CI 0.35-0.76).",
"     </li>",
"     <li>",
"      Major bleeding (RR 1.04; 95% CI 0.74-1.46) and clinically relevant bleeding (RR 1.03; 95% CI 0.88-1.21) were similar between NAs and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of 22 randomized trials that compared oral factor Xa inhibitors with LMW heparins in adults undergoing hip or knee replacement noted no important differences between the two drug classes in terms of all-cause mortality or nonfatal pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/116\">",
"     116",
"    </a>",
"    ]. While the factor Xa inhibitors decreased the risk of symptomatic DVT more than the LMW heparins, high doses of factor Xa inhibitors, but not lower doses, increased the risk of bleeding more than the LMW heparins.",
"   </p>",
"   <p>",
"    While these data and observations are intriguing, additional trials will be required to establish the dosing, overall relative safety, and efficacy of these new anticoagulants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , with or without other antiplatelet drugs, is highly effective in reducing major arterial thrombotic events in patients who are at risk or who have established atherosclerotic disease. On the other hand, there is little evidence that aspirin has a significant effect on the prevention of venous thromboembolic events in surgical patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H22#H22\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early meta-analysis and a later literature review indicated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduced the incidence of VTE by approximately 20 percent compared with placebo or no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/173,174\">",
"     173,174",
"    </a>",
"    ]. However, other studies have shown either no significant benefit or inferiority when compared with other modalities such as LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2008 American College of Chest Physicians (ACCP) Anticoagulation Guidelines recommended",
"      <strong>",
"       against",
"      </strong>",
"      the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone as thromboprophylaxis against VTE for any medical or surgical patient group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"       149",
"      </a>",
"      ]. UpToDate agrees with this position.",
"     </li>",
"     <li>",
"      The 2012 ACCP Guidelines included",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      among those agents recommended for thromboprophylaxis in patients undergoing total hip or total knee arthroplasty or hip fracture surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/175\">",
"       175",
"      </a>",
"      ]. This recommendation was not unanimously supported by their rating panel, and is not supported by UpToDate for the reasons outlined above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MECHANICAL METHODS OF THROMBOPROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical methods for the prevention of VTE are primarily indicated in patients at high risk of bleeding (eg, following neurosurgery, patients with intracranial hemorrhage) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ]. They are also used in patients because of the presence of a bleeding lesion, such as peptic ulcer.",
"   </p>",
"   <p>",
"    Mechanical methods of thromboprophylaxis are placed on the patient just prior to the start of surgery and used continuously until hospital discharge. Intermittent pneumatic compression devices may be removed while the patient is ambulating, but should be put back on when the patient returns to a seated or supine position.",
"   </p>",
"   <p>",
"    When used in any of these circumstances, it is recommended that consideration be given to the use of a pharmacologic agent, such as LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , as soon as the bleeding risk becomes acceptably low (eg, 48 to 72 hours following neurosurgery) or when the bleeding lesion or bleeding risk has been reversed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Intermittent pneumatic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent pneumatic compression (IPC) prevents venous thrombosis by enhancing blood flow in the deep veins of the legs, thereby preventing venous stasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/176\">",
"     176",
"    </a>",
"    ]. IPC also reduces plasminogen activator inhibitor-1 (PAI-1), thereby increasing endogenous fibrinolytic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/177\">",
"     177",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28297?source=see_link&amp;anchor=H8#H8\">",
"     \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\", section on 'Plasminogen activator inhibitor-1'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link&amp;anchor=H6#H6\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Plasminogen activator inhibitor-1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IPC is virtually free of clinically important side effects and therefore offers an alternative for VTE prevention in patients with a high risk of bleeding should anticoagulants be employed. However, IPC is contraindicated in patients with evidence of leg ischemia due to peripheral vascular disease. There is also a hypothetical concern that patients who have been at bed rest or immobilized for a period of &ge;72 hours without any form of prophylaxis may be at risk of dislodging recently formed venous clots in the lower extremities following the use of IPC.",
"   </p>",
"   <p>",
"    In the 2008 ACCP guidelines, the uses of IPC, graduated compression stockings (GCS), and the venous foot pump (VFP) were critically reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ]. The best evidence for efficacy is with IPC devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/178-182\">",
"     178-182",
"    </a>",
"    ]. However attention must be paid to optimal patient compliance as well as insuring proper fit and duration of compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/183\">",
"     183",
"    </a>",
"    ]. IPC should be started as soon as possible, preferably in the operating room or recovery room and continued with few interruptions until discharge. As an example, in a study of 957 consecutive patients with no history of prior VTE who had laparoscopic Roux-en-Y gastric bypass, calf-length pneumatic compression devices were placed before anesthesia induction and mandatory ambulation was begun on the day of operation without the use of pharmacologic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/184\">",
"     184",
"    </a>",
"    ]. The incidences of clinically evident postoperative VTE and bleeding complications were 0.42 and 0.73 percent, respectively.",
"   </p>",
"   <p>",
"    While a meta-analysis has shown that IPC is effective in the prevention of VTE, the combined use of IPC and a pharmacologic agent was found to be superior to IPC alone in reducing the overall incidence of VTE, particularly the incidence of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/109\">",
"     109",
"    </a>",
"    ]. The fact that the length of stay for most patients has become much shortened means that patients will require a pharmacologic agent in addition to IPC in most circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Graduated compression stockings and venous foot pump",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less convincing evidence regarding the efficacy of graduated compression stockings (GCS) and venous foot pump (VFP) in randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/182,185\">",
"     182,185",
"    </a>",
"    ]. In one study, GCS for seven days was compared with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    given for either 7 or 14 days in patients undergoing knee arthroscopy with or without more extensive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/186\">",
"     186",
"    </a>",
"    ]. LMW heparin was superior to GCS in the prevention of asymptomatic proximal DVT, symptomatic VTE and all cause mortality compared with GCS. There was no difference in bleeding rates.",
"   </p>",
"   <p>",
"    In one study, the addition of GCS to LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in patients undergoing total hip replacement or hip fracture surgery did not improve efficacy over use of the pharmacologic agent alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/187\">",
"     187",
"    </a>",
"    ]. However a Cochrane meta-analysis has concluded that, although the use of IPC alone was effective in the prevention of DVT in surgical patients (relative risk reduction 54 percent; 95% CI 42 to 63), the combined use of IPC and a pharmacologic agent was superior in reducing the overall incidence of DVT (RRR 72 percent; 95% CI 59-81) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/188\">",
"     188",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, where mechanical prophylaxis is recommended, the choice should be IPC, rather than GCS or VFP devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14373183\">",
"    <span class=\"h2\">",
"     Inferior vena cava filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of an inferior vena cava filter as an alternative to pharmacologic or mechanical prophylaxis in selected surgical patients is discussed elsewhere in UpToDate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link&amp;anchor=H2#H2\">",
"     \"Placement of inferior vena cava filters and their complications\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Medical center policies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every hospital should develop a formal active strategy for the prevention of VTE in medical and surgical patients. This should be in the form of a written institution-wide thromboprophylaxis policy endorsed by department heads and medical advisory boards. Strategies should be developed to increase compliance with thromboprophylaxis recommendations, including the use of computerized order sets and prompts, pre-printed orders, and periodic audit, including follow-up with feedback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Problem overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The article \"Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition)\" is an extensively referenced guideline for the prevention of VTE, which may be useful in formulating these policies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"     149",
"    </a>",
"    ]. Their grading system is identical to that used in UpToDate, and includes both the strength of the recommendation as well as the quality of the available evidence. The concept of values and preferences has also been incorporated into a number of these recommendations. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Values and preferences'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Group versus individual recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous attempts have been made to develop risk assessment models for VTE in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/43,44,47,49,52-55\">",
"     43,44,47,49,52-55",
"    </a>",
"    ]. At this time, none of the risk stratification models has been validated in prospective trials, although this subject is under active study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/60,149\">",
"     60,149",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since clinical trials for the prevention of VTE have been successfully carried out only in specific surgical groups, the following recommendations are therefore group specific, with important caveats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with additional risk factors (eg, previous VTE, advanced age particularly &gt;75, active cancer or a history of cancer, a more extensive than usual surgical procedure) consideration should be given to",
"      <strong>",
"       more",
"      </strong>",
"      aggressive prophylaxis in the form of increased intensity or duration of a pharmacologic agent, or the addition of a mechanical device such as IPC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients from specific ethnic groups in which the incidence of post-surgical venous thromboembolism is low (eg, Asian populations), consideration may be given to",
"      <strong>",
"       less",
"      </strong>",
"      aggressive prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/52/41802/abstract/189\">",
"       189",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Assignment of surgical risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of post-operative VTE depends upon the surgical procedure (eg, degree of invasiveness, type and duration of anaesthesia, requirement for immobilization), as well as patient-related variables (eg, increasing age, prior VTE, presence of malignancy or obesity, presence of an inherited or acquired hypercoagulable state). Patients have been generally divided into very low, low, moderate, and high risk categories. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Surgical risk groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Group specific recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group specific recommendations are based upon the surgical risk group classification noted above, based in part on the use of the modified Caprini risk assessment model (",
"    <a class=\"graphic graphic_table graphicRef83739 \" href=\"mobipreview.htm?22/50/23341\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Contraindication to anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For surgical patients with risk factors for VTE for whom there is a contraindication to anticoagulant thromboprophylaxis, we recommend the optimal use of mechanical methods of thromboprophylaxis (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Mechanical methods of thromboprophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Consideration should be given to the use of a pharmacologic agent (eg, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) as soon as the bleeding risk becomes acceptably low or when the bleeding lesion or bleeding risk has been reversed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Very low risk general and abdominal-pelvic surgery patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For very low risk general and abdominal-pelvic surgery (Caprini score zero) we recommend against the use of specific thromboprophylaxis other than early and frequent ambulation (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3288083\">",
"     'Very low risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288146\">",
"    <span class=\"h3\">",
"     Low risk general and abdominal-pelvic surgery patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For low risk general and abdominal-pelvic surgery (Caprini score 1 to 2) we suggest the use of mechanical prophylaxis, preferably with intermittent pneumatic compression, over no prophylaxis or prophylactic anticoagulation (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Low risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Moderate risk general and abdominal-pelvic surgery patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For moderate risk general and abdominal-pelvic surgery (Caprini score 3 to 4) we recommend the use of prophylactic anticoagulation over no prophylaxis (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Moderate risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reasonable choices include LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low dose unfractionated heparin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    at doses recommended by the manufacturer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     High risk general and abdominal-pelvic surgery patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For high risk general and abdominal-pelvic surgery (Caprini score 5 or more) we recommend the use of prophylactic anticoagulation over other methods (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'High risk patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reasonable choices include LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , low dose unfractionated heparin three times daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    . Additional guidance in patients undergoing gynecologic surgery can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because surgical patients with multiple VTE risk factors are thought to be at the highest risk for VTE, we suggest that a pharmacologic method be combined with optimal use of a mechanical method (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Surgical risk groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Special groups",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For obese patients, including those undergoing inpatient bariatric surgery, we suggest that higher doses of LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low dose unfractionated heparin than usual for nonobese patients be employed (",
"      <a class=\"graphic graphic_table graphicRef65464 \" href=\"mobipreview.htm?8/6/8302\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H14#H14\">",
"       \"Postoperative management of the critically ill obese patient\", section on 'Anticoagulants'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H26#H26\">",
"       \"Postoperative management of the critically ill obese patient\", section on 'Venous thromboembolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients admitted to a critical care unit, burn patients with additional risk factors, acute spinal cord injury, or those with major trauma, we recommend routine assessment for VTE risk and routine thromboprophylaxis in most (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients undergoing elective total hip or total knee replacement, we recommend the routine use of pharmacologic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Reasonable choices include: LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      at a usual high-risk dose,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , a vitamin K antagonist (target INR 2.5, range: 2.0 to 3.0), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      . All have been approved for this indication.",
"     </li>",
"     <li>",
"      For patients undergoing total knee replacement, the optimal use of intermittent pneumatic compression (IPC) is an alternative option to anticoagulant prophylaxis for patients with a high bleeding risk, or can be employed in combination with other thromboprophylactic options. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Intermittent pneumatic compression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Length of treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing major general and abdominal-pelvic surgical procedures, we recommend that thromboprophylaxis continue until hospital discharge, rather than for a shorter or longer period (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For selected high risk general and abdominal-pelvic surgery patients, including those who have undergone major cancer surgery or have previously had VTE, we suggest that continuing thromboprophylaxis after hospitalization with LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for up to 28 days be considered (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Extended prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing total hip replacement or hip fracture surgery, we recommend that thromboprophylaxis be extended beyond 10 days and up to 35 days after surgery (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients undergoing total knee replacement, we suggest that thromboprophylaxis be extended beyond 10 days and up to 35 days after surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Options include LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , or a vitamin K antagonist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/58/33706?source=see_link&amp;anchor=H9#H9\">",
"       \"Medical consultation for patients with hip fracture\", section on 'Thromboembolic prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728034\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Graham F Pineo, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/1\">",
"      Anderson FA Jr, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/2\">",
"      Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991; 78:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/3\">",
"      Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/4\">",
"      White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/5\">",
"      Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/6\">",
"      Martino MA, Borges E, Williamson E, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006; 107:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/7\">",
"      Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. JAMA 1986; 255:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/8\">",
"      Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.qualityforum.org/Projects/s-z/VTE_Phase_I/Venous_Thromboembolism_(VTE)_I.aspx (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     Surgical Care Improvement Project (SCIP) file://www.jointcommission.org/surgical_care_improvement_project/ (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services and Joint Commission on Accreditation of Health Care Organizations file://www.hhs.gov/ and file://www.jointcommission.org/ (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/12\">",
"      Rathbun S. Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation 2009; 119:e480.",
"     </a>",
"    </li>",
"    <li>",
"     Safer Healthcare Now www.saferhealthcarenow.ca (Accessed on May 02, 2011).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Available at: file://www.nice.org.uk/CG092. Accessed on June 9, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/15\">",
"      Hill J, Treasure T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ 2010; 340:c95.",
"     </a>",
"    </li>",
"    <li>",
"     Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality. Available at www.ahrq.gov/clinic/pt-safety/. Accessed January 3, 2002.",
"    </li>",
"    <li>",
"     Specifications Manual for National Hospital Inpatient Quality Measures www.qualitynet.org (Accessed on March 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/18\">",
"      Sutedjo JL, Ng RK, Piazza G, Goldhaber SZ. Medicare's new regulations for deep vein thrombosis as a \"never event\": wise or worrisome? Am J Med 2009; 122:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/19\">",
"      Passman MA. Mandated quality measures and economic implications of venous thromboembolism prevention and management. Am J Surg 2010; 199:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/20\">",
"      Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/21\">",
"      Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/22\">",
"      Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992; 305:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/23\">",
"      Nurmohamed MT, Rosendaal FR, B&uuml;ller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/24\">",
"      Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/25\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/26\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/27\">",
"      Kucher N, Tapson VF, Goldhaber SZ, DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/28\">",
"      Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/29\">",
"      Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005; 165:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/30\">",
"      Rahme E, Dasgupta K, Burman M, et al. Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ 2008; 178:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/31\">",
"      Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/32\">",
"      Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/33\">",
"      Muntz J. Duration of deep vein thrombosis prophylaxis in the surgical patient and its relation to quality issues. Am J Surg 2010; 200:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/34\">",
"      Kakkar AK, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg 2010; 251:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/35\">",
"      Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/36\">",
"      Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005; 241:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/37\">",
"      Stinnett JM, Pendleton R, Skordos L, et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005; 78:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/38\">",
"      Sch&uuml;nemann HJ, Cook D, Grimshaw J, et al. Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:688S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/39\">",
"      Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/40\">",
"      Piazza G, Rosenbaum EJ, Pendergast W, et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation 2009; 119:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/41\">",
"      Boddi M, Barbani F, Abbate R, et al. Reduction in deep vein thrombosis incidence in intensive care after a clinician education program. J Thromb Haemost 2010; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/42\">",
"      Baglin T. Defining the population in need of thromboprophylaxis - making hospitals safer. Br J Haematol 2010; 149:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/43\">",
"      Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/44\">",
"      Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Br J Haematol 2008; 141:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/45\">",
"      Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001; 38:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/46\">",
"      Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/47\">",
"      Haas SK, Hach-Wunderle V, Mader FH, et al. An evaluation of venous thromboembolic risk in acutely ill medical patients immobilized at home: the AT-HOME Study. Clin Appl Thromb Hemost 2007; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/48\">",
"      Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:I9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/49\">",
"      Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/50\">",
"      Memtsoudis SG, Della Valle AG, Besculides MC, et al. Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges. J Arthroplasty 2010; 25:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/51\">",
"      Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/52\">",
"      Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. J Thromb Haemost 2006; 4:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/53\">",
"      Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/54\">",
"      Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/55\">",
"      Samama MM, Dahl OE, Quinlan DJ, et al. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 2003; 88:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/56\">",
"      Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. Ann Surg Oncol 2008; 15:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/57\">",
"      McColl MD, Walker ID, Greer IA. Risk factors for venous thromboembolism in pregnancy. Curr Opin Pulm Med 1999; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/58\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/59\">",
"      Petralia GA, Kakkar AK. Venous thromboembolism prophylaxis for the general surgical patient: where do we stand? Semin Respir Crit Care Med 2008; 29:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/60\">",
"      Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010; 251:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/61\">",
"      Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009; 339:b4583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/62\">",
"      Schultz DJ, Brasel KJ, Washington L, et al. Incidence of asymptomatic pulmonary embolism in moderately to severely injured trauma patients. J Trauma 2004; 56:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/63\">",
"      Nokes TJ, Keenan J. Thromboprophylaxis in patients with lower limb immobilisation - review of current status. Br J Haematol 2009; 146:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/64\">",
"      Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010; 199:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/65\">",
"      Arnesen H, Dahl OE, Aspelin T, et al. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 2003; 1:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/66\">",
"      Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e227S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/67\">",
"      Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost 2012; 108:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/68\">",
"      Pannucci CJ, Shanks A, Moote MJ, et al. Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. Ann Surg 2012; 255:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/69\">",
"      Fang MC, Maselli J, Lurie JD, et al. Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery. J Thromb Haemost 2011; 9:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/70\">",
"      Dattani R, Smith CD, Patel VR. The venous thromboembolic complications of shoulder and elbow surgery: a systematic review. Bone Joint J 2013; 95-B:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/71\">",
"      Persson LM, Lapidus LJ, L&auml;rfars G, Rosfors S. Deep venous thrombosis after surgery for Achilles tendon rupture: a provoked transient event with minor long-term sequelae. J Thromb Haemost 2011; 9:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/72\">",
"      Pelet S, Roger ME, Belzile EL, Bouchard M. The incidence of thromboembolic events in surgically treated ankle fracture. J Bone Joint Surg Am 2012; 94:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/73\">",
"      Johanson NA, Lachiewicz PF, Lieberman JR, et al. American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am 2009; 91:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/74\">",
"      Kwon S, Meissner M, Symons R, et al. Perioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgery. J Am Coll Surg 2011; 213:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/75\">",
"      Januel JM, Chen G, Ruffieux C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 2012; 307:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/76\">",
"      Samama CM, Ravaud P, Parent F, et al. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study. J Thromb Haemost 2007; 5:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/77\">",
"      Chandrasekaran S, Ariaretnam SK, Tsung J, Dickison D. Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis. ANZ J Surg 2009; 79:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/78\">",
"      White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/79\">",
"      Sadeghi B, Romano PS, Maynard G, et al. Mechanical and suboptimal pharmacologic prophylaxis and delayed mobilization but not morbid obesity are associated with venous thromboembolism after total knee arthroplasty: a case-control study. J Hosp Med 2012; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/80\">",
"      Pryor HI 2nd, Singleton A, Lin E, et al. Practice patterns in high-risk bariatric venous thromboembolism prophylaxis. Surg Endosc 2013; 27:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/81\">",
"      Kothari SN, Lambert PJ, Mathiason MA. Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. Am J Surg 2007; 194:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/82\">",
"      Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 2003; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/83\">",
"      Meyer CS, Blebea J, Davis K Jr, et al. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg 1995; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/84\">",
"      Schellong SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost 2007; 5:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/85\">",
"      Hull RD, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J 1982; 127:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/86\">",
"      Hull RD, Brant RF, Pineo GF, et al. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med 1999; 159:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/87\">",
"      Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000; 160:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/88\">",
"      Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001; 161:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/89\">",
"      Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003; 124:379S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/90\">",
"      Hamilton MG, Yee WH, Hull RD, Ghali WA. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. Neurosurgery 2011; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/91\">",
"      Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/92\">",
"      Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/93\">",
"      Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/94\">",
"      Sobieraj DM, Lee S, Coleman CI, et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med 2012; 156:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/95\">",
"      Samama CM, Vray M, Barr&eacute; J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/96\">",
"      Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/97\">",
"      Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/98\">",
"      Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001; 83-A:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/99\">",
"      Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/100\">",
"      Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev 2002; 28:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/101\">",
"      Rasmussen MS, Jorgensen LN, Wille-J&oslash;rgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/102\">",
"      Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/103\">",
"      Kakkar VV, Balibrea JL, Mart&iacute;nez-Gonz&aacute;lez J, et al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/104\">",
"      Streiff MB, Bockenstedt PL, Cataland SR, et al. Venous thromboembolic disease. J Natl Compr Canc Netw 2011; 9:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/105\">",
"      Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 2010; 8:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/106\">",
"      Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004; 2:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/107\">",
"      Akl EA, Terrenato I, Barba M, et al. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008; 168:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/108\">",
"      Testroote M, Stigter W, de Visser DC, Janzing H. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev 2008; :CD006681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/109\">",
"      Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008; :CD005258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/110\">",
"      Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/111\">",
"      Nurmohamed MT, van Riel AM, Henkens CM, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/112\">",
"      Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/113\">",
"      Nieto JA, Espada NG, Merino RG, Gonz&aacute;lez TC. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 2012; 130:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/114\">",
"      Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012; 94:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/115\">",
"      Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010; 3:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/116\">",
"      Neumann I, Rada G, Claro JC, et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012; 156:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/117\">",
"      Sobieraj DM, Coleman CI, Tongbram V, et al. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. Pharmacotherapy 2012; 32:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/118\">",
"      Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 2:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/119\">",
"      Bergqvist D. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1998; 85:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/120\">",
"      Leonardi MJ, McGory ML, Ko CY. The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials. Arch Surg 2006; 141:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/121\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/122\">",
"      Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/123\">",
"      Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2012; 9:CD007557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/124\">",
"      Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet 1993; 341:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/125\">",
"      Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/126\">",
"      Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/127\">",
"      Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/128\">",
"      Hamuly&aacute;k K, Lensing AW, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb Haemost 1995; 74:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/129\">",
"      Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/130\">",
"      Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/131\">",
"      Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 1997; 77:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/132\">",
"      Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/133\">",
"      Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med 2002; 347:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/134\">",
"      J&oslash;rgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. Thromb Res 2002; 105:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/135\">",
"      Lapidus LJ, Rosfors S, Ponzer S, et al. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. J Orthop Trauma 2007; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/136\">",
"      Camporese G, Bernardi E, Prandoni P, et al. Graduated compression stocking (GCS) versus low-molecular-weight heparin (LMWH) for prevention of deep vein thrombosis (DVT) after knee arthroscopy (KA): a randomized study (KANT). J Thromb Haemost 2007; 5:OT-052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/137\">",
"      Hull RD. Thromboprophylaxis in knee arthroscopy patients: revisiting values and preferences. Ann Intern Med 2008; 149:137.",
"     </a>",
"    </li>",
"    <li>",
"     Ramos J, Perrotta C, Badariotti G, et al. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev 2007; issue 2: article No. CD005259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/139\">",
"      Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/140\">",
"      Norwood SH, Berne JD, Rowe SA, et al. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma 2008; 65:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/141\">",
"      Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010; 68:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/142\">",
"      Bush S, LeClaire A, Hampp C, Lottenberg L. Review of a large clinical series: once- versus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients. J Intensive Care Med 2011; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/143\">",
"      Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997; 84:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/144\">",
"      Andtbacka RH, Babiera G, Singletary SE, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006; 243:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/145\">",
"      McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001; 233:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/146\">",
"      Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/147\">",
"      Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/148\">",
"      Beyer-Westendorf J, L&uuml;tzner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J Thromb Haemost 2012; 10:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/149\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/150\">",
"      Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997; 79:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/151\">",
"      Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/152\">",
"      Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/153\">",
"      Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/154\">",
"      Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/155\">",
"      Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/156\">",
"      Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/157\">",
"      Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/158\">",
"      Beyer-Westendorf J, L&uuml;tzner J, Donath L, et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thromb Haemost 2013; 109:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/159\">",
"      Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/160\">",
"      Eriksson BI, Dahl OE, B&uuml;ller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/161\">",
"      Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/162\">",
"      Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/163\">",
"      Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/164\">",
"      RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/165\">",
"      Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/166\">",
"      Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/167\">",
"      Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/168\">",
"      Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/169\">",
"      Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/170\">",
"      Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/171\">",
"      Botticelli Investigators, Writing Committe, Buller H, Deitchman D, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6:1313.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.discoverymedicine.com/Ingo-Ahrens/2012/06/23/development-and-clinical-applications-of-novel-oral-anticoagulants-part-i-clinically-approved-drugs/ (Accessed on November 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/173\">",
"      Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994; 309:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/174\">",
"      Karthikeyan G, Eikelboom JW, Turpie AG, Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol 2009; 146:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/175\">",
"      Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e278S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/176\">",
"      Roberts VC, Sabri S, Beeley AH, Cotton LT. The effect of intermittently applied external pressure on the haemodynamics of the lower limb in man. Br J Surg 1972; 59:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/177\">",
"      Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/178\">",
"      Hull R, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/179\">",
"      Turpie AG, Delmore T, Hirsh J, et al. Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. Thromb Res 1979; 15:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/180\">",
"      Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA 1990; 263:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/181\">",
"      Ramos R, Salem BI, De Pawlikowski MP, et al. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/182\">",
"      Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Ann Surg 2010; 251:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/183\">",
"      Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. J Arthroplasty 2001; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/184\">",
"      Clements RH, Yellumahanthi K, Ballem N, et al. Pharmacologic prophylaxis against venous thromboembolic complications is not mandatory for all laparoscopic Roux-en-Y gastric bypass procedures. J Am Coll Surg 2009; 208:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/185\">",
"      Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000; :CD001484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/186\">",
"      Camporese G, Bernardi E, Prandoni P, et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med 2008; 149:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/187\">",
"      Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 2007; 89:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/188\">",
"      Sachdeva A, Dalton M, Amaragiri SV, Lees T. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2010; :CD001484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/52/41802/abstract/189\">",
"      Lee CH, Cheng CL, Chang CH, et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. J Thromb Haemost 2012; 10:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1339 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41802=[""].join("\n");
var outline_f40_52_41802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROBLEM OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS FOR VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgical risk groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3288083\">",
"      - Very low risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Low risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Moderate risk patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - High risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11971783\">",
"      Orthopedic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12423403\">",
"      Obese patients and those undergoing bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION OF VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overall approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Timing of commencement of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Values and preferences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Definition of major bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extended prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHARMACOLOGIC AGENTS FOR VTE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Low dose unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      New oral antithrombotic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dabigatran etexilate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3436597\">",
"      - Apixaban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9637947\">",
"      - Edoxaban",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10240393\">",
"      - Enoxaparin versus the new orally active anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MECHANICAL METHODS OF THROMBOPROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Graduated compression stockings and venous foot pump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14373183\">",
"      Inferior vena cava filters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Medical center policies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Group versus individual recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Assignment of surgical risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Group specific recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Contraindication to anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Very low risk general and abdominal-pelvic surgery patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3288146\">",
"      - Low risk general and abdominal-pelvic surgery patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Moderate risk general and abdominal-pelvic surgery patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - High risk general and abdominal-pelvic surgery patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Special groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Length of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728034\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/54/35693\" title=\"table 1\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/50/23341\" title=\"table 2\">",
"      Caprini risk assessment model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/6/8302\" title=\"table 3\">",
"      LMWH doses in obese patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/58/33706?source=related_link\">",
"      Medical consultation for patients with hip fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_52_41803="Organizations eating disorders";
var content_f40_52_41803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National organizations for eating disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Academy for Eating Disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        111 Deer Lake Road, Suite 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deerfield, IL 60015",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        847-498-4274",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        www.aedweb.org",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        National Eating Disorders Association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        603 Steward Street, Suite 803",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seattle, WA 98101",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        206-382-3587; 800-931-2237",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        www.nationaleatingdisorders.org",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Anorexia Nervosa and Related Eating Disorders, Inc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        P.O. box 5102",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eugene, OR 97405",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        541-344-1144",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        www.anred.com",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        National Association of Anorexia Nervosa and Associated Disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        P.O. box 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Highland Park, IL 60035",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        847-831-3438",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        www.anad.org",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41803=[""].join("\n");
var outline_f40_52_41803=null;
var title_f40_52_41804="Colposcopy equipment supplies";
var content_f40_52_41804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Colposcopy equipment and supplies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            General colposcopy equipment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colposcope",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Speculums (variable sizes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervical punch biopsy instruments",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocervical curettes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tenaculum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometrial sampling devices",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Additional equipment and supplies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ring or sponge forceps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Needle holder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Long Debakey forceps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anoscope, clear plastic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vulvar biopsy supplies (consent form, betadine, 1 percent lidocaine, small syringe with 27-gauge needle, 3-5 mm punch biopsy instruments, suture removal kit, silver nitrate sticks)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Written material",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Consent forms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Documentation forms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Post biopsy instructions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Educational materials",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Supplies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pap test supplies (liquid based cytology or Glass slide and fixative, spatula, cytobrush)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3-5 percent acetic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Schiller's solution",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Large and small cotton swabs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Silver nitrate sticks",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Monsel's solution",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Small histology jars with permanent fixative and labels",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Betadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1 percent lidocaine (with and without epinephrine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            22-gauge spinal needle and 10-cc syringe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pantiliners",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suture material",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chux pads",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41804=[""].join("\n");
var outline_f40_52_41804=null;
var title_f40_52_41805="Contents: Bariatric metabolic surgery";
var content_f40_52_41805=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bariatric metabolic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bariatric metabolic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/58/41898\">",
"           Complications of bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/52/28489\">",
"           Endoscopy in patients who have undergone bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/18/27945\">",
"           Fertility and pregnancy after bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/23/16758\">",
"           Ghrelin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/63/20472\">",
"           Hospital accommodations and staffing for care of the bariatric surgical patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/41/666\">",
"           Imaging after bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26362\">",
"           Medical management of patients after bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/50/13094\">",
"           Physiology of leptin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32810\">",
"           Postoperative management of the critically ill obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12615\">",
"           Screening for and clinical evaluation of obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/31/33274\">",
"           Surgical management of severe obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29882\">",
"           The impact of obesity on fertility and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-336CCEE26E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_52_41805=[""].join("\n");
var outline_f40_52_41805=null;
var title_f40_52_41806="Sweet syndrome II";
var content_f40_52_41806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 318px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE+AUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fooopki1o2HWOs4Vfsmwqn0bFDNKTtI7/R5z5KLxnbxVwcyN5g9zWTojZUZB+oroo7YNEXDc/wA65a+x7+Hkh1oq7lwAP9nua0F2hBgEcc9azRJ5YO8D1yOv+eatwyuQpHPsa54vqb1SYLv3AhSpGevBp0kiqAQ3Kg9OmKRZQRxjGemKglwMgc8jPbFdcdjB6syb+UDKpx3x6VjSkklj681sX3DMSMisyVQd2T344q0bRdkZkm5mIOc/zpcCOPr164qeRecAVSmY42ryRwcVVzOckMT5nJOOeKZMwxjqKepbdxkCobg7d351L1OZuyuULt8A1lscsTVq8cnNVK0R5VWXNIaaKU0lMxClpKWgArU0iXG5T65FZY6VPaSGOdfQ8UjSnLlkmdHcyYe3k4wGx9a6mxuDsQgjGK5Rz5lsp/LFa+nSsYxk/MBjikz0onVRSghWHQjvQqqC3ljaGO445yazIJnRdo5I9atpKcrhgD+lBokW7diGxtwe+K17OTOA5C+1YduTvBLdu9aEUmWU5yv94U4uzM6kbmpdHdFvx84HCkcY/wAn9KwLw/fJZfm6it5pSlsNpy2Cee/+cVzmoOWPZOOnpWk+5jB6WMG8B84huSOmPSpbaAAAjJOe/aoEVrjUSQcrnt3rbitwiDt2rMqzZWVQwHAxwT9ao37Agj5cDkZ6ZrSmUJG2wblyOfQVn3QVwQBnI+9+NMlqxgXm0GQAnn+Vc1fpiTNdNeR8nOc4xWBqK/M3HShmNVaGbSN0p1NbpSZyi0UUUCFFXrFS8UgHUciqIrZ0GLzCw9TikzWkrysdNoErGCJlOSOSMV1Eb4B4wDg1xmizNbzPB/dJwPWuzgIkt0Y4yB2rCsro9ajK1rkqBJVzIp6cmlcKqgpk46c1CGIn24GwkEY6VIWcyAkfKP055zXNCOp1Tb0CQlDnjcD0bvUEtwqphsdPpzSyuAQQMtkbgapTsxJG0bAf/wBddK2J1GTSCTJbr0wKz5zxtI79+9XjbSFRwSnXJqvPb4xvJB6/Sq5havYy53LEgckc8VEsZ6E49T6Vpta/gO9RSwBemWJNHNcm3cz2VVX684qhcH5efxrVugqrnPNYl82F9KpHPVl7rZlztueoqVuSTTe9aHlN3ENFLSdqBBRRS0CAU5Tgg+nNNFLTA6G1O+3OMeore0sKyDoBiuZ0h90BX3xXT6Yu1cDHPQipZ6lKV4ovoCr+pB4Iq/bfOAWB6kH2qCCMOhG3nPHtVi3tnWd2LblPPXr60jZWLsUYI+U4PQZq6kYH3wBgE1WRCqhk65FX7RSwIx1AOcdu/NC3JexbIVbVhvwAMdDyK5fUYmlDY4HTiuxaFvs58tW27PmyMH/OBWNNbLu/HscVpUZjStqYOm2AiUMw6Hv1rQmUkqHx17VoeRG0bbeWIx+FU7ohjgZyvQdfz/KoQ76lGVFVVQg+WTnn/PWs28VY9wUY6Ad6150PUgbQMn1rOuIixzxj1qkS0c/dgqNuAec57Gucvk5P0rq7+MoCQPlH9K5u+AOcY9qRE4+6YZ601ulSSDDkVG3ShnCLRRRQIUda6Hw0OR75rnhXU+GkwiufSlLY3oK8jT+ziK9icdWBziuvsrfeilsEHj0rAELPKjKuBmuksZMY6/L2Pb/Oayep6UbpaEptdrD5dx6cnjHrSPaShQCoC/wk8DGfU1qQQiYKQcMvGQKux2STwK07lQAcgDPQ5/p+tYuDRftbHNtYyyMWKkJ2J9eM/lSxWKbcMuScdM8iujNuwZ4ow7RfeUcgkcDp9DUdwUhypyrjPT+79OtaLa5aqN6GBfwmOLC5x9fxrBkVmfnIGcV092wOGTpmsidMAkDnuRUc12dMJcsbGeELfKfXNV7ofJ8oxk81euGK4wfYj2rPnfapyRyaq9jnmmZF8+eoHesDUZOw7Vs375YlenaudvGy1aw1OPFO0bFem0tBrQ80Q0lKaSmAUtJRQIUUtJSigDR0l8F19wa7HTsGMAEjHFcPp7bblQf4uK7PSzlBzyewpM7sPK8TetScZIwPatBVLHIBB4PtVO3UgLkcgYNaSISoMZxzyPUd6hnYWIVZ1yWGRz0q3CpUAbhnjJI/SoraJgX3nCk4Df0rUit2kUOchzt96cdSZtRLtjbs9vhhlVOOOCRx+lU7+zaPaUH3hypHI7/1roNPi2Wn7zcsbEGQleMZ/wDr1S1UFpHLAh8ZwOMH0rqnFcp58Kr52c0VEbk565yMd6y58LKODwe1a90Co+XBB4+tZske5/mByR1x0Ncx2LXUiYeZl24zxkGqlzCdrhsYIBA6VdYBGyc+lQ3TBgfkbaB1/SqJauczqabdy5z6muVvBycdK7HUVBOQRjtjiuVu48H+dBTV4mDOPnqA9Kt3S4PSqrdKR5slZhRRS0ECjrXY6FE2xFA6AVyVspedF9TXe6Qn7leOvtSkzrwy1ubsSZiXaPlx1rSswc5dcg/xdqq2SNt6cDtWxAFMQRCN3pjof85rHY9BK2xYi4XgD5gCPx/pWpBvZxGoBTH5j+VUlVXiC5IK+g7dq1rPagGGwcYHHSr30IqO2pI1ph1faVH3hLt+b1wfx9KxNViEFyzxklXO7rnGfWujcExhYx8204z0B6Y/+vXPX0chYqwAHI+vFTOHKtBUJty1ZhzlSrAnJ6YB7VQfOQDnPQ+9WriMoTkY57cVSkDYY4yB0rns0z0VaxUuiVOQQeOf8/jWTOfk5YDnGDWk/mnOBgH1FULiIEEdSevtVxTZlNpbmHekEtjgVz85y5rotRwqkd+c+lc5MPmNdEVY8vGSu0R0UUVZxDaKU0lMAooooEKKWkFLQBJCdsqN6MDXY6S53e1cWK6rRZN2xj6ZNJnVhnujs7VmcHLDjBGPSti1hMm0nvxjPr6ViaWd6nOOTxit6CcQNx9AMfrUvU7ddkbFsgDqrYxya2bCOPDMMZVsgDp9Sa5q1uCWDkE44HNb+nvnZgFlDLntV00rmOIpySNuSJ/s42kKQuBt7A9sd+1YuqKVI4+YDkE9/r9a6KNXEGGKkBD82D+H8qxNRQ72Vw2VA4NdE/hOCi/esc3MGbjGAB0J/KqpiUqDGCDj1rXkQNkbdvQfjVCVeHLdBwa50j0EzOnjAABGRnv9Kr3WNpCdx61amHybgcoedx9KqOw2FiMH0z2pg9rnP36Eod3JHpXN3i4LDp7V1t5gpyfm9cVzt7CAXxyMd/WkCl0ZzN+m3jvWe3StTUR1PbFZbdKTOCoveCloooMy7pK771B6A16DpyKIlB478Vw/h2PddlvQYr0DTY8hT1OMAVMjuwy0Rt26YjBJ3Buq+ua17SEtiRQAM8kDoKoWkI2bmAIHAAPOK3bVRgBW49+lYyR1OVth9tk5UjKgZ3Yq3AgeNTgLtOBnp/nFIkJYYJwCOe3NXIINqfOvykc5qoau5FSQGMxx7lC5xkDpisu7j8xAjjA7DkHvWrOrhOeg5Bz0rOv+drDkY5x1FdbiramMG7nN3dvnBXdgHksePrWe6DBQg4Htxj1rau/4sBc+x7VnyZAGB8xP51hyrodvM7amPcYBbA6Djisudjgjbz71sz4BO7qD2rGmwjHPKn0pqJEpHP6kvByc5JrnZvvmui1Fcjk/h6Vz1wMOabOCuQ0UtIaDnENJS0lMAooo70hCilFJS0AKK6Dw8S0Y/wBk4/Cufrd8NZLNjs1BtRdpHd6ScJ7Y+laMbHIOSazNPz5fv61ejY7sDv1qT18PG+pqWj7uM9sdOtdHppKswVcjGfx9f1rBtFww+X3PbFbtogY9s56ZrSDsyMS7o6uykWaLYH+UkE56nj/EVm3sbZZmGHPucYB9/armmyEhRHyoJUfMMLnjOPpU2oxK6yMpDk4H17cflXS9UeInyTOXmiDRHaRtBBz1zVG4hCx5ZdvVh/Wtua2RQFAbYVxt9KoXMBEeDkgABQT0PTFYSVjshO5jTIApDLwoyCTWZdAncCoAPv146Vtzp1DjjOcn0rJu1UOxY89h61O7NDn7pSC3HOAOBxWTqAyG2gAHrW/doFzjk5GPTFYWoqdkhPPOKQmcnqAyG9Kxz0rav+hz6VjP3pHNVWoUCkpRQYnReGIs/N6mvQNNjAWMA4xxz0ri/DUf+joccYP8676wTbCN4645qZHo0VZI2NMTcecBe54/Kti0gIkQgDYQCPrWVp7KJkQrgAktgd8f/qrdjbaBsYZABrN7mk7ovwR5YhgWY856c5q0QfM2HO4jBI571XsyMZBPXJA9fWrcUmZBkcjrjJxn+lb04o5Jt3EnXG7AHHA9smsjUVcR8DK84BHTFdBIodQVXqeR0ycVjXqF5Np6YIUj2Pp+NbyWhNKWpzcsJJKuMcA4ArMlKg4P8PYVr6oWzgZDAflWQ6nGGxuAzk96wcbHpfZuzLkUEnrnJzgZrGvE+Ugjnr6VuXDZLBeAM8YrDvk+6ScjsCOgoM5MwNR5IHHHWudufvGujvVy2Afc1z12MMcetJnJW2K1JSmkoOYQ0lKaKYCUUtJ3oELS0g6UvegBRW34bLCV9vqOtYlbHhw4umGfSka0viR6Dp8ZaM8DbngZrTtYi5zt+Xrk9qpaQMquRkE9K3LeEsuEIVh+tI9anPkVizBGWTcvIB5PbFamnfLuBBUE5JP0qpCmxGAIxyT7Vbi+QHacY5qloY1Zc+h0ek43My4LkAggdcnv7VrTII7ZgA2F+7jj/wDV3rn9LkxMiodoJ6fjXStGkkHy/M5AznHXvmuuD908mvG09Tn7qPy0KFcEZGe3rWfOo2kg5UHkmtK+UqfnJwfvHP6flWVKVA28FcAA56ev9KzmjoplKSDEYbgLjoewxWLexMyZx8ykEY/WuhZzt5+bDcMO/bFZV6rYYnaxbg47H2rJo2i3fU5q9T5SQACOOKwL1SWfcvzd8cV1F3tJYAAcE5rnr9QjOM5I68UmDOP1Bcb8jBrDlGGIro9QG5n75Fc9cjDmpZjWWpFSiiihHOd54aXFrED0AArtrVgUVlfDdMVxvh9cxRYGOOtddCSYwcDj+dSz06S1sjVDDbmElGxk5q9AQVX5stgEg1kwPwpKg4PNalvgN1AH05GKg6pK2htWJwAB9wde9aEDZ+VSDgYJ9u9Y9sSgUEDlsjFXYEYqzBVzngDrW1NnHUinubOd6oA4BY8eo7Vm3a5hZh1PAJ46DmrEZZBlvmAxnJHWq82NxDMcjPA963ZzRVmYM68N5iAJ13DrWPcYGcDniugvEbBx8u05NYd6QGOcbRWTO2LuYk6gAgk5Jzn0rDvVzu5wM81r3hdGcLwegz61k3CsScjJPapCRh3aEBm655rnb4c10uoHoO2a57UBSZhWXumeaQ0tJQcYhpKU0UwEoopaBAKWkFKKAFrX8N/8f3tisitfw5/x+E+mP50jWl8aPS9MYbAvUcVuIdpUj15rntObbgjP0NbVrJlDk96R6aV9TWR0KJtAxx161NDIA21j8x6e9UIWGFxzn731qchg4faNwOcg4pj5Vex0enFd6nBwW69MV1lrCHgCKOAAML6ev864jTHL4DYKtwR2Ndvo7l7UR5zjoTzyfWuunsePi00zK1S3AJC4IxwR1rnryMIxBUDGeg6etdbqyKu7BwSDg479z+PNcvMqtIZQMgrjGcZFE1cqhPQpBFWPqSVXIJ6HNZN0dzAqTvQYPcZrckYAMHAZe38/5Vk3qbnIH8XB4x9BWLRupa6nPX6/N0GR1zXN6p1LDHfOa6rUExDtYLuwCQORXMXoJzuGcjJFS0aKV9TmrzliRjnmufvVAbI6V0d2uGbjgVg6gvX86lmdbVFKl7UlHakjkO68PSYiiYcHaDXW2bZXqcjBPoPauN8PN/o0ZYcBRiuw01SQOQwbjb/n6VLPVo9zVtAxJIIAyMY69a14GXO0DkZPr1zWVb/KDt+72HpV+2kBUOuQSOT61nLc6GrmgrfLGATnpg+vrWpbOhwNxB6H6isNJuQ4xn7o9c9f5VY+1+WxwWIHpWtN2Mp03LRG+WUxEEliP7vrVK4mwSSDuBGT7kVWW8JUEkDHUKelRSTbxnJCjpz/AJ9K6WYKi4vUivJlCFdxzkZ46/Wse5DYPcZ+761end1UkqCDjk9KzbiRhkep+uKzdjTltojHu9xkYe5rLulCPz26471tSrgOScEngkVl3XQ7foeeakTMG7QsWVsKMZGT2rmtQHWukvR8xGQOxrndRqWY1PhMo0GlPek+lBxiGkpTRTEJR3ope9AAKWkFLQAtbHhz/j6bj0rHrV0BgLh/Xj+dBrR+NHomnE+WATnHetu1OAu5QeOKwtO+7ya27QnOcYAH86R60FoaURAAySD/AJ4qdXDtgZ9T9fSqAdFcICST0BqYTKi5zhs9qE0VyNmzaPtmj2j5sn8PQV2GikGIK5VjnknpwecfTrXCWUo6oAxPzD/P1rsNGbbGpUbO4x6kEk12UtUeZjIWL+psT8pIJwSoHJwOnbrXM3WVmfzGwMDODXQXx3xgKgChc9etc/c4xjBw2cHr0pzVjCgtDNvZJAu2NhkEZGPWs+WZVhALEsOQxHU/49au3A6quAmDyPpWZcglV6jHOfSuds7YwTRnXkoMZVsgcjgY/OsDUVUA7RwQOK2Lo5fqShPfqTWNdycOeTgYFTe4pU7bHNahzI2MjFYOojKE/St+/bL56HGKwdR+634VLMqitEzqKKBSRyHYeHT+6ix/drs7DHBHBwf8a4nw8x8hOONvH1rsLVsRkg9P0pM9WhsjYTfhI1I6Dknp2xWhE21sJwPY9OKyYHAfBI5GfYf5NX4ZV2quM9GwPWspbnaomihBXfjAwCfrTyMsMZV+ckmq0TseXBC4zipo5CdoGd3X8KuD1JasSJhVLMM9CeePpUM0jknacKOAMflV9wphBJGD39s1WdAHOCTkg9K3b6GamnqyjK7uG3H5scgVQkz5JCnAPOSa0ZAdwwPlBzms+6yxKjg8DIHHNQxNpmfcdCGBDDHes24cDIPcY/StG6zn5hkD3rKufulRyc496CJoyLsfKc981zuodK6C5cuhDqQQcYrntQPpS6HLU+EyjSUppKDjENFB6UUwCiiigQope9IOlLQAVqaGcTv9BWXWlo/+tf6Cg2o/Gj0LTpCUU556VuQuADj865XSp8Lxn0FdFCwKDgk56VJ7MY2RoqFJDOQcHOfQ0sO5pWyCQP0qJGwMHpwTViKRTk9s5ag2WxpWi7HAAxkHGOw7V1mjSdARgEYJyK5KFsuDxnvz1rqdLiAQ71+YYOe+c9K7KJ5WMWmpqXmGkYFCM/KR0Pp0rnrqVZJMbgSM8fpit29dQo8hNx5LO3BH+eKwdT/dkkKAXPPrWlQ46CvoZ9yh34HA6EdKoTx8sckD09z3rRllUuzgHHJ96oXD5ZmOOmScda5pHZG5h32xlbKntXN3vysRjCn0rpb4gOqrnjJIPNc5qJBLDGcjis2adDnNQ4dlzkA8Y96wtQ+41bt9gliPTmsG++43+e9JmFbYz6WkpaRwnT+H2xHEc9sYrsLZ2wnGVPBHpXFeHmOEAxntn6129pjYM49DipZ62HeiNFRyuDgkcVcgd8hRyfT0PaqkKncADkZ6Vp26qgO4ZI71DZ6F0kSqT/EcA9R396tQljjbkr61WCpLKH6HGMn61dtdqAAAZB45pw1MpvQuIcr9zjbkk9Qe/FRHayrycjuOO1SblY8MTlc8gdCainYfKACo9SOlbo5OpQnMm7pwOvvms24Vh/tY5FaUgIYhmJ6nIH6frWVey7UZhnAOG45/CpehtFX0KNwwAYPxwazLjaR33DqcVdnfIHAGaoTMvReOhyDzQKasZN7hUIPHp71zV/3z1re1An149a56+70mcVX4TPNJQaDQcYhooopiCikpaAFopBSigBa0NJOJX/Cs+rmmHE7D1H9aRrR+NHX2UhXAb8q6KxlyBkngDoa5Wzfnk/TNbVnLjpx6ZoZ79LVWN8OJBhcinQlkIUDgnPNVElD4J64q3bOGYjOTUmyVkbVgd+A3JORxXV6CWcAMPm3FgMe/Bri7J0R0U545wK7DR2ICvuIyRyOeMV2UDysatDcu1L2xztbjH59v0rn9QC+bggDA5AHI+lb2ZDFtKghR9/puOf5YrndSZRucOhcdwO3atqi0uebQTvYzJ5EEgwTjrms6Vldtz4Jx1H1oup9rOCeBnBz2qgkrLGwLAl8YPoa5Jbnq+ztEjuyu1mOcn8eK529xyMAYHrWxdzEt8rnGSMY61h3pyzBeFxwPWoZElbc568PXsDWFffcatu/OGYcDAxxWFeH5GpSOevsUqWkpaSOE29AkwwwcEGu6smUxjdxxXnuhPi4IOPXmu7sWBiUcjHt1pM9HDO6RuQkE88njk1aEvDMpBAPaslJlHUfN/MVbguOQRg5H/wCus2evCHU0IpwWO5sjHAAq/buRncOvfr+FZNu+GJYYB7jrVuOfam1W57Ypx0JqR1sjYMqrGMnYQNpx9DmqtxOWbbkgA5yeee9UHuCxyWz7YqCS6Yg8k89Pwra5nGhrcmnmGQRk4OeO9ULiTcx3Nyef06U2WfcMLnJ6VUklGP8Ab75qbmrppFeSQN06A9DVGVskkcY6ds1ZmYc4Xg8VRupNwwKEc1VGPfNjIyeuawbw1s3rHLZxxWHdtycetNnn13ZWKppKDRSOMQ0UUUxBRRRQAopaSigBRVqwOLlfeqtS2xxOh96RcHaSZ1Fow6EenStSBuQVODWVaDKn+Yq7EwPBPPp0oZ79J9TbtpsDnvxxWhbyYyT+QrGtMhtwI2+takRBxn1yMjpUnWnc2LZsJnOMnjj3rqtFcBIVY4+bgg47VyFvnA34J55rb06RovmY4UcA46f/AFq6KLszgxceaNjr7zcQQzqiYxgdcf5/nXNakyAccAng9ffnNaBuI5BhsmQpkE8j6/nXPaxI/wBTjqBXTUascGGpvmsYd9Ph9wbjjHHSqj3KyKxU59B6etOuyc5P5GqgLbSSApPJxXEevJLlEeUlSOSSc49aoXMhIwemPSrJKiMkH5VNUrgkR7znd/MUHFWMHUGBc46AYxisS7OVPNbGof6xtvTp9axbk8GkzhrsqilpBS0kcZd0ptt2PpXb2LsUTDZ4FcFZttuUPvXZ6ZISFwx6dKTO/CPQ1bgybDsbBPfNT2ErKo8w5PrikiKkDfjaOoxViFULKFGAT0xWbPdpS90uRSNxnOB+VTicBMjhc84qijMsrbmAGOTiiWRlHHJPQ0JltK4+WUkB84Of0qCSUADqTjn6VAzMW+U5GOM1GWJGM59Ku5dkOaU4XB3HPTpSM5b5sjIxULNgnI6c5NRs4DDB6UzKeo+4ft079etZ10xCnkAZ/KrE0mWGKzLuXk4Pr2po4ZmfePx6DNYtw2WrSu5M9ayZDljQeViJXY00lKaSmcwUUGg0AFFFFIApaSloAWnxHEin0IqOnDrQNHUWLHkA1bHy5bB9qzrBsjr171pDnaV7nnJoZ7+H1RpWb5YA/hWnBwhAPQ5J9vSsK2kIXHbOBWvaSAn5s+2Kk67WNu3YcMCME9+1adpI2Qck89Ouax7UrtABGBkjPf2q/aSfMQTkeo962pswqRumbnm4VtgJYDg59e1Z18zkkbRs6nnrU2/K+2KinAIORtJGea2k2zkjaLMS5iXDKANx9uMYrOcMGxgAegrduIMk427RyaovbZDMw2t78isGjd1FYy3jygGBgc1lXzfJnt39q27jKxHnknkg9a5/UGGSuAABnFSzkbbZgXrHzGDHJxWRcHrWnfHk4rJm5JpM4qz1I6WkpaDmHIdrg56Guw0h92Mc5FcaK6bRZMrGSf4eaTOvCP3rHTg4jzzgdhVmKTYQeTnt6VRgkGMt0zxVkNhQcjB7Vmz3qLsi2XIB6behNNeT5ciot22MEZPOMYpGkwDnoaRs3cQMGJz8p9qY2Oc4H9aZvy2QOPSh34OR39KtFNjHAUZycn9Khc855x3FOkcYPIHANV5WweTweeaaMZsbLIckcntmsu6fknNWZpME+tZlzJ19c1Rw1pcqKV09UCamuHy2KgNB405XYhooNFBAUUhopgFLSUo60gAUUUUALSikFFA0bWmPmNea2FB5xkE9BXP6W+Bj0NbsJ+7zzQe5g5XgjRtwNu7J9av2x9OOevSqEDAnH8ORirkWSVI4Ge9SdyZrW/QcfKT271pW7jflQR2waybdscHk5q7BIwIG7PpWkHYmaubkLKYzkkk9qjmlErkqCcH09qgiZjGeeBwAKJmPzBcA4z+Vat6HHyq4SSlWxnJA5ArGvZ2Mg2g7e5q3I5BPc4/KqkjAnPG09PSsnqHKolK6Y45weM/SsDUTjPU57mtq6k3L8uMjjA7Vz2oybiSPTFI5m7sxL9gGwPTOay3OSav3bZLE+lZ7Ujhqu8hoooopGAora0hiyKoODisUda0tJb5iKbN8O7TR1lo42Ek9uBVotgLgZ46VStEUqCzDntVlCRJgZzjPtWctz6Ci7osbhjbvOadkEAnp9aYwIAOPalWTKDIGM0kdIm8Ku09cVFNJg59aWU4zge3FVnJNMGOZsD5vwqrNJyMEg5xSzOwXI6mqkrHrxyeKtGEkR3D471lXL4GKtzPjIxWXcvnjNB5GKqdCuxySabS0hpnnBRRSUAFFFFABRRRQIWikpaBhS0lLQBbsGw5H410VpymQa5e2bbMvvxXRWTkLig9XASvFo1bc4X0xxV6E4AJ571ThO7Pr9auxD5dvTkVJ6aZbikySBxmrtum/5sgE4GM/lVCNcMOp5/Or0J+YEEr9e1VEbdkaVqTwNxJHOKbdSMNuMcde2KSHOOAAT0xVS+yCSBjAJwa1voc+8iCS8DzFc8j+dQvJnBb7p6e1RmMrMzKMHGeBUcrEPioFVStoV7wgblGCfbgVz+oN8xGMY6DOa2rp1XJweB/WsG/YMzHGDnpSON31Ma6brVI96s3R5xVY0jzpvUSikpaDMWrumNtnIPTFUatWBxcj3FBdJ2mjr7I7kHPQVejAzjOT7Vl6c5ACn7prSyEO7PHes2fQ0nqW/l8sg9SeKR4gVKg8VFFIGHXt1NIshBGeh/OkjpuEtuSpUd++OtQsgHXGasGQkn0/lUDfeO85Y+naqJcmipcHHyjjFZ0p44HNackeeCR+dZ0+0Z61aOSpVsjMuT1zWbIctV28bBP1rPPJNB41aV2JRRRQYCUUUUDCiiigAooooAKWiigApaSigByHDA+9dFYmucrc0uQGNSSfeg7sDK07G/aZI9a1IlO3nFUbEA4Gc56GtKNCME+nQ1J7HNcI1PmAg5AHSrsEoxllO0+lVxtOOu098d6sWp2EDknt71UboqVmjRilAi9AcAjv1zRLGr89QOhpsZVugBI59almkVAU24ZlAzitTjm9dCpcQ7STjJIz15rMuFXOOQBxgGrtyxXeXOQT8oA6D0Pv71lXUjNLuBIHXHcVDFZ2KV2wUMQMnoPeufvDwc/rWzeyY5BwV7DvWFeNlTnrSZzz0TMi5PzVAaknOXqOkedLcbS0UUkQA61PanbOlQCnxnEin3pji7M6uzZflyeo61qj54yOnFY9jgouT15rXiVyPUZ6Vme9TeiBEI3AdO1PzuyD196eI8OQfSrUEO5ux55pWOn2itdlJeCCePr2p7YAyTz9KsXaBAduAR1rJllYnAJPP4GqRLfOtB9ywPOcHGayLhsZ4zzVqRmPOegwQazrpsDv6VZw1vdTMu7fcx+tVqlnOWqI0Hkyd2J+NBoooJEooooGFFFFMAooopAHalpKWgQUUUUDCtXR5MZB5ANZdXNMfbPgnAPJoNqEuWaZ2dm+1cjOK1IZCV+uD83asux+6ATnHT6VpKPlAGTgYzSPWUyyV3RbeQc/pT4iqlMnaM8VDnCZ5BbvnkVGjtt+92xjHWmjdSujWVwCNp+ZefrxUNzKPKY5JJ4B7j8KpGUjHzHGKie43A5yAatyM1DW425uMt16+/WqE02ScEHAwOafcvuyejHJFZ0pYsWGR04qSpK6IZnZ9xySD3rLvDwevArQlYc+9ZV4cZpM4cQ7KxmyHLU2lbrSHpQzzWNpaKKRAd6UdaSlpjOksDmNTk5x2ro7XIVSTzgA4rnNG5jj57V0Fuozjk4x+NQz2qMrxSLw2k5UEnvU3ljaRkj6UkUZCq2DjGMVPGpKPuGFwOv1oVmac1kU7uLecZyD3xWdPbjHGQPWtp0VWBGSc4OT1qtNGNpPUdqdrEupYwbsYXPWsS/JwMcHvWzqMoUY/WsG8fOc0+hy1m+XUzX5Y02lPU0lM80DR2oooASig0UDA0UGimAUUUUgClpB0ooELRRRQMKntG23EZ9TioKchw6n0OaBxdnc7jTiGjPHTpWvGucjPPWsDTX+Uc5ya342J6Dg9ak9eDuOYnaAGHHrSYbaAM8dqlEROQw6d6Q8AketNHRFkWxmTIOMdQagdlDtGcnjOaviLEeOBnkHOap3WDISBz9OKou99ClICVHoO+eazXJaZ8Zwtacx2IWx+GaoEgEknOc8kUES2KcwG07jWTdt19a1rkgA4PHWsW8NJ7nm4hlOkpaSg4QooopEhS0lLTGb+jsPLTO75eeK6eNQUBjJ45rldDYYUEkdc4rrbX7m3PH9KzZ6tCVoqxpWrLtBJyw65q4p8yPHc/pWXBuV8biRnPH8q00+5hjwefSqibSVtSrMSc9znniqNy2BtLYHWr1zIBy2M5IrJuyd29s88Yob1JaujGvxkn6ZrCvOMitq7Jx7e9YV43PWmcld6FOkpaSmcIUlKaKAEooooGFFBooAKKKKBBS0UUAFFFFABS0lFAzqNFfcEIPpxXS2jYLEncD/ADrkdCf90vPQ4rqrclumPr6VLPUou8UaKYK7TkDPUGnuojiaTllQE4HVvaowWUknBJXJz2q3agSEDtnGMdapI2cmlcFUGFWz1Gdo5+vNUbsAI2AT7ntV8bUZlVC24denNRPCo+UncSOR+NXJCjOzMlrYMdzemPaqd0FClQBjHWtWdVRSN2e3FYd/Myy/dBUdDnrUBdzZm3RGD1A7ViXh+etS5bO/nise5OWoOLEshpKWkNBxhRRRQiQFLSDrS0DNTRX2yY966u0cHaeox0ritPbbLxXVaa4+UEkD69azl3PRw0rwOggOQMZyBV+AhU64IHes63YkALk8VobSIgWzzyacTok9CC5OVbdjHbisTUFckBXwBzitWZicgcDOeax78kIzLnik9xJtbGNdsTkHr3rDujlvxrYvG4JyetYk5+arRxYlkVBoopnIFFFIaACiiloAQ0UUUDCiiigQtFJS0AFFFFABRRRQM19DbqP9quvtm2DGM5rjdFOC31rq7XDEcnr06Ujvo35Ua8JBJOST/I1etmUA5zkcZFZULcj9QatwMQVJyV7U0dFrrU1ldGVWPUeveqNy2zdzwP51MrAK/P8AwE96ytTJZdqsfqTz9K1lsZwXvGfeOzEsuQc4/Csi7l38c9MZq3ds0cJJY4HGKzJXGPlPBrM6HtcpXLHJ5rLlOXNaF0c5NZznLGkeZXd2MoNLSdqGc4lLSUUiRRS0lFMZZsf9f+FdLpx5Unt0rmbI4mB9q6TT8lkx0z0qZHfhNmdRZAgjBrQCMQ25Rg81l2Dg42ryPWtdSw+VT9724pQR0Sj1Mi5OCcrgZ6+lY98CVJJ6mtu5TzNxGAc9fSse8ULuU5yehoaswizAvWx0zWPKcsa1bw1lSfeqkcOI3GikoBoJpnMFJS0nrQAUUUUAFFFFAwooo70CAUtIKKAFopKWgAooooGaOkHDN9a6qzbIH97POK5TST8x+tdPZnnr9eKR6eHV6ZpKvziTOD3rRgOec5xWch4yMcVetflIOSSvPPeqjuay2J5pQpCOrbuoK9Kzb+UKCcEgd61ZyNjLtyCN1Yd4Dkgng1ctDOGruZFzIXJJ6AdDWbNjdnPPpWjdDn3rOn4JH61mzaq/d0KU54NUT1q3cniqdB5VR6iUUUUGR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema nodosum-like lesions of the lower extremities in a patient with Sweet syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41806=[""].join("\n");
var outline_f40_52_41806=null;
var title_f40_52_41807="T2-weighted MRI Canavan disease";
var content_f40_52_41807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T2-weighted MRI, Canavan disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spongy degeneration of cerebral white matter (Canavan disease). Magnetic resonance imaging study. T2-weighted axial views show a marked increase in signal in the white matter that is most evident in the posterior portions of the hemispheres.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Franklin G Moser, Division of Neuroradiology, Cedars-Sinai Medical Center, Los Angeles, CA. Reproduced from: Menkes JH. Heredodegenerative Diseases. In: Child Neurology, 6th Edition, Menkes JH, Sarnat HB, Maria BL (Eds), Philadelphia, Lippincott Williams &amp; Wilkins, 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_52_41807=[""].join("\n");
var outline_f40_52_41807=null;
